Annexin A1 as an endogenous regulator of mast cell degranulation. by Sinniah, Ajantha
Annexin A1 as an endogenous regulator of mast cell degranulation.
Sinniah, Ajantha
 
 
 
 
 
The copyright of this thesis rests with the author and no quotation from it or information
derived from it may be published without the prior written consent of the author
 
 
For additional information about this publication click this link.
http://qmro.qmul.ac.uk/jspui/handle/123456789/9089
 
 
 
Information about this research object was correct at the time of download; we occasionally
make corrections to records, please therefore check the published record when citing. For
more information contact scholarlycommunications@qmul.ac.uk
 
 
 
  
Annexin A1 as an endogenous regulator of 
mast cell degranulation  
 
 
 
 
Ajantha Sinniah 
 
 
 
A thesis submitted to the University of London (Faculty of Science)  
for the degree of Doctor of Philosophy 
 
 
 
Centre for Biochemical Pharmacology 
William Harvey Research Institute 
Barts and The London School of Medicine and Dentistry 
Charterhouse Square, London, EC1M 6BQ 
  2 
I, Ajantha Sinniah, confirm that the work presented in this thesis is my own. 
Where information has been derived from other sources, I confirm that this 
has been indicated and appropriately referenced. 
 
Signed: …………………………………….. 
 
Date: ………………………………………...  
  3 
ABSTRACT 
 
Annexin A1 (Anx-A1) is a 37kDa protein that is secreted by some cells 
in response to glucocorticoids (GCs) and which mediates several of their 
acute anti-inflammatory effects. In addition to GCs, ‘mast cell stabilising’ 
cromones such as nedocromil also mobilise Anx-A1 by promoting its 
phosphorylation by protein kinase C (PKC) and hence its secretion, which 
explains their acute efficacy as anti-allergic agents. This thesis addresses a 
fundamental aspect of Anx-A1 in the actions of anti-allergic drugs. In this 
study, anti-allergic drugs such as H1 antagonists, mast cell stabilisers and 
‘dual action’ drugs were first tested for their ability to enhance Anx-A1 
phosphorylation in a model system using U937 cells.  
Biochemical and immuno-fluorescent techniques were used to study 
the mechanisms by which these drugs suppress mediator release from cord 
blood derived mast cells (CDMCs) and murine bone-marrow derived mast 
cells (BMDMCs) from wild type and Anx-A1 null-mice. This thesis suggest 
that PKC activation is crucial for Anx-A1 export in mast cells and nedocromil 
in the presence of dexamethasone, prolongs the duration of PKC activation 
and subsequently phosphorylation, externalisation and release of Anx-A1 
from CDMCs. The ability of nedocromil to inhibit β-hexosaminidase, tryptase, 
histamine and PGD2 release are dependent on Anx-A1 in CDMCs. 
Interestingly, ketotifen, a ‘dual action’ drug possesses a similar 
pharmacological profile to nedocromil, but not promethazine, which does not 
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act through the Anx-A1 release. Strong evidence supports the notion that the 
mechanisms of action of nedocromil are modulated by Anx-A1, thus the 
possibility that FPR2 might be involved in the acute actions of nedocromil was 
tested. Nedocromil inhibits the release of PGD2 through the activation of 
FPR2 but not the inhibition of histamine release. A possible explanation for 
this finding could be that Anx-A1 might be interacting with other FPR family 
members to exert the histamine inhibitory effects. Although only a small 
subset of the downstream intracellular signaling pathway of MAPK was 
tested, the results indicate that Anx-A1 differentially regulates the activation of 
p38 and JNK in CDMCs treated with nedocromil.  
These findings indicate a novel model system in which Anx-A1 
mediates the pharmacological actions of anti-allergic drugs and thus has an 
important role in preventing the mast cell degranulation. 
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Ig Immunoglobulin 
IL interleukin 
IP3 inositol-1,4,5-triphosphate  
ITAM immunoreceptor tyrosine-based activation motif 
JNK c-jun N-terminal kinase 
KO knock-out 
LAT linker of activated T cells 
LT leukotriene 
LXA4 lipoxin A4 
M1 macrophage 1 
M2 macrophage 2 
mAb monoclonal antibody 
mACh muscarinic acetylcholine  
MAP mitogen-activated protein  
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MAPK mitogen-activated protein kinase 
MC-CPA mast cell carboxypeptidase A 
MMC mucosal mast cell 
mMCP-6 mast cell-restricted tryptase  
mRNA messenger Ribonucleic acid 
Na2CO3/ 
NaHCO3 Sodium carbonate/Sodium bicarbonate 
Na3VO4 Sodium orthovanadate 
NaCl Sodium Chloride 
NF-Kb nuclear factor-kappa activated B  
NSB non specific binding 
NSF N-ethylmaleimide-sensitive factor 
PAF platlet activating factor 
PAMPs Pathogen Associated Molecular Patterns 
PBS Phosphate buffered saline 
PFA paraformaldehyde 
PG prostaglandin 
PGD2 prostaglandin D2 
PGF2 prostaglandin F2 
PH pleckstrin homology 
PI3K Phosphatidylinositol-4,5-bisphosphate 3-kinase 
PIP2 Phosphatidylinositol 4,5-bisphosphate 2 
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PKC Protein Kinase C 
PLA2 Phospholipase A2 
PLCy Phospholipase gamma  
PLD phospholipase D 
PMA phorbol 12-myristate 13-acetate 
PMN polymophonuclear 
PMSF phenylmethanesulfonylfluoride 
PP2A phosphatase 2A 
PRR Pattern-recognition receptors 
PS phophatidylserine 
PVDF Polyvinylidene fluoride 
RACKS Receptors for activated-C kinases 
RBL-2H3 rat basophilic leukemia 
RNA Ribo Nucleic Acid 
RNS reactive nitrogen species 
ROS Reactive Oxygen Species 
RU486 Mifepristone 
SAA serum amyloid A 
SAC seasonal allergic conjunctivitis  
SCF stem cell factor 
SDS-PAGE sodium dodecyl sulfate-polyacrylamide gel electrophoresis 
SEM standard error mean 
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Ser27 serine 27 
Ser45 serine 45 
SNARE soluble NSF attachment protein receptor 
TEMED tetramethylethylenediamine 
TGF Transforming growth factor 
Th2 T-helper 2 
TLRs Toll-like receptors 
TNF tumour necrosis factor 
TPH tryptophan hydoxylase 
Tris-HCl Tris(hydroxymethyl)aminomethane hydrochloride 
TRPM7 
Transient receptor potential cation channel, subfamily M, 
member 7 
TTBS Tween 20-Tris Buffered Saline 
TxB2 thromboxane B2 
Tyr21 tyrosine 21 
U937 pro-monocytic cell line 
VAMP-8 vesicle associated membrane protein 
VEGF Vascular endothelial growth factor 
WRW4 Trp-Arg-Trp-Trp-Trp-Trp-CONH2 4 peptide 
WT wild-type 
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1.1 OVERVIEW OF THE INFLAMMATORY PROCESS 
Inflammation may be defined as a constellation of rapid and 
coordinated process of adaptive response that is provoked by tissue damage 
or infection by pathogenic and non-pathogenic microbes (Barton, 2008). 
Although the cardinal signs of inflammation had been mentioned in ancient 
medical texts, the physiological basis of the clinical signs of inflammation was 
only revealed in 1846 by Augustus Waller who also discovered the leukocyte 
emigration into tissue (Medzhitov, 2010). The cardinal signs of inflammation 
are redness (rubor), heat (calor), swelling (tumor), pain (dolor) and eventually 
loss of function (functio laesa). These signs represent the macroscopic 
culmination of a myriad of molecular and cellular processes during 
inflammation. 
A typical inflammatory response consists of four components, which 
are the inflammatory inducers, the sensors that detect them, the inflammatory 
mediators induced by the sensors, and the target tissues that are affected by 
the inflammatory mediators (Figure 1.1). The ideal inflammatory response 
eliminates the infectious agents and is followed by resolution and repair 
phase and a return to homeostasis. However, the orchestrated coordination 
of inflammation is dependent on the mechanism required to resolve 
inflammation, while limiting the damaging aspects of inflammation to the host 
tissue (Segal et al., 2000; Nathan, 2002).  
In many organs such as lung, skin and nose, intact epidermal or 
epithelial surfaces form the main interface between pathogens in the external 
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environment and host tissue. These interfaces are lined by continuous layers 
of specialised epithelial cells that serve as a physical barrier preventing the 
entry of microbes (Bulek et al., 2010). There are two types of immunity that 
protects the host from infections, which are the innate and adaptive immune 
system. The innate system is a first line of defense as it acts as both a 
physical and chemical barrier to infectious agents (Janeway et al., 2002). The 
innate system comprising macrophages, neutrophils, mast cell, basophils, 
eosinophils and dendritic cells, among others, is genetically programmed to 
detect the invariant features of invading pathogens. Even though the main 
immune cells in the brain are the microglial cells, recent evidences have 
indicated that neurons do express TLRs and that they detect intrinsic danger 
signals and modulate neuronal morphology and function in response to 
pathogen infection (Liu et al., 2014). By contrast, the adaptive system 
comprising T and B-lymphocytes, are highly specific in that the generation of 
responses is tailor-made to maximise the elimination of specific inducers of 
inflammation. The adaptive immune system develops immunological memory 
of invading pathogens, which is ‘remembered’ by signature antibodies or T 
cell receptors. These memory cells will be immediately recruited to eliminate 
the pathogens should any subsequent pathogenic invasion occurs 
(Medzhitov, 2007). 
An acute inflammatory response, depends upon the converging 
actions of various inflammatory mediators such as chemokines, cytokines, 
vasoactive amines and eicosanoids (Medzhitov, 2008). This conspicuous 
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event is initiated at the site of injury by the resident cells, notably 
macrophages and mast cells that secrete the pro-inflammatory mediators, 
which are considered pivotal for the progression of inflammation. These 
inflammatory mediators will provoke an inflammatory exudate locally by 
facilitating the infiltration of plasma proteins and neutrophils through the 
postcapillary venules to the extracellular tissue at the site of infection or injury 
(Pober et al., 2007). Upon reaching the afflicted site of injury or infection, 
neutrophils will become activated either by direct contact with pathogens or 
through the actions of cytokines produced by tissue-resident cells. The 
neutrophil then attempts to destroy the invading agents by releasing the toxic 
contents of their granules, which includes reactive oxygen species (ROS), 
proteinase 3, cathepsin G and elastase (Nathan, 2006). However, these 
potent effectors are not able to distinguish between host targets and 
pathogens, thus collateral damage to the host tissue is often inevitable 
(Nathan, 2002). Interestingly, this equilibrium is really precise such that any 
modifications, through the release of enhanced pro-inflammatory factors 
would lead to cellular and tissue damage (Perretti et al., 2009). 
By contrast, chronic inflammation is a prolonged and dysregulated 
response that involves active inflammation, tissue destruction and attempts at 
tissue repair. As such persistent inflammation is often associated with many 
chronic human conditions and diseases, including atherosclerosis, arthritis, 
allergy, cancer and autoimmune diseases (Medzhitov, 2008).  
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Conventionally, it was thought that pro-inflammatory mediator 
catabolism was sufficient for inflammation to ‘switch off’ and the response 
would subsequently just finish ‘spontaneously’. However, we are now aware 
that the next concomitant event is cell clearance.  For the inflammation to 
resolve, the inflammatory leukocytes need to exit through the available routes 
including systemic circulation or are removed by apoptosis followed by 
phagocytosis by macrophages, which would then egress from the inflamed 
site by lymphatic drainage (Davies et al., 2013). The acute inflammation 
phase would then resolve without causing excessive tissue damage provided 
all these pathways are exactly adhered.  
  29 
 
Figure 1.1: The inflammatory pathway consists of inducers, sensors, 
mediators and target tissues.  
Upon exposure to pathogens or injury, pathogen associated molecular patterns 
(PAMPs) and damage-associated molecular patterns (DAMPs) are recognised by 
sensors such as Toll-like receptors (TLRs), which are expressed on macrophages, 
dendritic cells and mast cells. These cells induce the production of mediators, 
including cytokines, chemokines, eicosanoids, bioactive amines and products of 
proteolytic cascades, such as bradykinin. These inflammatory mediators act on 
target tissues to modify the functional state to maximise adaptation to injury or 
infection that initiated the inflammatory process (Medzhitov, 2010).	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1.1.1 Inducers and sensors of inflammation 
The innate immune system engages with invariant pattern-recognition 
receptors (PRRs), such as toll-like receptors (TLRs) that recognise 
evolutionarily conserved structures such as pathogen-associated molecular 
patterns (PAMPs) or damage-associated molecular patterns (DAMPs) (Akira 
et al., 2006). In contrast, the adaptive immune system not only depends on 
the production of a repertoire of antigen receptors located on the T and B-
lymphocytes but also strongly relies on the essential signals that are 
delivered by the innate the immune system (Schenten et al., 2011). The 
crosstalk between innate and adaptive system determines the nature and 
duration of inflammation (Iwasaki et al., 2010). 
Inducers of inflammation could be classified as either exogenous or 
endogenous.  Exogenous inducers of inflammation consist of microbial or 
non-microbial inducers. There are two further sub-classes of microbial 
inducers, which are PAMPs and virulence factors. PAMPs are a limited and 
conserved molecular patterns that is found in all microorganisms and there 
are receptors that specifically recognise PAMPs (Tang et al., 2012). 
Therefore this evolutionary tactic of the host allows the adaptive immune 
response to discriminate between self and non-self. The second class of 
microbial inducer are virulence factors and one feature that distinguishes 
between PAMPs and virulence factors is that the latter are not sensed by 
receptors; therefore the adverse effects of their activity on host tissue are 
enough to trigger the inflammatory response (Medzhitov, 2008).  
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 By contrast, damage-associated molecular patterns (DAMPs) are 
associated with cell damage and released in response to trauma, ischaemia 
or tissue damage, either in the absence or presence of pathogenic infection 
(Tang et al., 2012). Many DAMPs are either nuclear or cytosolic proteins and 
when released from the cell, the oxidising extracellular milieu results in 
DAMPs denaturation (Rubartelli et al., 2007). DAMPs include intracellular 
proteins, such as heat-shock proteins (Panayi et al., 2004), high-mobility 
group box 1 (HMGB1) (Scaffidi et al., 2002) and proteins derived from the 
extracellular matrix that are generated following tissue injury (Scheibner et al., 
2006). Whereas, non-protein DAMPs include ATP, uric acid, RNA and DNA. 
DAMPs also induce substances released from mitochondria, consisting of 
formyl peptides and mitochondrial DNA, which activate human 
polymophonuclear (PMN) neutrophils. It is noteworthy to mention that N-
formylated peptides can be recognised by formyl-peptide receptors (FPR), 
which is also activated by the anti-inflammatory endogenous ligand, Anx-A1. 
Interestingly, PAMPs and DAMPs can share the same receptor, particularly 
the TLRs, indicating similarities do exist between pathogen-induced and non-
infectious, inflammatory responses. 
Non-microbial exogenous inducers include allergens, irritants, foreign 
bodies and toxic compounds. The inflammatory response provoked by 
allergens relies on expulsion and clearance mediated by the epithelial 
mucosa (Tillie-Leblond et al., 2005). Foreign bodies such as silica and 
asbestos are indigestible particles that are either too big to be phagocytosed 
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by macrophages. These particles cause the generation of reactive oxygen 
species and reactive nitrogen species (ROS / RNS), which triggers signal 
transduction pathways that initiate inflammation (Fubini et al., 2003; Shukla et 
al., 2003). 
 
1.1.2 Mediators and effectors of inflammation 
  The inducers of inflammation trigger the release and generation of 
various inflammatory mediators, which are the downstream effectors of the 
inflammatory pathway. Most of these mediators influence the vasculature and 
the recruitment of leukocytes. The cellular mediators are synthesised by 
specialised leukocytes such as macrophages or mast cells. Some mediators 
exist and circulate as inactive precursors in the plasma while others are 
preformed and stored in the granules of mast cells, basophils or platelets 
(Medzhitov, 2008).  
 Inflammatory mediators can be classified based on their biochemical 
properties. Vasoactive amines such as histamine and serotonin are produced 
when mast cells degranulate and they cause increased vascular permeability 
and vasodilation (Bach, 1982).  
Other types of inflammatory mediators include vasoactive peptides, 
such as substance P, which are stored in an active form in the secretory 
vesicles or kinins, fibropeptide A and fibrin degradation products that are 
generated by inactive precursors in the extracellular fluid. Substance P is 
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released by sensory neurons and also cause mast cell degranulation 
(O'Connor et al., 2004). Other vasoactive peptides are generated through 
proteolysis by thrombin or plasmin that cause vasodilation and increased 
vasopermeability. These vasoactive peptides affect the vasculature as well as 
triggering a pain sensation, which is one of the most important components of 
inflammation (Lühder et al., 2009; Bhatia, 2010). 
 The third group of mediators of inflammation are the anaphylatoxins, 
which are produced by complement activation. These mediators promote 
granulocyte and monocyte recruitment, stimulate mast cell degranulation and 
affect the vasculature (Schmudde et al., 2013). 
 Lipid mediators such as eicosanoids and platelet-activating factors are 
derived from phospholipids. Upon activation by intracellular Ca2+ ions, 
cytosolic PLA2 generates arachidonic acid and lysophosphatidic acid. 
Arachidonic acid is metabolised to form eicosanoids either by 
cyclooxygenase, which generates prostaglandins and thromboxane (Scott et 
al., 1999), or by lipooxgenases, which generate leukotrines and lipoxins 
(Serhan, 2006). The prostaglandins cause vasodilation, hyperalgesic and 
induce fever (Higgs et al., 1984; Ivanov et al., 2004). Meanwhile, lipoxin is an 
anti-inflammatory mediator, which inhibits inflammation and promotes the 
resolution of inflammation and tissue repair (Serhan, 2007). The second class 
of lipid mediator, which is platelet activating factor (PAF) is involved in platelet 
activation, recruitment of leukocyes, vasodilation and vasoconstriction and 
increased vascular permeability (Serhan, 2006). Stimulated basophils, 
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monocytes, PMNs, platelets, and endothelial cells produce PAF primarily 
through lipid remodeling. A variety of stimuli can initiate the synthesis of PAF, 
which could be either macrophages going through phagocytosis or the uptake 
of thrombin by endothelium cells. PAF could be synthesised by two different 
pathways, which includes de novo and the membrane-remodeling pathway. 
The former maintains the levels of PAF during normal cellular functions whilst 
inflammatory agents activate the latter pathway and it is thought to be the 
primary source of PAF under pathological conditions. 
 Inflammatory cytokines and chemokines are produced and secreted by 
many cell types. Cytokines activate the endothelium and induce an acute 
phase response (Cohen et al., 1996) while the chemokines regulates 
leukocyte extravasation and chemotaxis towards the affected tissues (Zlotnik 
et al., 2000; Moser et al., 2004).  
Lastly, proteolytic enzymes including elastin, cathepsin and matrix 
metalloproteinase have diverse roles in promoting inflammation such as 
tissue defense, tissue remodelling and leukocyte migration (Mithieux et al., 
2005; Le et al., 2007; Conus et al., 2010).  
  
1.1.3 Homeostatic control through stress response and adaptation 
Homeostasis is defined as a collection of control mechanisms that 
ensure that internal environmental parameters are maintained, within a 
normal equilibrium near a certain set point usually through a system of 
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feedback controls (Cannon, 1929). Abnormality in the homeostatic range 
could result in either acute stress response that causes a temporary 
adaptation to the new conditions or a more prolonged adaptive change that 
shifts the relevant set points (Medzhitov, 2008).  
In the same vein, we can also appreciate that the acute and chronic 
inflammation are different types of adaptive response that occurs when the 
homeostatic mechanisms are insufficient. Acute inflammatory responses will 
resolve when the abnormal conditions are transient, thus functionality is 
restored and basal homeostatic checkpoints are maintained. However, when 
the abnormal conditions are sustained, the equilibrium shifts to extreme end 
of the spectrum resulting in chronic inflammation (Medzhitov, 2010).  
 
1.1.4 Resolution of inflammation 
Perpetuation of inflammation is an innate risk because it causes tissue 
damage that leads to scarring and loss of function. The paradox of 
inflammation is not how often it starts, but how often it fails to subside 
(Nathan et al., 2010).  Resolution of inflammation could be defined as an 
active endogenous program involving various biochemical processes and 
multiple signaling pathways that switch from the production of pro-
inflammatory mediators to pro-resolving molecules such as lipid mediators 
and Annexin A1 (Anx-A1) that ensure rapid restoration of tissue homeostasis 
(Serhan et al., 2007; Alessandri et al., 2013).  
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 At certain ‘checkpoints’ during the inflammatory process, appropriate 
‘stop signals’, which include lipoxins and resolvins, are activated to prevent 
further leukocyte traffic into the tissue (Serhan et al., 2008). These pro-
resolving mediators pave the way for monocyte migration and differentiation 
into phagocytosing macrophages, which remove dead cells and then exit the 
site of inflammation (Ortega-Gómez et al., 2013). There are two different 
subsets of macrophages, which are the classically activated M1 
macrophages and the alternatively activated M2 macrophages. M1 
macrophage mediates defence of the host from a variety of bacteria, protozoa 
and viruses, and has roles in anti-tumour immunity. In contrast, M2 
macrophage have anti-inflammatory function and regulate wound healing. 
Fibroblasts contribute to the resolution of inflammation by withdrawing the 
survival signals and normalisation of the chemokine gradients, by allowing 
infiltrating leukocytes to undergo apoptosis or leave the tissue site through 
the draining lymphatics (Barone et al., 2012). The events that governed the 
resolution phase are essential for complete resolution and restoration of 
inflamed tissue to ensure physiological functioning.   
Currently, most therapies are targeted to inhibit the production of pro-
inflammatory mediators, however an equally important target would be the 
initiation of endogenous pro-resolving mediators (Sousa et al., 2013) . With 
the notion that inflammation is resolved in a time- and space- specific 
manner, elucidation of a certain pathway or mediator could lead to the 
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recognition of the molecular targets that could prompt novel drug discovery 
for the treatment of chronic inflammatory conditions (Serhan et al., 2007). 
 
1.2 ANX-A1 AS AN ENDOGENOUS ANTI-INFLAMMATORY 
PROTEIN 
1.2.1 Annexin superfamily 
The annexin superfamily in mammals consist of 12 calcium and 
phospholipid binding proteins with a 40-60% structural homology (Raynal et 
al., 1994), and these are thought to derive from the ancestral Annexin A-13 
(Anx-A13) gene (Gerke et al., 2005). A common characteristic of annexins is 
their ability to bind to negatively charged phospholipid membranes in a 
calcium-dependent manner. The evolutionary difference between these 
subfamilies is the ability of these proteins to preferentially localise to 
accessible sites on the protein surfaces that determine membrane binding 
and the interaction with cytosolic proteins (Moss et al., 2004).  
A common trait of the family is a core domain, which normally 
comprises four conserved 70 amino acid motifs, which bear the calcium or 
phospholipid binding consensus sequence. The N-terminus which is thought 
to be responsible for the unique biological activity and specific functions of 
each member of the annexin superfamily, is of varying amino acid sequence 
and length (Gerke et al., 2002).  
Annexins are mainly localised in the cytosol either in a soluble form or 
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associated with S-100 proteins or components of the cytoskeleton (Moss et 
al., 2004). Anx-A2 and Anx-A11 have been found in the nucleus under certain 
circumstances (Eberhard et al., 2001; Tomas et al., 2003). Anx-A1 was 
shown to be expressed on the cell surface despite the absence of any 
secretory signal peptide (Solito et al., 1994) and Anx-A2 is constitutively 
expressed at the surface of vascular endothelial cells where it regulates 
blood-clotting mechanisms (Brownstein et al., 2001). The tissue distribution 
and expression of these annexins range from being ubiquitous and abundant 
(Anx-A1, A2, A4, A5, A6 and A7) to selective (Anx-A3 in neutrophils and A8 in 
placenta and skin) or restrictive (A9 in tongue and A10 in the stomach).  
The development of knock-out (KO) mice has provided immense 
understanding into the functions of annexins. Anx-A1 KO mice exhibit 
increased inflammatory responses and are resistant to glucocorticoid 
treatment (Hannon et al., 2003) and the loss of Anx-A2 causes defects in 
neovascularisation and fibrin homeostasis (Ling et al., 2004b). Anx-A7 null 
mutant mice strains show changes in calcium homeostasis (Herr et al., 2001). 
This diversity of phenotype in the annexin KO mice suggests that these 
proteins have largely independent functions.  
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1.2.2 Structural characteristics of Anx-A1  
 Our laboratory pioneered the work on the 37kD endogenously 
expressed protein called Anx-A1, finding that this mediator is able to inhibit 
PGE2 release by inhibiting the action of PLA2 (Flower et al., 1979). This 
protein was previously termed macrocortin (Blackwell et al., 1980), renocortin 
(Russo-Marie et al., 1982), lipomodulin (Hirata, 1981) or lipocortin 1 
(Browning et al., 1990). There were several other proteins with a homology to 
lipocortin and due to the ability of this protein to ‘annex’ phospholipid 
membranes, another name was agreed upon, Anx-A1 (Gerke et al., 2002).  
Anx-A1 was purified to homogeneity from peritoneal lavage fluid 
obtained from rats treated with GCs (Pepinsky et al., 1986b), and 
subsequently cloned and sequenced in 1986 (Wallner et al., 1986). Anx-A1 is 
found in many differentiated cells and tissues and it makes up 2-4% of the 
total cytosolic protein in the PMN although it is not normally detectable in the 
plasma membrane (Perretti et al., 1996c). However, Anx-A1 is found in many 
tissues, including the lungs, bone marrow and intestine, at concentrations of < 
50ng/ml, with the highest levels reported to be in the seminal fluid (150ug/ml). 
Anx-A1 comprises 346 amino acids and the N-terminal domain, which 
contains 41 residues (Rosengarth et al., 2001a) contains several putative 
Ser, Tyr and Thr phosphorylation sites as well as consensus sequences for 
glycosylation, transglutamination and proteolysis (Raynal et al., 1994). 
Crystallographic analysis of the Anx-A1 protein (Figure 1.2) suggests that the 
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alignment of the four repeated sequences creates a pore, giving the molecule 
a ‘doughnut-like’ appearance. It was disclosed that the N-terminus is 
embedded within the core domain on the concave surface, but increased 
Ca2+ concentrations (≥ 1mM in plasma or other biological fluids) causes the 
N-terminus region to ‘flip out’ and may thereby influence the biological activity 
of this protein (Rosengarth et al., 2001a). 
Anx-A1 is found mainly in the gelatinase granules of neutrophils 
(Perretti et al., 2000), and α-granules of mast cells (Oliani et al., 2000) 
whereas in the macrophages, it is found mainly within the cytoplasm although 
it is also associated with the membrane, cytoskeleton and nucleus depending 
upon the state of cell activation (Peers et al., 1993; Seemann et al., 1997). 
Anx-A1 is highly expressed by differentiated cells, as past studies have 
shown that Anx-A1 expression is lower in monocytes as compared to those in 
macrophages retrieved from the same donor (Perretti et al., 1996c). Whilst, T-
cells express Anx-A1, B cells only express it at low levels, whereas platelets 
do not express this protein at all (Cirino et al., 1987; Morand et al., 1995; 
Rescher et al., 2004).  
Work within our group has demonstrated that a peptide spanning the 
first 24 amino acids of Anx-A1, known as acetyl 2-26 (Ac2-26), mimics the 
anti-inflammatory effects of the human recombinant Anx-A1, indicating that 
this short region is responsible for the specific effects of the parent protein 
(Perretti, 1997).  
Interestingly, Anx-A1 possesses proteolytic motifs and a N-terminal 
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truncated moiety which is commonly found in inflammatory fluids (Liu et al., 
2005) and the physiological and biological properties of Anx-A1 are destroyed 
by proteolysis of the N-terminal domain (Cirino et al., 1993). 
 
 
Figure 1.2: Anx-A1 peptide and molecular structure.  
A) Schematic representation of Anx-A1 and peptides derived from the primary 
sequence. B) Ribbon presentation showing the 3-dimensional fold of Annexin A1 
with four repeats and the N-terminal domain is folded into core domain on the 
concave surface. The N-terminal domain is shown in yellow, repeat 1 in red, repeat 2 
in green, repeat 3 in blue and repeat 4 in purple. C) In the presence of Ca2+ ions 
(orange spheres), the N-terminal helix is exposed from the protein core and most 
likely becomes accessible for other interactions (Rosengarth et al., 2003). 
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1.2.3 Post translational modification of Anx-A1 
Many anti-inflammatory and other regulatory actions of Anx-A1 appear 
to be exerted extracellularly via membrane-bound cell surface receptors 
(Goulding et al., 1992; Christian et al., 1997; Gerke et al., 2002; Perretti et al., 
2002). The availability of endogenous Anx-A1 to bind to these receptors is 
thus mainly dependent on the translocation of these proteins from its 
cytoplasmic storage sites to the cell surface. For example, within the 
neuroendocrine system, Anx-A1 is expressed in folliculostellate cells in 
regions adjacent to its target cells (Traverso et al., 1999) and this protein is 
then translocated to the cell surface in response to appropriate stimuli (Loxley 
et al., 1993b; Taylor et al., 1993).  
Substantial evidence supports the notion that secretion of Anx-A1 is an 
important event within the host defence system, for example in modulating 
neutrophil migration (Perretti et al., 2002). However, since this protein does 
not possess a leader sequence or a secretory signal, the mechanism by 
which Anx-A1 is translocated from the cytoplasm to the cell membrane is not 
well understood. There maybe more than one pathway as secretion is 
independent from the classical endoplasmic reticulum/Golgi route of 
exocytosis (Philip et al., 1998) and de novo protein synthesis (Solito et al., 
2003b). Moreover, in cells that do not store Anx-A1 in granules, secretion 
must be mediated through a separate mechanism. Some evidence does 
indicate that it is exported by the ATP-binding cassette  (ABC) transporter 
system (Morris et al., 2002; Chapman et al., 2003).  
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Our past work has demonstrated that the externalisation of Anx-A1 
from the cell requires a signalling cascade involving protein kinase C (PKC) 
leading to Anx-A1 phosphorylation prior to being rapidly mobilised to the 
outside leaflet of the plasma membrane (Yazid et al., 2009). This post-
translational modification occurs prior to the exportation of Anx-A1 out of the 
cell, however when Ser27 was mutated to Ala27, there was no accumulation of 
Anx-A1 at the cell membrane further reiterating the role of Anx-A1 
phosphorylation at Ser27 residue (Solito et al., 2003c). At this location, the 
intact 37kDa Anx-A1 undergoes a conformational change, exposing the N-
terminal region, resulting in a structure that is the active form of Anx-A1 
(Rosengarth et al., 2001b).  
 
1.2.3.1 Phosphorylation of the N-terminal domain 
The interactions between Anx-A1 and the cellular membrane are 
reversible and regulated by post-translational modification such as 
phosphorylation. The N-terminal domain of Anx-A1 contains several sites 
where post-translational modification occurs, and this process is fundamental 
for protein function (Table 1.1). 
It has been previously reported that the N-terminal domain of Anx-A1 
binds to the epidermal growth factor receptor (EGF-R) (Pepinsky et al., 
1986a) prior to phosphorylation at Tyr21 residue. This is crucial for the 
inhibitory effects of GCs on EGF-R, thus leading to a blockade of cytosolic 
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PLA2 translocation to the membrane and inhibition of the release of 
arachidonic acid (Croxtall et al., 2000). Anx-A1 was rapidly phosphorylated at 
tyrosine residue and translocated to the membrane fraction within 10 min of 
exposure to hepatocyte growth factor (HGF) in A549 lung carcinoma cells, 
suggesting that the phosphorylation of Anx-A1 may regulate cell proliferation, 
chemotaxis and vascular remodelling (Melki et al., 1994). Anx-A1 expression 
and phosphorylation at Tyr21 residue was also implicated in liver regeneration 
and tumorigenesis either through modulating cPLA2 activity or EGF-R 
function (de Coupade et al., 2000). Interestingly, a study by Solito and co-
workers using both sense and anti-sense Anx-A1 plasmid transfection in 
U937 cells, have demonstrated that the tyrosine phosphorylation is not 
essential for the blockade of cytosolic PLA2 as only 10% of Anx-A1 is 
phosphorylated on the tyrosine residue (Solito et al., 1998b). Intriguingly, 
Croxtall et al have demonstrated that the cPLA2 and arachidonic release by 
the A549 human lung adenocarcinoma epithelial cell line was controlled by an 
EQEYV domain localised at the N-terminal region of Anx-A1, which 
comprises the Tyr21 phosphorylation motif (Croxtall et al., 1998).  
Dorovkov and colleagues have reported that the TRPM7 channel 
kinase (Chak1) is involved in Anx-A1 phosphorylation at the Ser5 residue 
(Dorovkov et al., 2004). Another study had established an association 
between Anx-A1 and TRPM7 by confirming the presence of a TRPM7/Anx-
A1/Mg2+ complex, suggesting a novel pathway for bradykinin signalling, which 
is dependent on PKC and c-src (Callera et al., 2009). Anx-A1 phosphorylation 
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at Ser5 residue had also been shown to regulate the interaction between Anx-
A1 and the calcium binding protein, S100A11 (Dorovkov et al., 2011). This 
complex is considered to be biologically relevant as the disruption of this 
complex increased cervical cancer HeLa cells migration and clonogenic 
growth through the EGF signalling (Poeter et al., 2013).  
A key paper by John and colleagues has shown that PKC 
phosphorylates Anx-A1 and this event is crucial for the cellular export and 
biological activity of Anx-A1 in anterior pituitary glands and the Anx-A1 
exported from these cells contains phospho-serine (John et al., 2002). 
Following this lead, Solito et al demonstrated that dexamethasone induces 
rapid serine phosphorylation followed by membrane translocation of Anx-A1 
via novel GC receptor-dependent mechanism, which is dependent on MAPK, 
PI3K and Ca2+-dependent PKC pathway (Solito et al., 2003c).  
Anx-A1 also regulates hormone exocytosis, whereby the release of 
adrenocorticotrophin from a corticotroph-like cell line is inhibited by GCs. 
Furthermore, phosphorylation at Ser27 and Ser45 residues of Anx-A1 is crucial 
in the translocation of the protein to the cell membrane and inhibition of 
adrenocorticotrophin release involving the enhancement of actin (McArthur et 
al., 2009). Work within our own group has shown that GC treatment of U937 
cells induced a rapid concentration-dependent activation of PKCα/β prior to 
the Anx-A1-Ser27 phosphorylation, which precedes export of the protein. 
Cromoglycate-like drugs have minimal effects on the phosphorylation of 
either proteins, but greatly potentiate the effect of the GCs resulting in the 
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inhibition of thromboxane B2 generation (Yazid et al., 2009). Petrella et al 
have shown that the Ser27 phosphorylated form of Anx-A1 was exposed to 
the cell surface when an histone deacetylases (HDAC) inhibitor was used to 
induce apoptosis in U937, K562 and Jurkat leukemia cells, suggesting that 
Anx-A1 is present on the apoptotic cell surface and may be functioning as a 
putative pro-apoptotic signal (Petrella et al., 2008).  
These studies have roused attention on the regulatory role of post-
translational modifications of Anx-A1, whereby the understanding of the 
mechanism of the structural switch on the phosphorylation of this protein 
could be fundamental in delineating the physiological functions of Anx-A1 
especially the specific intracellular pathway and receptor interactions.  
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Kinase Residue Cellular effects References 
 
 
 
EGF-R 
 
 
 
Tyrosine21 
• Cell proliferation, 
chemotaxis, vascular 
remodeling  
• Liver regeneration and 
tumorigenesis 
• Inhibition of cPLA2 and 
arachnidonic release 
• Melki et al., 1994 
 
 
• de Coupade et al., 
2000 
 
• Croxtall et al., 2000 
 
Chak1 
 
Serine5 
• Binding with S100A11 
• TRPM7/Anx-A1/Mg2+ 
bradykinin pathway 
• Dorovkov et al., 2011 
• Dorovkov et al., 2004 
 
 
 
PKC 
 
 
 
Serine27 
• Translocation of Anx-
A1 to membrane 
• Hormone exocytosis 
• Inhibition of TxB2 
• Induce pro-apoptotic 
signal 
• John et al., 2002; 
Solito et al., 2006 
• McArthur et al., 2009 
• Yazid et al., 2009 
• Petrella et al., 2008 
Table 1.1: Principal cellular effects on the N-terminal domain of Anx-A1 
phosphorylation of its respective residues.   	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1.2.3.2 Proteolytic regulation of N-terminal domain 
Whilst there is much evidence supporting the need for N-terminal 
serine phosphorylation preceding Anx-A1 release, it is still unclear whether 
Anx-A1 externalisation requires N-terminus cleavage. Anx-A1 harbours 
several proteolytic motifs and an N-terminal truncated moiety, is commonly 
found in the inflammatory fluids. Thus, proteolysis of the N-terminal domain 
modifies the physical and physiological functions of Anx-A1.  
Several enzymes cleave Anx-A1 into a 33kDa fragment, including 
elastase (Rescher et al., 2006), metalloprotease (Movitz et al., 1999) and 
proteinase 3 (Vong et al., 2007). The purpose of this cleavage process is yet 
to be unravelled, although there have been studies reporting that the 
cleavage of the N-terminal domain occurs either to allow Anx-A1 to act as a 
pro-drug through the production of a bioactive fragment (Gavins et al., 2003) 
or to limit the actions of Anx-A1 (Pederzoli-Ribeil et al., 2010).  
Moreover, a modified recombinant form of Anx-A1 known in our 
laboratory as the ‘super’ Anx-A1, which is resistant to the cleavage by the 
proteinase 3 enzyme have been shown to have longer lasting effects on 
neutrophil adhesion in vivo as compared to the native Anx-A1 (Pederzoli-
Ribeil et al., 2010).  
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1.2.4 Activation of N-formyl peptide receptors by Anx-A1 
The way in which Anx-A1 mediates its cellular effects remained largely 
unknown until the year 2000. Goulding and co-workers postulated that 
exogenous Anx-A1 mediated its effects through specific cell surface receptors 
in peripheral blood monocytes and PMNs (Goulding et al., 1996). However a 
breakthrough came through the work of Gerke and colleagues, demonstrating 
that formyl peptide receptor (FPR) antagonists blocked the anti-inflammatory 
effects of both the intact Anx-A1 and the Anx-A1-derived peptide Ac2-26, 
suggesting an important role for FPRs in regulating the functional effects of 
Anx-A1 (Walther et al., 2000).  
The anti-migratory effects of exogenous Anx-A1 were blocked by FPR 
antagonists, such as ‘Boc’ (butyloxycarbonyl) derivatives (Boc-MLF), on 
human neutrophils across a monolayer of endothelial cells.  This effect was 
characterised by a transient calcium flux and L-selectin shedding (Walther et 
al., 2000). These in-vitro data were supported by in-vivo studies from our own 
lab using the fpr2/3-/- mice, in which the inhibitory actions of Anx-A1 and its 
mimetics in a model of peritonitis were attenuated (Perretti et al., 2001). 
These fundamental studies have opened up new avenues of research in the 
field of Anx-A1, paving way for further investigations into the possible 
functional and molecular links between Anx-A1 and this family of receptors. 
FPR is a member of a seven-membrane spanning G-protein coupled 
receptors (Perretti et al., 2002), which are expressed by several types of cells 
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including human neutrophils, monocytes, macrophages, mast cells, epithelial 
cells and endothelial cells (Serhan et al., 2008). In human, there are three 
FPRs, which are termed FPR1, FPR2, and FPR3 (Ye et al., 2009). FPR2 is 
otherwise known as FPR2/ALX as it is also the receptor for lipoxin A4. On the 
contrary, the mouse Fpr gene family is more complex and contains at least 
eight related genes, including Fpr1, Fpr2, Fpr-rs1, Fpr-rs3, Fpr-rs4, Fpr-rs5, 
Fpr-rs6, Fpr-rs7, and Fpr-rs8 (Gao et al., 1998; Ye et al., 2009). 
By sequence homology human and mouse families share two gene 
clusters. hFPR1 (human formyl peptide receptor 1) and mfpr1 (murine formyl 
peptide receptor 1) share ∼77% homology whilst hFPR2 and mfpr2 genes, 
share approximately 76% homology, also share similarities with hFPR3 (Ye et 
al., 2009).  
The generation of fpr2/3 null mice, in which the murine homologue of 
FPR2 were deleted, has led to the greater understanding of the roles played 
by this receptor. This study reported that these mice were unable to respond 
to the N-terminal peptide Ac 2-26 and other agonists of the FPR2 receptor 
and exhibited an exacerbated inflammatory response when compared to the 
WT mice (Dufton et al., 2010a).  Intriguingly, these observations were found 
to be similar to Anx-A1 null mice (Hannon et al., 2003).  
FPR2 is a promiscuous receptor in that it recognises a repertoire of 
protein/peptides agonist as well as high affinity endogenous lipid ligands such 
as lipoxin A4 (LXA4) and resolvin D1 (Chiang et al., 2000; Perretti et al., 
2002). This receptor not only transduces the anti-inflammatory effects of LXA4 
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in many systems (Chiang et al., 2006) but also mediates the pro-inflammatory 
responses to serum amyloid A (SAA) and other peptides (He et al., 2003). 
The possibility that this receptor mediates two opposing effects could be due 
to the different binding site domains used by different agonists (Le et al., 
2005).  
It was established in previous studies that LXA4 and its analogs have 
contrasting effects to Anx-A1 and its mimetics even though both interact with 
the same receptor on peripheral leukocytes. LXA4 causes increased basal 
surface expression of L-selectin (Gavins et al., 2005b) whereas Anx-A1 and 
its mimetics cause L-selectin shedding by both neutrophils and monocytes in 
vitro (József et al., 2002; Solito et al., 2003a). These findings could be 
possible due to the ligand-specific conformational changes (Gavins et al., 
2005a) or the dimerisation state of the receptor (Cooray et al., 2013) that 
yields specific cellular effects unique to each ligand.  
An elegant study by Cooray and co-workers has shown that FPR2 
homodimerisation displayed a higher tendency to signal in response to pro-
resolving and anti-inflammatory agonist stimulation when compared to FPR1 
and FPR3, whilst the pro-inflammatory agonist, serum amyloid A (SAA) did 
not share this feature. It is probable that the agonist-biased FPR2 
dimerisation is able to discriminate between agonists with varying biological 
properties (Cooray et al., 2013). 
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1.2.5 Anx-A1 as a mediator of GC action 
Glucocorticoids (GC) induce the synthesis and secretion of Anx-A1 
utilising both genomic and non-genomic pathways (Parente et al., 2004). The 
underlying mechanism of GCs that regulate Anx-A1 gene transcription has 
not fully elucidated, it has been shown that even though the Anx-A1 promoter 
does not have a canonical sequence for GC response, it does have a binding 
site for IL-6, which suggest that GCs indirectly regulates Anx-A1 expression 
(Solito et al., 1998a).  
A substantial body of evidence shows that Anx-A1 is indeed an 
endogenous protein mediating many anti-inflammatory effects of GC. COX-2 
mRNA and protein levels were constitutively increased in Anx-A1 null mice 
and more importantly, GCs were ineffective in models of inflammation 
(Hannon et al., 2003), reiterating the homeostatic anti-inflammatory ability of 
Anx-A1 to resolve inflammation. 
An intricate interplay between Anx-A1 and corticosteroid hormones 
was discovered when it was observed that Anx-A1 modulates GC-induced 
secretion of adrenocorticotrophic hormone  (ACTH) from the anterior pituitary 
gland (Loxley et al., 1993a; Taylor et al., 1993). Anx-A1 levels in murine 
peripheral blood leukocytes were found to be elevated 2-3 fold with a peak at 
2 h after steroid treatment and the GC receptor antagonist, RU486, blocked 
this effect (Perretti et al., 1996c).   
During the inflammatory process, GCs cause rapid non-genomic 
mobilisation and secretion of Anx-A1 at the cell surface, and a slower (2-4 h) 
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upregulation of Anx-A1 gene transcription through genomic mechanisms 
(Croxtall et al., 2000). The way by which GCs inhibit eicosanoids could be 
grouped into two main mechanisms based on Anx-A1 dependency. Firstly, 
rapid exposure of GCs prevent the phosphorylation or activation of cPLA2 
through Anx-A1 dependent mechanism (Croxtall et al., 1996), and secondly, 
a more delayed exposure of these drugs down-regulates Cox-2 mRNA 
through an Anx-A1 independent mechanism (Masferrer et al., 1992).  
Exogenous recombinant Anx-A1 mimics corticosteroid suppression of 
monocyte functions such as superoxide generation (Maridonneau-Parini et 
al., 1989) and autoimmune T lymphocyte proliferation (Gold et al., 1996). An 
impaired induction of Anx-A1 by GC in monocytes (Morand et al., 1995) and 
lowered Anx-A1 binding capacity in both neutrophils and monocytes were 
observed in rheumatoid arthritis (Goulding et al., 1992). Failure of this 
regulatory system may be due to a defective HPA axis response to 
inflammatory or autoimmune injury resulting in reduced Anx-A1 expression. 
Anx-A1 is also involved in the anti-pyretic actions of GCs in rabbits (Davidson 
et al., 1991) and in the GC inhibiting effect of hyperalgesia mediated by COX-
2 induction in rats (Ferreira et al., 1997).  
Interestingly, clinical data also shows that leukocytes from patients with 
Cushing’s disease, which is associated with higher cortisol levels, have 
elevated intracellular Anx-A1, whilst patients with Addison’s disease, which is 
associated with lower cortisol levels have decreased intracellular levels of 
Anx-A1 in comparasion with healthy controls, suggesting that levels of Anx-
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A1 is mediated by GCs during disease (Mulla et al., 2005). Collectively, GCs 
have been shown to positively regulate the concentrations of Anx-A1, thereby 
assuring an appropriate level of activation of innate immune cells while 
limiting the duration of the pro-inflammatory response. 
 
1.2.6 Anti-inflammatory effects of Anx-A1 
Anx-A1 exerts anti-inflammatory effects in many experimental settings 
(Table 1.2). Anx-A1 was first discovered in an in vitro experiment whereby 
dexamethasone was shown to rapidly reduce the release of arachidonic acid 
through the inhibition of PLA2 and COX-2 enzyme activity, which was 
dependent on the synthesis of a mediatory protein (Blackwell et al., 1980; 
Hirata et al., 1980). These actions of Anx-A1 seem to mimic the activity of 
aspirin. However, it is important to note that in asthmatic patients, aspirin 
provokes pro-inflammatory symptoms such as bronchoconstriction in the lung 
(Lee et al., 2011). Since some reports have demonstrated that Anx-A1 is anti-
inflammatory in allergic inflammatory models (Teixeira et al., 1998; Bandeira-
Melo et al., 2005; Ng et al., 2011; Wang et al., 2011), this leads to the 
question on how Anx-A1 is anti-inflammatory in the lungs. A recent literature 
shows that Anx-A1 down-regulates ERK and NF-κB activity, which leads to 
the inhibition of TNF-induced proliferation and inflammatory responses in lung 
fibroblast (Jia et al., 2013).  
Anx-A1 was also reported to inhibit the synthesis of eicosanoid 
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mediators such as prostaglandins, leukotrines and PAF in in vivo model 
(Fradin et al., 1988; Peers et al., 1993). The role of the endogenous GC 
mediated protein, Anx-A1 was further confirmed via the use of DNA antisense 
oligonucleotides (Croxtall et al., 1994; Perretti et al., 1996a; Solito et al., 
1998b) or by the administration of human recombinant Anx-A1 (Errasfa et al., 
1989) and the KO mice. 
 Anx-A1 plays an important role in regulating neutrophil adhesion and 
transmigration (Perretti et al., 1996b), which are the basis for the 
development of inflammation. The precise role of Anx-A1 during leukocyte 
transmigration has been defined using intravital microscopy techniques. Anx-
A1 promotes L-selectin shedding in the neutrophils and induces detachment 
of the adherent leukocytes in the endothelium (Strausbaugh et al., 2001). 
These actions are crucial to restrict leukocyte transmigration and recruitment 
during inflammation. An important observation reported by Hayhoe and 
colleagues was that full length Anx-A1 had no effect on PMN capture or 
rolling on TNF-α stimulated HUVECS but instead had an effect on cell 
adhesion (Hayhoe et al., 2006). Anx-A1 also possess anti-migratory effects, 
whereby it reduces the α4β1 integrin-dependent monocyte adhesion and 
migration (Côté et al., 2010). However Anx-A1 may produce more than one 
effect as Williams et al., have shown that activated neutrophils release a 
cleaved product from the C-terminus of Anx-A1, which acts to promote 
neutrophil transmigration by inducing the release of intracellular adhesion 
molecule (ICAM-1) on the endothelial surface (Williams et al., 2010). In a 
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zymosan-peritonitis model, the Anx-A1 null mice displayed a higher degree of 
PMN recruitment, which was found to enhance cell emigration using intravital 
microscopy as compared to the wild type mice (Chatterjee et al., 2005). 
Neutrophils isolated from Anx-A1 null mice and the WT cells treated with 
neutralising anti-Anx-A1 monoclonal antibody (mAb), exhibited hyper-
reactivity to stimuli such as chemotactic factors (Chatterjee et al., 2005), 
leading to increased superoxide radical release (Perretti et al., 1995). 
Collectively these data indicate that the anti-inflammatory effects of Anx-A1 
on PMNs may be attributed to their ability to enhance leukocyte detachment 
and inhibit emigration. 
 Several studies have indicated that Anx-A1 is involved in neutrophil 
apoptosis, thus limiting the inflammatory responses (Solito et al., 2003a; 
Ishido, 2005; Petrella et al., 2008). Specific ‘eat me’ signals on apoptotic cells 
contribute as markers for phagocytes to recognise and ingest as a means of 
clearing cell debri. The hallmark of apoptosis is the exposure of 
phophatidylserine (PS) on the outer leaflet membrane and this action inhibits 
the release of pro-inflammatory cytokine, TNF-α, although Il-1β stimulates the 
release of anti-inflammatory cytokines such as TGF-β and IL-10. Past studies 
have highlighted the possibility that Anx-A1 might serve as an endogenous 
PS ligand, thus mediating the engulfment of apoptotic cells, by demonstrating 
that Anx-A1 is recruited to the PS-rich region of apoptotic surface in a 
caspase-dependent mechanism and involves the release of intracellular 
calcium (Arur et al., 2003).  
  57 
The anti-inflammatory effects of Anx-A1 (Figure 1.3) counteract the 
inflammation and ensure a prompt resolution. The complete understanding of 
the effects of Anx-A1 should aid the development therapeutic drugs for the 
resolution of inflammation of both acute and chronic diseases. 
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System Anti-inflammatory effects References 
 
 
 
 
In vitro 
• ↓ cPLA2 activation 
• ↓ Eicosanoid production 
• ↓ Superoxide generation 
• ↓ Phagocytosis 
• ↓ Histamine release 
• ↑ L-selectin shedding 
• ↑ PMN apoptosis 
 
• (Solito et al., 1998b) 
• (Yazid et al., 2009) 
• (Perretti et al., 1995) 
• (Becker et al., 1988) 
• (Yazid et al., 2013) 
• (Parente et al., 2004) 
• (Solito et al., 2003a) 
 
 
 
 
In vivo 
•  ↓ PMN trafficking 
 
• ↓ histamine release 
 
• ↓PMN adherence 
• ↓cytokine generation 
• ↓ hyperalgesia/nociception 
• ↓fever 
• ↑ cerebral protection 
• (Getting et al., 1997; 
Chatterjee et al., 2005) 
• (Bandeira-Melo et al., 
2005) 
• (Perretti et al., 1996b) 
• (Loxley et al., 1993b) 
• (Ferreira et al., 1997) 
• (Davidson et al., 1991) 
• (Gavins et al., 2007) 
 
Table 1.2: Some anti-inflammatory actions of Anx-A1 in both in-vitro and 
in-vivo settings. 
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Figure 1.3: The principal mechanisms of Anx-A1 anti-inflammatory 
actions.  
A) Exogenous Anx-A1 binds to formyl peptide receptors (FPR) to inhibit cell 
adhesion, migration and induce detachment of adherent cells. B) Anx-A1 expression 
and release is up-regulated with GC treatment through the GC receptor (GR) either 
through genomic or non-genomic mechanisms, which contributes to the anti-
inflammatory effects of Anx-A1. GCs induce rapid Anx-A1 phosphorylation via the 
activation of PKC and initiate the membrane translocation of Anx-A1 molecule. C) 
Anx-A1 inhibited the cytosolic phospholipase A2 (cPLA2) and cyclooxygenase 2 
(COX-2), thus exhibiting anti-inflammatory, anti-pyretic and anti-hyperalgesic activity. 
D) Anx-A1 is recruited to the cell surface, where it binds to phosphatidylserine (PS) 
and mediates the phagocytosis of apoptotic bodies (Lim et al., 2007). 
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1.2.6.1 Tools developed to study the role of Anx-A1 
Experiments using neutralising anti-Anx-A1 monoclonal antibody have 
provided substantial evidence that Anx-A1 is a key mediator of GC action in 
both the innate and adaptive immune systems. The acute inflammatory 
response in mice was exacerbated and did not respond to GC treatment in 
the presence of neutralising anti-Anx-A1 monoclonal antibody (Perretti et al., 
1996a). Other reports have demonstrated that the neutralising anti-Anx-A1 
monoclonal antibody reversed GC-mediated inhibition of leukocyte migration 
in mouse peritonitis and air pouch models (Teixeira et al., 1998) as well as 
the anti-inflammatory effects of GC in a rat carrageenin oedema model 
(Duncan et al., 1993) and the GC-induced growth arrest in A549 lung 
adenocarcinoma cell line (Croxtall et al., 1992). Anti-sense RNA to Anx-A1 
has also been employed to explore the Anx-A1 mediated anti-inflammatory 
effects of GC providing data consistent with the above interpretation (Croxtall 
et al., 1994; Taylor et al., 1997).  
Interest in exploiting Anx-A1 as a potential therapeutic target stemmed 
from the fact that administration of exogenous Anx-A1 rescues the 
inflammatory conditions in vivo models of ischaemia reperfusion (Gavins et 
al., 2003). Human recombinant Anx-A1 has been shown to exert anti-
inflammatory effects in a carrageenan-induced edema model of inflammation 
(Wu et al., 1995). Following the discovery that the biological activity of Anx-A1 
could be replicated by the first 26 amino acids of the N-terminus (N-acetyl 2-
26), this peptide is commonly used instead of the full-length recombinant 
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molecule (Cirino et al., 1993). The anti-inflammatory effects of both the 
human recombinant Anx-A1 and peptide Ac2-26 have been demonstrated in 
many models such as ischaemia/reperfusion injury (D'Amico et al., 2000; La 
et al., 2001), mouse air-pouch and rat edema models of inflammation (Cirino 
et al., 1993; Perretti et al., 1993), allergic inflammation models (Bandeira-
Melo et al., 2005), neutrophil and monocyte trafficking models (Szabó et al., 
1997) and pleurisy model in rats  (Teixeira et al., 1998).  
The generation of Anx-A1 null mice by our laboratory has enabled 
researchers to study the functional and crucial role of this protein. The Anx-
A1-/- mouse line was generated by homologous recombination, with a 
transgenic gene that disrupted the Anx-A1 gene, and inserted LacZ gene 
under the control of the Anx-A1 promoter (Hannon et al., 2003). Mice lacking 
the Anx-A1 gene have been reported to have overzealous inflammation with 
an increase in COX-2 and PLA2 expression (Roviezzo et al., 2002) and are 
not responsive to GCs (Croxtall et al., 2003). Anx-A1-/- mice have increased 
inflammatory responses as they display higher levels of inflammatory markers 
in joints (Reddy et al., 2010), increased leukocyte transmigration (Chatterjee 
et al., 2005), increased neutrophil recruitment in peritonitis model of 
inflammation (Damazo et al., 2006), delayed resolution in a model of colitis 
(Babbin et al., 2008) and increased neurological deficit in stroke (Gavins et 
al., 2007). In particular relevance to this thesis, mast cells from the Anx-A1-/- 
mice were shown to exhibit histological signs of constitutive activation and 
increased basal mediator release (Lloret et al., 1994). 
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To further elucidate the role of FPR in the mechanisms of Anx-A1, 
fpr2/3 null mice were generated (Dufton et al., 2010a). Inflammation was 
more marked in the fpr2/3-/- mice with a more pronounced increase in cell 
adherence and emigration in the mesenteric microcirculation following 
ischaemia/reperfusion injury. In the model of carrageenan-induced paw 
edema, an increased acute response was observed in the fpr2/3 null mice in 
relative to the findings from the WT controls. Fpr2/3−/− mice also displayed a 
higher sensitivity to arthrogenic serum and this chronic pathology did not 
resolve over time (Dufton et al., 2010a), suggesting that indeed fpr2/3 is a key 
receptor that mediates a variety of functions during host defense response.  
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1.3 GLUCOCORTICOIDS (GC)   
One anti-inflammatory endogenous mediator, hydrocortisone (cortisol) 
and its synthetic analogues that have been widely used therapeutically in 
chronic inflammatory diseases (Barnes, 2011a).  Despite the great benefits, 
GCs also incur a heavy burden of side effects over a prolonged exposure or 
in inappropriate doses. Nevertheless, GCs remain widely employed in the 
management of many inflammatory and autoimmune diseases.  GCs activate 
many anti-inflammatory genes and repress many pro-inflammatory genes that 
are activated in inflammation (De Bosscher, 2010).  
 The main endogenous GCs are cortisol and corticosterone in 
mammalian species, however the amount produced varies amongst species. 
Cortisol is the predominant GC found in man whereas rodents produce 
corticosterone. Increased levels of cortisol dampen local and systemic 
inflammatory events during inflammation, thereby favouring proper resolution 
of the inflammatory response (Rhen et al., 2005).  
GCs have been described as ‘anti-defensive’ hormones that are 
released during any situation that threatens to compromise the homeostatic 
functioning of the body (Munck et al., 1984; Sapolsky et al., 2000). Correctly 
timed release of GCs is essential for human to respond and recover from 
stress, inflammation, injury or infection. This stress response is independent 
of the existing circadian cycle and varies in magnitude according to the 
nature, intensity and duration of the stimulus (Buckingham et al., 1996).  
The hypothalamus-pituitary axis (HPA) governs the circadian and 
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stress-induced secretion of GCs. The hypothalamus receives and integrates 
neural and humoral information, and thus acts as a sensor to monitor 
changes in the external and internal environment (Figure 1.4). The 
hypothalamus responds to these changes by activating the final common 
pathway to stimulate the synthesis of GC. Two hypothalamic neurohormones, 
corticotrophin-releasing hormone (CRH) and arginine vasopressin (AVP) are 
released into the the portal blood supply and act synergistically via specific 
receptors to trigger the release of adrenocrticotropic hormone (ACTH) from 
the corticotrophs of the anterior pituitary gland into the systemic circulation. 
ACTH then acts on the adrenal cortex to initiate the synthesis of cortisol or 
corticosterone, which is released into the systemic circulation. Since the 
sensitivity of the HPA to incoming stimuli is regulated by a negative feedback 
mechanism, the magnitude of HPA response to stress depends upon the pre-
existing GC in the circulation (Buckingham et al., 1977).  
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Figure 1.4: Interaction networks between HPA axis and the immune 
system via hormonal signals. 
The HPA axis regulates the function of the immune system by releasing ACTH and 
cortisol/cortisone. GCs play an important end point role in the neuroendocrine 
system in regulating the network and affecting immune cells and molecules (Adapted 
from (Kadmiel et al., 2013). 
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1.3.1 Glucocorticoid receptors (GR) 
GCs exert pleiotropic effects on many target cells, tissues and organs 
through specific cytoplasmic and nuclear receptors known as GR.  There are 
two different isoforms that have been cloned, hGRα and hGRβ (Encío et al., 
1991). While closely related to hGRα, hGRβ isoform is located in the nucleus 
and acts as a natural dominant negative inhibitor of hGRα (Kadmiel et al., 
2013). Although hGRβ lacks the GC binding domain (Oakley et al., 1996), it 
has been reported that GR antagonist, RU486 (mifepristone) binds with hGRβ 
and regulates its transcriptional activity (Lewis-Tuffin et al., 2007) 
hGRα resides predominantly in the cytosol but upon GC binding, it 
translocates into the nucleus to play a role as a transcription factor (Adcock et 
al., 2004) or by initiating intracytosolic signal transduction cascades (Solito et 
al., 2003c). In the absence of GC, hGRα exists as a large heteromeric 
complex consisting of the receptor polypeptide, two molecules of hsp90, and 
one molecule of the hsp56 (Nicolaides et al., 2010). The association of hGRα 
with hsp90 maintains the receptor in a conformation that will not bind to DNA, 
but will bind to the GC with high affinity. Whereas, the hsp56 which 
associates with GRα-hsp90 complex, has an important chaperone role 
(Renoir et al., 1990). Once activated, GR exert effects through both genomic 
and non-genomic mechanism, both of which are relevant to the notion that 
Anx-A1 pathway is an important mediator of the anti-inflammatory effects of 
GCs (Perretti et al., 2009). 
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Upon ligand binding, hGRα undergoes a conformational change that 
results in the dissociation of the hsp90 and hsp56.  The receptor translocates 
to the nucleus and binds to specific sequences of DNA known as 
glucocorticoid response elements (GRE), to either activate anti-inflammatory 
genes such as IL-10, Anx-A1 and MAPK or suppress pro-inflammatory 
transcription factors such as AP-1 and NF-kB (Figure 1.5). This action is 
regulated by phosphorylation signals on GR, which contains multiple 
phosphorylation sites in the N-terminal domain (Bodwell et al., 1991; Clark et 
al., 2003).  
Human GR has serine phosphorylation sites on Ser203, Ser211 and 
Ser226 and it had been shown that these sites have enhanced 
phosphorylation in response to GC (Ismaili et al., 2004). Phosphatases such 
as PP2A and PP5 regulate the phosphorylation of GR and indeed a recent 
study have shown that the defects in PP2A causes GC insensitivity in severe 
asthma (Kobayashi et al., 2011).  
In addition to this genomic pathway, GC also exert acute non-genomic 
actions that occur immediately after GR ligation (Song et al., 2006).  It has 
been shown that transgenic mouse expressing mutant form of GR, which 
does not allow translocation of GR upon ligand binding, was still viable 
suggesting that there may be a substantial number of key effects that are 
mediated through such cytosolic-GR actions (Reichardt et al., 1999).   
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Figure 1.5: Schematic diagram of GR activation and genomic actions. 
The inactive GR is localised in the cytoplasm with multiple complex of heat shock 
proteins (hsp). Upon binding with GCs, the GR undergoes a conformational change, 
becomes phosphorylated and then dissociates from the hsp complex to translocate 
to the nucleus. The GR regulates and modulates the inflammatory genes in the 
nucleus by binding to ‘positive’ or ‘negative’ GREs. 
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1.4 MAST CELLS 
1.4.1 Introduction and overview 
Paul Ehrlich made the discovery of mast cells in 1878 and first 
described them on his doctoral thesis. He named them ‘mastzellen’, which in 
German ‘mast’ means fattening, as he believed that these cells had nutritional 
functions because of the granules (Beaven, 2009). Mast cells have long 
fascinated researchers, and part of this attraction seems to be derived from 
the lack of consensus of their exact biological functions.  
Mast cells are derived from CD13+ CD34+ CD117+ haematopoetic 
progenitors in the bone marrow (Metcalfe et al., 1997). However mast cells do 
not circulate in a mature form, instead these cells differentiate and mature in 
the tissues in which they ultimately reside (Kitamura, 1989; Kawakami et al., 
2002). Mast cells are well distributed throughout vascularised tissues, 
especially near surfaces in contact with the external environment such as the 
skin, airways and gastrointestinal tract (Metcalfe et al., 1997). Mast cells are 
similar to monocytes and macrophages, in that they are long-lived cells. 
Following appropriate stimulation mast cells re-enter the cell cycle and 
proliferate. 
Mast cells have been well characterised as initiators of IgE-dependent 
allergic diseases but recently, they have also been shown to actively 
participate in innate and adaptive immune responses to infections and 
inflammatory autoimmune diseases (Galli et al., 1999; Abraham et al., 2010). 
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Mast cells have also been reported to participate in inflammatory responses 
in developing tumors by either enhancing or retarding tumor growth 
depending on the type of cancer (Galinsky et al., 2008; Ribatti et al., 2012).  
Other non-immunological roles for mast cells include promotion of 
angiogenesis, tissue remodelling and wound healing (Noli et al., 2001; Ribatti 
et al., 2011). 
Mast cell degranulation produces a range of characteristics symptoms, 
which are instantaneous and conspicuous. These includes a string of events 
including vasodilatation, oedema, muscle contraction, coughing, sneezing, 
itching, vomiting, diarrhoea and bronchoconstriction (Kaur et al., 2013). 
Histamine and PGD2 release are largely responsible for the typical allergic 
inflammatory symptoms, however PGD2 also inhibits platelet aggregation and 
promotes neutrophil infiltration (Schulman et al., 1983; Kovarova et al., 2004).   
Mast cells possess a phenotypic ‘plasticity’, which is characterised by 
their survival, proliferation, and susceptibility to activation by various stimuli.  
The ability of these cells to store or produce various secreted mediators and 
the magnitude of inflammatory responses produced upon activation are ‘fine-
tuned’ by differential expression of receptors and granule constituents (Galli 
et al., 2005a).  Precisely how the mast cells adapt in different immunological 
or pathological settings remains a matter for debate. However it is now 
evident that the interaction between surface receptors and the alternative or 
complementary intracellular signalling pathways profoundly determines the 
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relative composition and amount of mediators released from activated mast 
cells (Gilfillan et al., 2011).  
Although the activation of mast cells due to the endogenous and 
exogenous stimuli is a protective mechanism, it could be detrimental in an 
allergic individual. Pioneering work from Galli’s laboratory have highlighted 
the immunomodulatory role of mast cells and these cells have earned the 
sobriquet of  ‘double-edged sword’ because of their ability to possess both 
negative, as well as positive, immunomodulatory roles (Galli et al., 2008). 
  
1.4.2 Mediators released and generated by mast cells 
The acute reactions that occur during mast cell activation are triggered 
by the constitutive release of granules from mast cells and the generation of 
lipid derived mediators. Histamine is the prevalent granule mediator that 
initiates the acute reactions due to mast cell activation even though mast cell 
proteases, such as tryptase, chymase and carboxypeptidase constitute 
approximately 30-50% of the total protein content of mast cells. Chronic 
symptoms associated with mast cells are an outcome of the delayed 
generation of chemokines, cytokines and growth factors (Iwaki et al., 2005b). 
The process of mast cell degranulation occurs within seconds of mast cell 
activation and the initial rapid phase is essentially complete within 5-10 min. 
The late phase reaction develops 2-6 h after exposure of allergen reflecting 
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on the local recruitment and activation of Th2 cells, basophils, leukocytes and 
mast cells. 
1.4.2.1 Preformed mediators in granules 
Mast cells generate and release a group of pre-formed mediators, such 
as biogenic amines, lysosomal enzymes, proteoglycans and proteases 
(Figure 1.3). These mediators are heterogenous, pleiotropic and redundant in 
that each mediator may have more than one function and the biological 
effects initiated by the mediators may overlap between one another (Metcalfe 
et al., 1997).  
 
1.4.2.1.1 Biogenic amines 
The principal biogenic amines found in the mast cells are histamine, 
serotonin and dopamine. 
I) Histamine 
Histamine was first discovered to be present in the tissue mast cells by 
Riley and West (RILEY et al., 1952). Histamine is sequestered in mast cell 
granules by proteoglycans such as heparin and chondroitin E. Storage of 
histamine is not exclusive to mast cells and basophils as it has been 
previously demonstrated that histamine is present in a variety of cell types 
that expresses histidine carboxylase (HDC) such as gastric cells, 
histaminergic nerve cells, lymphocytes, monocytes, platelets, dendritic cells 
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and neutrophils (MacGlashan, 2003; Jutel et al., 2005). Histamine modulates 
cellular activity in many tissues including the dermis, small intestine, stomach, 
lung and brain. In the mast cells, the classical pathway for histamine release 
is in response to antigen exposure whereby the surface Fc receptor would 
bind and crosslink with IgE, resulting in the liberation of large amounts of 
histamine (10-5 to 10-3 molL-1) during the early allergic response (Jones et al., 
2011). 
Histamine exerts its biological effects by binding to histamine 
receptors, which are found in many tissues (Lippert et al., 2004). There are 
four specific histamine receptors (H1, H2, H3 and H4) and the effects produced 
by histamine expression depend on the subtype of receptor involved. All 
histamine receptors are members of the G-protein coupled receptors (GPCR) 
family and are coupled to a specific G-protein, resulting in the activation or 
inhibition of specific pathway (Akdis et al., 2006).  
The role of the H1 receptor is well characterized within the context of 
allergic inflammation. Liganding of this receptor is followed by activation of 
the inositol-1,4,5-pathway which leads to the formation of inositol-1,4,5-
triphosphate (IP3) and diacylglycerol (DAG), hence mobilization of intracellular 
calcium. This causes the vascular endothelium to release nitric oxide, which 
in turn results in vasodilatation, erythema, increased vascular permeability 
and edema (Li et al., 2003). The activation of the H1 receptor also causes 
stimulation of sensory nerve endings and leads to the itching sensation of the 
  74 
mucosa and dermis (Schmelz et al., 1997). H1 receptor occupancy in 
bronchial smooth muscles leads to bronchoconstriction.  
The H2 receptor is expressed on gastric mucosal cells, vascular 
smooth muscle, brain, adipocytes and immune cells. Activation of this 
receptor results in relaxation of smooth muscle in the airway and vasculature 
(Akdis et al., 2006). This receptor has also been reported to be involved in the 
regulation of cell proliferation, particularly in carcinoma cells. However the 
most studied physiological response of H2 receptor is gastric acid secretion, 
and this receptor is involved in the regulation of gastric motility and intestinal 
secretion of bicarbonate through the inhibition of prostaglandin E2 (PGE2). 
Whereas in the cardiovascular system, activation of this receptor causes 
decreased chronotropic and ionotropic effects (Del Valle et al., 1997).  The H2 
receptor also regulates the immunoregulatory function of histamine as it has 
been shown that the activation of this receptor has inhibitory actions on the 
chemotaxis of neutrophils, basophils and eosinophils (Jones et al., 2011). 
Interestingly, it has been demostrated that H2 receptor may have 
immunosuppressive effects in the control of inflammation induced by 
histamine (Jutel et al., 2001) because Th1 and Th2 cells are negatively 
regulated by this receptor (Seligmann et al., 1983).  
The H3 receptor was discovered in 1983 (MacGlashan, 2003) and 
cloned in 1999, and was found to be expressed not only on histaminergic 
neurons but also on eosinophils, monocytes and dendritic cells (Lovenberg et 
al., 1999). This receptor regulates the neuronal-mast cell feedback loop by 
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mediating the synthesis of histamine and inhibition of its release from 
histaminergic neurons. The H3 receptor has been implicated in regulation of 
sleep-wake cycles (Griebel et al., 2012), obesity (Hancock, 2003), cognition 
(Fox et al., 2003) and allergic rhinitis (Suzuki et al., 2008). Exploitation of this 
receptor could lead to a potential therapeutics in the field of neuro-
inflammatory research.  
The H4 receptor is the latest addition to the histamine receptor family. It 
was identified in 1994 and cloned in 2000 (Nijmeijer et al., 2012). The H4 
receptor shares 35% amino acid homology to H3 receptor. This receptor is 
expressed on eosinophils, basophils, T-cells, monocytes, mast cells, spleen, 
thymus, small intestine, colon and heart (Akdis et al., 2003; Akdis et al., 
2006). The physiological functions of H4 receptor demonstrated so far are on 
eosinophils (Ling et al., 2004a), mast cells (Hofstra et al., 2003) and 
monocyte-derived dendritic cell chemotaxis (Gutzmer et al., 2005), regulation 
of T-cells or dendritic cell functions and mast cell dependent neutrophil 
migration (Takeshita et al., 2003). Activation of this receptor leads to the 
calcium ion mobilization in mast cells and inhibition of cAMP increase (Hofstra 
et al., 2003). A separate study has shown that activation of the H4 receptor 
induces mitogen-activated protein kinase (MAPK) phosphorylation, which was 
inhibited by pertussis toxin (Morse et al., 2001). The H4 receptor may play a 
role in pruritis as it was demonstrated that H4 receptor knock-out mice 
experienced significantly lesser pruritis after exposure to exogenous 
histamine as compared to the wild type mice, and that treatment with a 
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selective H4 receptor inverse agonist significantly reduced the itch (Dunford et 
al., 2007). 
An elegant study by Thurmond et al demonstrated the importance of 
H4 receptor in mast cell chemotaxis (Thurmond et al., 2004). Experimental 
mice were challenged with aerosolised histamine to mimic the allergic 
response in the lungs and a redistribution of mast cells in the tracheal 
epithelium was observed. This effect was blocked by systemic administration 
of a known selective H4 inverse agonist. 
	  
II) Serotonin  
Serotonin is a bioactive mediator associated with many physiological 
processes including immunomodulation (Arzt et al., 1988), cell growth and 
development, mast cell adhesion and chemotaxis (Kushnir-Sukhov et al., 
2006), tumor growth (Siddiqui et al., 2005), and tissue regeneration (Lesurtel 
et al., 2006). Serotonin binds to the 5-hydroxytryptamine (HT) receptor, which 
mediates both excitatory and inhibitory neurotransmission. Serotonin is 
synthesized by the hydroxylation of tryptophan, in a reaction catalysed by 
tryptophan hydroxylase (TPH). Several functions of serotonin have been 
elucidated in animal strains lacking TPH1 and TPH2 (Alenina et al., 2009), 
which are the two crucial isoforms of tryptophan hydroxylase (TPH). TPH1 
appears to be the more predominant isoform in mast cells and its levels 
correlates well with the degree of mast cell maturation (Ringvall et al., 2008). 
The notion that serotonin was mainly found in the granules of rodent mast cell 
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and that human mast cells lacked stored serotonin (SJOERDSMA et al., 
1957)  has recently been challenged by Metcalfe and colleagues, who 
demonstrated that human peripheral blood-derived mast cells contains 
serotonin and plasma serotonin levels were elevated in patients suffering 
from mastocytosis (Kushnir-Sukhov et al., 2007).	  
	  
III) Dopamine 
To date there has been very little evidence that suggest that dopamine 
is synthesized and stored in mast cells. However it has been shown that mast 
cell activation results in the depletion of cell-associated dopamine (Lesurtel et 
al., 2006), although mRNAs coding for the enzymes that catalyses the 
formation of dopamine has not been identified in mast cells (Lundequist et al., 
2011).  
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Preformed mediators stored in MC secretory granules 
 
1. Biogenic amines 
• Histamine 
• Serotonin 
• Dopamine 
 
2. Lysosomal enzymes 
• β-hexosaminidase 
• β-glucuronidase 
• β-D-galactosidase 
• Arylsulfatase A 
• Cathepsin C 
• Cathepsin B 
• Cathepsin L 
• Cathepsin D 
• Cathepsin E 
 
3. Proteoglycans 
• Serglycin (with heparin and/or chondritin sulphate 
GAG chains) 
 
4. Proteases 
• Chymase 
• Tryptase 
• MC-CPA 
• Cathepsin G 
• Granzyme B 
• MMP-9 
• Renin 
 
 
Table 1.3: Main preformed mediators, which are stored in the secretory 
granules of mast cells. 
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1.4.2.1.2 Lysosomal enzymes 
A variety of enzymes have been localized to mast cell granules as 
evidenced by histochemical techniques and subcellular fractionation. Mast 
cell secretory granules are quite similar to lysosomes in terms of their acidic 
pH and membrane components such as vesicle associated membrane 
protein (VAMP-8) and soluble NSF attachment protein receptor (SNARE) 
proteins; hence these granules are often referred to as ‘secretory lysosomes’ 
(Puri et al., 2008; Tiwari et al., 2008). The biological functions of lysosomal 
enzymes in mast cells has not been well elucidated yet, however these 
enzymes might have a role not only in the normal intracellular turnover of the 
cells but also in the extracellular sequence of mast cell degranulation 
(Lundequist et al., 2011). The most ubiquitous lysosomal enzyme present in 
mast cells is β-hexosaminidase, thus its release is frequently used as means 
of quantifying the extent of mast cell degranulation. Other lysosomal enzymes 
present in mast cells are a number of saccharide-degrading enzymes, 
including β-glucuronidase, β-galactosidase and arylsulfatase A (Schwartz et 
al., 1981).  
Recent studies have also shown that mast cell granules contain 
lysosomal proteases such as cysteine cathepsins (cathepsin C, B and L) 
(Dragonetti et al., 2000; Wolters et al., 2000) and aspartic acid proteases 
(cathepsin D and E) (Dragonetti et al., 2000; Henningsson et al., 2005). IgE-
mediated mast cell degranulation was shown to induce the release of 
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cathepsin B, D, and L (Dragonetti et al., 2000), thus further indicating their 
presence in the secretory granules. 
Traditionally, lysosomal enzymes have been considered to be mainly 
active within the acidic environment of lysosomes and then to become rapidly 
inactivated after exposure to extracellular pH. However, recent studies have 
revealed that several lysosomal cathepsins possess significant enzymatic 
activity even after cellular release (Turk et al., 2001). Hence, the extracellular 
functions of lysosomal enzymes should not be disregarded.  
 
1.4.2.1.3 Proteoglycans 
The major constituents of mast cell granules are serglycin 
proteoglycans, which contain a protein core that is attached to heavily 
sulfated and negatively charged glycosaminoglycan (GAG) side chains. The 
expression of serglycin varies depending on cell types. In the connective 
tissue-type mast cells of rodents, highly sulfated GAGs of heparin are more 
prevalent, whereas in mucosal mast cells, chondroitin sulfate is the 
predominant GAG component of serglycin (Yurt et al., 1977; Enerbäck et al., 
1985). However, in human mast cells, serglycin contains both heparin and 
chondroitin sulfate in a ratio of 2:1 (Metcalfe et al., 1979; Thompson et al., 
1988).  
A unique characteristic of mast cell serglycin is that the GAG chains 
have a high level of sulfation as compared to serglycins from other cell types. 
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This feature enables them to form tight electrostatic interactions with other 
basic compounds that co-exist in the granules. Even though the reason for 
this is not completely understood, recent research has shown that mast cell 
maturation correlates positively with the expression of chondroitin sulfate and 
heparin sulfotransferases (Duelli et al., 2009).  
 The high degree of overall sulfation by mast cell serglycin results in an 
elevated total anionic charge density, which forms the basis for the strong 
staining with cationic dyes (Braga et al., 2007). Histologically, mast cells are 
easily distinguished by their strong granular staining with various cationic 
dyes such as Toluidine blue, Alcian blue, Berberine sulphate and May 
Grünwald/Giemsa. The staining with these dyes are explained by their strong 
binding to serglycin present in mast cell granules as it had been previously 
demonstrated that the mast cells from serglycin null mice completely lacked 
metachromatic staining (Abrink et al., 2004).  
 
1.4.2.1.4 Proteases 
Mast cell proteases accounts for more than 25% of the total protein 
content of mast cells, thus representing the major group of mediators 
released during mast cells degranulation (Schwartz et al., 1987). Even though 
a myriad of potential functions of mast cell proteases have been previously 
outlined, it is only recently that the in-vivo functions of these proteases have 
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been clarified by experimental approaches using mast cell protease deficient 
mice (Pejler et al., 2007). 
The proteases expressed specifically by mast cells include tryptase, 
chymase and carboxypeptidase A. Indeed, mast cells also express a number 
of additional non mast cell-specific proteases such as lysosomal cathepsins, 
granzyme B (Pardo et al., 2007), neurolysin (Pejler et al., 2007), cathepsin G 
(Schechter et al., 1990; Schechter et al., 1994), matrix metalloprotease 9 
(MMP 9) (Baram et al., 2001) and renin (Silver et al., 2004). It is noteworthy 
that the specific mast cell protease repertoire differs between mast cell 
subsets depending largely on phenotype and distribution of mast cells within 
the tissue.  
In humans, mast cells are classified according to their protease 
content, with the MCT subclass expressing tryptase only and the MCTC 
subclass expressing tryptase, chymase and carboxypeptidase A (Irani et al., 
1986). Past research has shown that the mast cells derived from the cord 
blood exhibit a phenotype in common with MCTC subclass of human mast 
cells (Nilsson et al., 1996). However in mouse, mast cells are sub-divided into 
the connective tissue mast cell (CTMC) and mucosal mast cell (MMC) 
subtypes. Storage of mast cell proteases are highly efficient, made possible 
by their tight packaging in complexes with serglycin proteoglycan (Pejler et 
al., 2009). In support of this notion, the deletion of the serglycin gene was 
shown to almost completely eradicated the ability of mast cells to store mast 
cell proteases (Abrink et al., 2004).  
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Recent studies with the mast cell-protease null mouse strains have 
highlighted the important roles of these enzymes.  There are two main 
enzymatically active tryptases, α- and β- tryptase, that are released during 
mast cell degranulation. The study of the biological functions of tryptase was 
made possible through the generation of mouse strains deficient in mMCP-6, 
the murine tryptase that shares a close homology to the human β- tryptase 
(Stevens et al., 2007). Past studies have demonstrated that tryptase 
contributes to the elimination of parasitic infestations by the innate immune 
response although it is not essential (Shin et al., 2008). Although mast cells 
play an important role in the defence against bacterial infections, the 
mechanisms by which this occurs have not been convincingly elucidated. 
Given the ability of mMCP-6 to recruit neutrophils, Thakurdass et al reported 
that indeed, mMCP-6 contributes to the defense againts intraperitoneal 
bacterial infection by inducing neutrophil infiltration, which was only evident 
during the early phases of infection, in line with the postulated primary role of 
mast cells as the first-line of defence against bacterial invasion (Thakurdas et 
al., 2007). An elegant study was conducted by McNeil et al to understand the 
role of mast cells in experimentally induced arthritis (McNeil et al., 2008). The 
authors have shown that mMCP-6-/- mice developed less severe joint 
inflammation as compared to the wild type mice when arthritis was passively 
induced by methyl-bovine serum albumin/interleukin 1β (IL-1β). A similar 
observation was noted in the K/BxN model of arthritis, whereby mMCP-6-/- 
mice developed lower clinical scores, inflammation and bone/cartilage 
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erosions as compared to the wild type strain. Even though these studies 
indicate that mast cell tryptase plays an important role in the development of 
arthritis, the involvement of tryptase in other models of arthritis such as by 
immunization of collagen II is yet to be investigated. 
Chymase, which is fairly selectively expressed by mast cells, has been 
associated in various pathological conditions (Caughey, 2007). To further 
investigate the role of chymase in human diseases, mouse strains deficient in 
mMCP-1, mMCP-4 and mMCP-5 genes have been generated. However, it is 
extremely important to determine which of the murine chymase enzymes 
shares the most sequence similarity with the human chymase. Even though 
mMCP-5 is the closest homolog to the human chymase, cleavage specificity 
investigations have revealed that this enzyme has elastase, rather than 
chymotrypsin-like substrate specificity. Hence mMCP-5 is not considered to 
be a functional homolog to human chymase (Kunori et al., 2002). mMCP-2 
strains have been reported to have different homology to the human chymase 
(Andersson et al., 2008b). Whereas the mMCP-4 gene has similar tissue 
redistribution, substrate cleavage specificity and serglycin-binding properties 
compared to human chymase (Andersson et al., 2008a; Andersson et al., 
2009). Collectively, these facts indicate that mMCP-4 is the closest functional 
homology to the human chymase and thus the mMCP-4 null mice would be a 
more relevant tool to elucidate the function of human chymase. Studies have 
shown that the phenotype of mMCP-4 null strain leads to less severe 
collagen induced arthritis (Magnusson et al., 2009), increased susceptibility to 
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allergic airway inflammation (Waern et al., 2009), decreased development of 
abdominal aortic aneurysm (Sun et al., 2009), increased tissue accumulation 
of extracellular matrix (ECM) due to the defective fibronectin (Tchougounova 
et al., 2003; Tchougounova et al., 2005) and reduced basal intestinal 
permeability (Groschwitz et al., 2009). Taken together, it cannot be excluded 
that other murine chymases might mimic the corresponding functions of 
chymase in human.   
Another mast cell protease is carboxypeptidase A (MC-CPA), which is 
a highly conserved secretory granule. The tissue location and other 
properties of MC-CPA enzyme between human and mouse are similar 
(Feyerabend et al., 2005), thus it is probable that functions of this gene 
determined in the MC-CPA null mouse would correspond to that of the human 
counterpart. Previous studies using MC-CPA knock-in strains and shRNA 
approach have shown that MC-CPA may play a role in the clearance of 
endothelin-1, an endogenous peptide released during bacterial infection 
(Maurer et al., 2004; Schneider et al., 2007) and degradation of certain snake 
venom toxins (Metz et al., 2006).   
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1.4.2.2 Eicosanoids and reactive oxygen species  
Mast cell activation also provokes acute de novo synthesis and release 
of lipid mediators such as eicosanoids. Upon stimulation with antigen, 
complement or other stimuli, mast cells release eicosanoids, growth factors 
and various cytokines and chemokines (Table 1.4). Among the known lipid 
mediators of mast cell, eicosanoid plays a prominent role.  
It has been established that mast cells release eicosanoids such as 
prostaglandin (PG) D2, leukotriene (LT) B4, and LTC4 (MacGlashan et al., 
1982; Peters et al., 1984; Murray et al., 1986) in response to appropriate 
stimuli. These eicosanoids are derived from arachidonic acid (AA), a 20-
carbon fatty acid released from the nuclear membrane phospholipids by 
cytosolic phospholipase A (cPLA2) (Clark et al., 1995). This functional 
activation requires intracellular calcium flux and phosphorylation of mitogen-
activated protein kinases (MAPKs) (Berenbaum et al., 2003).  When released 
each eicosanoid acts through specific G-protein coupled receptors (GPCRs) 
which in turn, regulate certain functions of mast cells through paracrine, 
autocrine and intracrine mechanisms (Boyce, 2007). These diverse lipid 
mediators are capable of initiating, amplifying or dampening the inflammatory 
responses. The magnitude, duration and nature of the subsequent immune 
responses are also regulated by eicosanoids released from mast cells. 
 PGD2 is the major cyclooxygenase (COX) metabolite of arachidonic 
acid that is released upon stimulation of mast cells. COX-1 and COX-2 are 
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both expressed in mast cells and the latter can be upregulated by interleukin 
(IL)-1β, suggesting a mechanism that can augment PGD2 production under 
inflammatory conditions.  
When atopic human subjects are challenged with specific allergen, the 
level of PGD2 is increased in the bronchoalveolar lavage (BAL) fluid (Wenzel 
et al., 1989). The amounts of 9α, 11β-PGF2 which is the primary PGD2 
metabolite and which shares the biological activity of its parent compound 
(Beasley et al., 1987) is also elevated in both serum and urine of patients with 
allergen-induced activation of mast cells (Bochenek et al., 2004). PGD2 was 
reported to induce bronchoconstriction at levels 10-fold lower than histamine 
when administered by inhalation to patients with asthma (Hardy et al., 1984) 
and to cause wheal-and-flare responses in the skin of atopic individuals 
indicating that PGD2 also has a role at the microvasculature (Soter et al., 
1983). To further elucidate the role of PGD2, animal models lacking DP1 and 
DP2 receptors for PGD2 have been generated. The human DP1 receptor 
mRNA is highly expressed in retina and small intestine (Boie et al., 1995) 
whereas the DP2 receptor is expressed almost by all tissues, however it is 
most abundant in heart, brain, stomach, adrenal gland, liver, small intestine, 
thymus and placenta (Sawyer et al., 2002).  
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Newly synthesised mast derived mediators 
 
 
1. Lipid-derived 
• Leukotrine B4 (LTB4) 
• Leukotrine C4 (LTC4) 
• Prostaglandin D2 (PGD2) 
 
 
2. Cytokines 
• Tumor necrosis factor (TNF)-α 
• Ganulocyte macrophage colony stimulating factor 
(GM-CSF) 
• IL-3 
• IL-4 
• IL-5 
• IL-6 
• IL-10 
• IL-13 
 
 
3. Chemokines 
• CCL2 
• CCL3 
• CCL5 
• CCL8 
 
 
4. Growth factors 
• SCF 
• FGF 
• VEGF 
• Angiogenin 
 
 
Table 1.4: De novo synthesized mast cell mediators. 
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1.4.2.3 Cytokines and chemokines 
It is clear from the seminal observations of several investigators, that 
cytokines are generated and stored within the secretory granules of mast 
cells (Burd et al., 1989; Plaut et al., 1989; Gordon et al., 1990a). Mast cell 
degranulation augments gene expression, which leads to the generation of a 
range of cytokines including tumor necrosis factor- α (TNF-α) (Gordon et al., 
1990b), granulocyte macrophage-colony stimulating factor (GM-CSF), IL-3, 
IL-4, IL-5, IL-6, IL-10 and IL-13 (Renauld, 2001).  
Chemokines such as CCL2, CCL3, CCL5 and CXCL8 and growth 
factors such as stem cell factor (SCF), fibroblast growth factor (FGF), 
vascular endothelial growth factor (VEGF) and angiogenin are released by 
mast cells during activation. There has also been increasing appreciation that 
mast cell activation can be regulated by these cytokines, chemokines and 
growth factors (Katsanos et al., 2008).  
Types of growth factors released upon mast cell degranulation include 
TGF-β (Lindstedt et al., 2001), nerve growth factor (NGF) (Leon et al., 1994), 
SCF (Zhang et al., 1998)  and IL-4 (Horsmanheimo et al., 1994) from various 
types of mast cells.  
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1.4.3 Mast cells activating ligands, receptors and signalling 
Antigen-dependent mast-cell activation is regulated by a complex 
series of intracellular signalling processes that is initiated following FcεRI 
aggregation. Although the immediate receptor-upstream signalling events 
seem to be common for mast cell degranulation, the receptor-downstream 
signalling events must converge to regulate the different mechanisms by 
which these mediators are released (Figure 1.7).  
 
1.4.3.1 High affinity receptor for IgE, FcεR1 
Mast cells play a part in a diverse array of physiological and 
pathological processes by responding to many different stimuli, such as stem 
cell factor (SCF), IL-3, lipopolysaccharide (LPS), certain products of 
complement activation and neuropeptides as a result of activation of their 
various receptors (Kitamura, 1989; Galli et al., 1994; Metcalfe et al., 1997). 
Nonetheless, the most researched mechanism by which mast cells execute 
immunological functions is through the antigen- and Ig-E-dependent 
aggregation of high affinity IgE receptor, FcεR1 (Galli et al., 2005a). 
Activation of this receptor leads to the downstream events that result in the 
generation or release of mast cell mediators (Gilfillan et al., 2006) and mast 
cell chemotaxis (Kuehn et al., 2010). However, it has been previously noted 
that FcεR1 also influences mast cell biology indirectly as monomeric IgE 
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promotes mast cell survival (Asai et al., 2001; Kalesnikoff et al., 2001), 
induces cell migration (Kitaura et al., 2005) as well as the generation of 
cytokines (Matsuda et al., 2005). 
FcεR1 (Figure 1.6) is a heterotetrametric receptor, comprising of IgE-
binding α subunit, four transmembrane-spanning β subunits, and two identical 
disulphide linked γ subunits (Turner et al., 1999). Monomeric IgE binds to 
FcεR1 with very high affinity, thus this complex is retained for long duration, 
thereby setting the platform for immediate allergic reactions or inflammatory 
response upon contact with antigen. The β subunits amplify the signalling 
events induced by IgE- and Ag complex and the γ subunits are essential for 
instigating the downstream signalling events because they contain one 
immunoreceptor tyrosine-based activation motif (ITAM) (Turner et al., 1999; 
Nadler et al., 2000).  
Coordinated orchestration of sequential, parallel and interacting 
signalling pathways are required to release all the major inflammatory 
mediators from mast cells. Indeed, it is the divergence of these pathways that 
allows chemotaxis or the release of one type of mediator in the absence of 
the others. Even though the pathways governing the mast cell activation are 
complex, they can be broadly divided into the following categories. 
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Figure 1.6: The subunits of FcεR1. 
FcεR1 comprises of one α subunit, four β subunits and two γ subunits. This receptor 
binds to IgE with high affinity. 
 
I) FcεR1 β and γ phosphorylation leading to Syk recruitment/activation  
Signalling events following FcεR1 aggregation require the initial 
phosphorylation of specific tyrosine residues in the immunoreceptor tyrosine-
based activation motifs (ITAMs) contained within the β and γ chains of the 
FcεR1. This leads to the recruitment of the proto-oncogene tyrosine-protein 
kinase Src family kinases, Lyn (Eiseman et al., 1992; Vonakis et al., 2005) 
and Fyn (Parravicini et al., 2002) to the β chain and spleen tyrosine kinase 
(Syk) to the γ chain homodimer (Shiue et al., 1995). Even though it has been 
suggested that the main kinase responsible for this initial phosphorylation is 
Lyn, there is convincing evidence suggesting that other kinases may 
alternatively regulate this compulsory event (Odom et al., 2004). However, 
the recruitment of Syk to the phosphorylated γ chains and the sequential 
downstream activation is a mandatory event for mast cell activation. 
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II) The LAT/PLCγ-Calcium/PKC Axis 
The receptor-signalling complex is synchronised through a series of 
constitutive and inducible protein-protein and protein-lipid interactions through 
a network of transmembrane and cytosolic adapter proteins (Iwaki et al., 
2005a). These interactions occur in glycolipids enriched localised regions, 
known as lipid rafts (Dráber et al., 2002; Sengupta et al., 2007). The ability of 
surface receptors to preferentially engage specific adaptor molecules to 
recruit a particular signalling element is reflected by the underlying capacity of 
these receptors to independently regulate the release of specific mast cell 
mediators.  
 The major substrate for Syk is the transmembrane adaptor molecule 
linker of activated T cells (LAT), but it is also the central regulator of the 
downstream events necessary for mast cell activation upon FcεR1 
aggregation (Wonerow et al., 2001). Syk and potentially other kinases 
phosphorylate LAT and the latter recruits phospholipase γ1 (PLCγ1) and the 
cytosolic adaptor molecules SLP76 and indirectly GRB2-related adapter 
protein (Gads) (Silverman et al., 2006). This interaction is considered vital, as 
it was previously demonstrated that there was a pronounced attenuation of 
the ability of antigens to elicit calcium response, mast cell degranulation and 
generation of cytokines in the mast cells derived from lat-/- (Saitoh et al., 
2000), slp-/- (Pivniouk et al., 1999) and gads-/- (Yamasaki et al., 2008) mice.  
PLCγ exists as two isoforms, which is PLCγ1 and PLCγ2. Both of these 
isoforms are expressed in mast cells and activated following FcεR1 
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aggregation, even though PLCγ1 is the more dominant form in human (Wilde 
et al., 2001). PLCγ activation leads to the hydrolysis of the membrane-
asscociated phospholipid, phosphoinositide 4,5 biphosphate (PIP2) thus 
liberating inositol triphosphate (IP3) and diacylglycerol (DAG) (Choi et al., 
2007). This events leads to the release of calcium from endoplasmic 
reticulum, and activates PKC isoforms, which are crucial for mast cell 
activation (Ozawa et al., 1993; Ma et al., 2009). The extracellular calcium 
influx is essential for a variety of downstream signalling processes not only 
triggering mast cell degranulation (Ashmole et al., 2013) but also for the 
generation of other mediators and for cell chemotaxis (Ma et al., 2011). 
Calcium is also critical for the activation of PLA2, which is essential for the 
generation of arachidonic acid leading to eicosanoid generation and cytokine 
production (Di Capite et al., 2011). 
 
III) The PI3K/BTK Axis 
The phosphatidylinositide 3-kinase/Brutons’ tyrosine kinase 
(PI3K/BTK) axis governs the maintenance and amplification of the signal 
derived from the activation of PLCγ (Iwaki et al., 2005b). Even though the 
initial phase of calcium signal mediated by PLCγ is unaltered by the inhibition 
of PI3K, the maintenance of this signal has significantly reduced following the 
depletion of PI3K (Ali et al., 2004).   
PI3K is recruited to the signalling complex following the Fyn-dependent 
binding of PI3K to Gab2 (Yu et al., 2006). The membrane localisation of the 
  95 
specific signalling molecule is promoted through the generation of 
phosphatidylinositol 3, 4, 5 triphosphate (PIP3), which bind to the pleckstrin 
homology (PH)-domains (Kim et al., 2008). Btk is activated once it is recruited 
to the cell membrane, and this activation further increases PLCγ activity and 
reinforces its capacity to promote calcium signal (Kuehn et al., 2010).  
The multifaceted role of PI3K is revealed through experiments utilising 
mouse mast cells expressing catalytically inactive PI3K or using PI3K 
inhibitors. PI3K regulates not only mast cell degranulation but also the 
generation of reactive oxygen species (ROS), eicosanoid and cytokine 
production, cell growth and survival, cell adhesion and chemotaxis (Kim et al., 
2008; Kuehn et al., 2008).  
 
IV) MAP kinase pathways and transcriptional regulation. 
The activation of the mitogen-activated protein (MAP) kinase pathways 
is crucial for receptor-mediated generation and release of cytokines, 
chemokines, growth factors and other proteins in mast cells. There are three 
major MAP kinase pathways, that is the extracellular signal regulated kinase 
(ERK), c-jun N-terminal kinase (JNK), and p38, which regulates the activity of 
numerous transcription factors important for cytokine production and the 
activity of PLA2 (Gilfillan et al., 2009).    
All these MAP kinases pathways are activated through the Ras-Raf 
pathway in antigen stimulated cells. The Ras-Raf-MAP kinase pathway and 
the PI3K-regulated signalling network contribute to the activation of the 
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transcriptional factors, which includes fos and c-jun (Turner et al., 1997; 
Novotny et al., 1998). These signalling cascades are vital to the generation 
and release of cytokines and chemokines (Gilfillan et al., 2006).  
Both PKC and calcium, which are regulated by the 
LAT/PLCγ1/calcium/PKC axis also contributes to transcriptional regulation 
independent of MAP kinases and PI3K (Gilfillan et al., 2006). The signal 
transduction events induced by these stimuli can interact with those initiated 
through FcεR1 to enhance cytokine production without altering degranulation 
(Qiao et al., 2006; Andrade et al., 2011).  
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Figure 1.7: Schematic representation of FcεRI-mediated mast cell 
activation.  
Mast cell FcεRI aggregation by receptor-bound IgE with an antigen leads to the 
phosphorylation of the receptors ITAMS by kinase Lyn. Sky is recruited to the 
complex and phosphorylates LAT, which activates PLCγ to degrade PIP2 to IP3 and 
DAG. IP3 induces intracellular Ca2+ mobilisation followed by extracellular influx whilst 
DAG activates PKC isoforms. LAT also serves as a docking site for adapter 
molecules, which leads to a downstream activation of MAP kinases (JNK, p38 and 
ERK). These sequential events lead to mast cell degranulation, cytokine and lipid 
mediator production (Karra et al., 2011).  
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1.4.3.2 C-kit receptor 
C-kit receptor is a growth factor receptor. Activation of this receptor is 
not only essential for the mast cell growth, differentiation and survival, but it is 
also extremely important for mast cell migration or homing through 
chemotaxis. The c-kit receptor consists of a single chain receptor with five 
extracellular immunoglobulin-like domains and a tyrosine kinase catalytic 
domain in the cytosolic tail. Binding of the c-kit receptor and its specific 
ligand, stem cell factor (SCF) triggers the catalytic activity and downstream 
signalling cascade. SCF is found in two major forms, the soluble form and the 
membrane-bound form. This ligand is primarily expressed by fibroblast but is 
also generated by mast cells and other tissues.  
 Under experimental conditions, SCF itself can regulate mast cell 
degranulation and cytokine production (Bischoff et al., 1992; Hundley et al., 
2004) However, some previous studies have shown that the signals 
generated by the activated c-kit receptors are insufficient to induce 
degranulation alone and need to be accompanied by other mast cell 
stimulants to trigger this effect.  Nonetheless, c-kit receptors could induce the 
generation of cytokines without the presence other stimulants (Hundley et al., 
2004; Tkaczyk et al., 2004). Additionally, SCF and monomeric IgE can 
promote mast cell degranulation synergistically, although neither can induce 
degranulation on their own (Cruse et al., 2005).  
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 The signalling pathways elicited by c-kit receptor ligation does overlap 
with those induced by FcεR1, although c-kit is unable to compensate for the 
critical signals required to induce mast cell degranulation (Hundley et al., 
2004). Even though, c-kit activates Src kinases, PLCγ, PI3K and MAPK 
cascade (Iwaki et al., 2005b), it is not able to recruit and activate Syk, 
phosphorylate LAT (Tkaczyk et al., 2004) and activate PKC (Hundley et al., 
2004). These absent or weak signals account for the inability of c-kit to 
produce mast cell degranulation.  However, in the presence of FcεR1 
aggregation, c-kit potentiates degranulation by other agents and cytokine 
generation.  
 
1.4.3.3 Other activators with undefined receptors and mechanisms of 
activation; compound 48/80. 
Mast cell ‘secretagogues’ are a diverse group of cationic compounds 
known to cause rapid mast cell degranulation, which were used before the 
mechanism of IgE induced mast cell activation was discovered. Examples of 
these secretagogues include the polymeric compound 48/80, polyamines 
such as spermine and spermidine, various kinins, cationic peptide hormones 
and hymenoptera venom substituents and mast cell degranulating peptides 
(Mousli et al., 1990a; Mousli et al., 1990b). 
Compound 48/80 is a mixed polymer of p-methoxy-N-methyl 
phenethylamine cross-linked to formaldehyde (Lagunoff et al., 1983) and is 
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widely used for non-IgE dependent stimulation of mast cells (Metcalfe et al., 
1997).  Compound 48/80 was first characterised as an agent that released 
histamine (PATON, 1951) and many studies have used this compound as a 
mast cell secretagogue or to evoke inflammatory responses in various animal 
models (Kubes et al., 1996; Schemann et al., 2012). 
However, identification of the signaling cascades triggered by 
compound 48/80 and other classic ‘secretagogoues’ is vague and incomplete. 
Several studies have revealed that compound 48/80 acts via the pertussis 
toxin-sensitive heterotrimeric Gi proteins and triggers the transient production 
of inositol phosphates and Ca2+-influx (Nakamura et al., 1985), which liberate 
rapid exocytosis (~ 10 sec) of histamine (Rothschild, 1970), arachidonic acid 
(McClain et al., 1984) and PGD2 (van Haaster et al., 1995). In contrast, IgE-
dependent exocytosis is relatively slow, extending over a period of ~ 2 min, is 
strictly dependent on the presence of external Ca2+ (Foreman et al., 1972), 
and is pertussin toxin insensitive. Hence, basic secretagogues appear to 
induce secretion by a different mechanism to that mediated by IgE.  
More recently, literature has suggested a direct interaction of 
compound 48/80 with the COOH-terminal end of α-subunit of Gi3 at the 
plasma membrane (Aridor et al., 1993). This induces signals such as PKC 
and PI3K activation (Shefler et al., 1998) essential for the activation of PLA2 
with the associated production of arachidonic metabolites such as PGD2 
(Byrne et al., 2007). In addition to degranulation, compound 48/80 induces 
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the production and release of IL-3, IL-8, TNF-α and GM-CSF (Kulka et al., 
2008).  
 
1.5 ALLERGIC INFLAMMATION 
Allergy was a term coined by Clemens von Pirquet in 1906, to refer to 
the abnormal adaptive immune responses involving allergen-specific IgE and 
T-helper 2 (Th2) cells that recognise allergen-derived antigens (Niederberger, 
2009). An allergic reaction could be defined as hypersensitivity of the immune 
system which is activated due to a complex interplay between inflammatory 
cells, including mast cells, dendritic cells, basophils and eosinophils (Barnes, 
2011b). This reaction is triggered when IgE excessively activates mast cells 
and basophils (Kay, 2000).  During an allergic reaction, IgE bound antigen 
that activates FcεRi increases calcium permeability of mast cells in a ATP 
dependent manner releasing pro-inflammatory mediators such as histamine.  
The common allergic diseases such as asthma, allergic rhinitis and 
atopic dermatitis (Broide, 2009; Hamid et al., 2009) share common features 
of the inflammatory processes. The characteristic of allergic inflammation 
involves the IgE-dependent activation of mucosal mast cells and the 
infiltration of eosinophils, which intertwines with the increased CD4+ Th2 
lymphocyte activation. However, the clinical differences between these 
diseases are apparent anatomically and by the interaction between allergic 
inflammation and structural cells. It is now apparent that the structural cells in 
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the airways and skin play an essential role in the secretion of inflammatory 
mediators and in maintaining the chronic allergic inflammation (Barnes, 
2011b). The changes in the smooth muscle cells in the lower airways, results 
in bronchoconstriction and vasodilatation that leads to nasal blockage and 
activation of keratinocytes in the skin.  
Genetic factors play an important role on whether atopy develops, and 
may exert an influence on the severity of the disease and the extent of the 
allergic inflammatory response. Allergy frequently starts in early childhood 
with initial eczema, followed by sequential development of food allergy, 
allergic rhinitis and asthma (Eder et al., 2006). Environmental factors such as 
pollens, dust mites, cat and food may influence whether an atopic individual 
develops a particular allergic disease. Several genes have been identified 
using the genome-wide association studies (GWAS) (Akhabir et al., 2011), 
although each identified gene only contributes to a small amount to the 
observed phenotype (Ober et al., 2006).  
Although priority has been given on the inflammatory mechanisms in 
allergy, there are several endogenous anti-inflammatory mechanisms that 
could be defective in allergic diseases. One such example is endogenous 
cortisol, which is an important regulator of the allergic inflammatory response. 
Exacerbation of asthma at night might be related to the circadian cycle of 
plasma cortisol and blockade of endogenous cortisol by metyrapone results in 
an increase in the late response to allergen in the skin (Herrscher et al., 
1992).  
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Even though allergic inflammation is a complex disease involving many 
cells and mediators, many therapeutic targets have been identified. However, 
treatment with a broad spectrum of action is needed as targeting individual 
mediators or cell types are unlikely to produce effective therapies for allergic 
diseases. Corticosteroids are very effective in treating allergic diseases as 
they have multiple anti-inflammatory effects, including suppression of 
inflammatory genes (Barnes, 2006), although it has been reported that 
inhaled corticosteroid treatment is more effective for asthma patients 
compared to patients with chronic obstructive pulmonary disease (COPD) 
(Belvisi, 2004). The recent recognition of epigenetic factors likely to be 
important in regulating the inflammatory genes involved in allergic diseases 
might lead new therapeutic targets in the future. 
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1.5.1 Histamine receptor 1 (H1) Antagonists 
A H1 antagonist drug is characterised by its ability to block the 
histamine receptor 1, hence reducing or eliminating the effects mediated by 
histamine during an allergic response. Only drugs that act by mediating the 
negative modulation of histamine receptors are termed anti-histamines 
(Simons et al., 1994). However, the first generation of anti-histamines 
possesses adverse effects such as sedation, impaired psychomotor ability 
and excessive mucosal drying (Simons, 1994). Thus the development of 
second-generation H1 antagonist drugs has much-improved efficacy in as 
much as these drugs do not cross the blood brain barrier and thus do not 
cause adverse central nervous system effects such as drowsiness (Estelle et 
al., 1999).  
In this thesis, three classical H1 antagonist drugs, promethazine, 
pheniramine and antazoline were utilised. Promethazine, a phenothiazine 
derivative is clinically used as a neuroleptic medication, anti-histamine and 
anti-emetic drug. This drug, however it has marked sedative effects. 
Promethazine is also used as an anaesthetic premedication to produce 
sedation, reduce anxiety (Lippmann et al., 1978), or to reduce post-operative 
nausea and vomiting as dose-controlled transdermal device (Golembiewski et 
al., 2005). This drug acts primarily as a strong H1 receptor antagonist and a 
moderate muscarinic acetylcholine (mACh) receptor antagonist (Strenkoski-
Nix et al., 2000)  and has a weak to moderate affinity for the 5-
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hydroxytryptamine (5-HT) receptor (Fiorella et al., 1995), and dopamine 
receptor (Seeman et al., 1985), where it acts as an antagonist as well. 
Antazoline is commonly used in eye drops, usually in combination with 
naphazoline, which is a vasoconstrictor and decongestant, to relieve 
symptoms associated with allergic conjunctivitis such as redness, puffiness, 
itchy and watering eyes associated with colds, allergies or eye irritations 
(Souri et al., 2006).  
Pheniramine, which also has anti-cholinergic properties is used to treat 
allergic conditions such as hay fever, urticaria and allergic conjunctivitis. 
However, sometimes pheniramine is also used as over-the counter sleeping 
pill (Wong et al., 1981).  
 
1.5.2 Cromoglycate-like anti-allergic drugs 
The cromoglycate-like anti-allergic drugs include cromoglycate, 
nedocromil, pemirolast, lodoxamide, traxanol and amlexanox. These drugs 
are also known as ‘mast cell stabilizers’ as they are able to prevent mast cell 
degranulation (Figure 1.8). This family also includes some antagonists such 
as ketotifen, azelastine, olopatidine and epinastine, which appears to share a 
similar pharmacology with cromoglycate (Cook et al., 2002).  
Cromoglycate sodium was first described by Altouynan in 1965 
(Howell, 2005). It was derivative of a naturally-occurring cromone from the 
Egyptian plant Khella in which the active constituent ‘khellin’ was found to 
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have muscle relaxing properties (Kuzemko, 1989).  Cromoglycate inhibits 
both the early and late phase of the asthmatic reactions (Rintala et al., 2001) 
and clinical studies have indicated that this drug has significant clinical benefit 
in asthmatic children and adults and the side effects are minor (Auty, 1986; 
van der Wouden et al., 2008). In animal models, cromoglycate has been 
shown to inhibit the allergic asthma and pulmonary inflammation (Abraham et 
al., 1988; Abraham, 1989; Lapa e Silva et al., 1995; Corbel et al., 1999). 
Cromoglycate-like drugs have been shown to inhibit mediator action (Dahlén 
et al., 1989), cytokine release (Rusznak et al., 1996) and reduction in the 
infiltration of immune cells (Blondin et al., 2003).  
Nedocromil sodium was developed in the 1980s and was 
demonstrated to be an effective treatment for airway inflammation and to 
produce clinically relevant therapeutic effects even though these were rapidly 
reversible effects (Creticos, 1996). This drug exerts an inhibitory effect on 
bronchial hyper responsiveness as well as on activation of cells such as 
eosinophils and mast cells and thereby preventing the release of pro-
inflammatory mediators. Nedocromil is also used as a clinical treatment for 
allergic conjunctivitis (Benbow et al., 1993) as it significantly inhibits zymosan-
induced complement activation when compared to other anti-allergic drugs 
such as azelastine or lodoxamide (Blondin et al., 2003). Interestingly, some 
evidence also shows that these drugs not only target the mast cells but 
influence other facade of the inflammatory process both in vivo (Kuriyama et 
al., 1986; Yazid et al., 2010b) and in vitro (Yazid et al., 2009).  
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Cromoglycate, nedocromil, lodoxamide, azelastine, olopatidine and 
ketotifen are used clinically in the UK for the treatment of mild to moderate 
asthma or for topical treatment of ocular and other allergic symptoms. 
Cromoglycate has also been used for treating ulcerative colitis (Grace et al., 
1987) and chronic enterocolitis (Rintala et al., 2001). Even though the exact 
mechanism of action of mast cell stabilisers was not understood for many 
years, studies demonstrated that these drugs prevented the Ca2+ influx, 
characteristic of mast cell activation. Pemirolast was reported to inhibit IP3 
and Ca2+ mobilisation in antigen stimulated rat basophilic leukemia (RBL-
2H3) cells (Fujimiya et al., 1994). 
Despite its safety and efficacy, the cromones suffer from several 
drawbacks. The main limitation of these drugs is that their action is short-
lived, thus the inhaled cromones need to be used four times daily, which is an 
inconvenient routine for chronic asthma patients. The inhaled cromones is 
less effective than the inhaled glucocorticocids although the former is more 
expensive than the latter (Barnes, 1997).  
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Figure 1.8: Structure of some of the cromoglycate-like drugs. 
Among the family of the cromoglycate-like drugs, nedocromil and cromoglycate are 
the best know and most commonly used drugs pharmacologically for the treatment 
of ocular disease, asthma and food allergies.	  
Cromoglycate 
Pemirolast 
Nedocromil 
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1.5.2.2 Interaction between cromoglycate-like drugs and Anx-A1 
Anx-A1 is found in substantial amounts in the granules of mast cells 
(Oliani et al., 2000).  Several studies have linked Anx-A1 and the mast cell 
function. Human recombinant Anx-A1 inhibited compound 48/80-induced paw 
edema (Cirino et al., 1989) and the Anx-A1 peptide N-acetyl2-26 suppressed 
mast cell degranulation, neutrophil and eosinophil migration in an allergic 
inflammation model in the rat pleural cavity and inhibited histamine release 
induced by ovalbumin in sensitised rats (Bandeira-Melo et al., 2005).  Upon 
LPS injury, mast cell degranulation was greatly enhanced in Anx-A1 null mice 
as compared to wild type (Damazo et al., 2005). 
Interestingly, it has been previously reported that cromoglycate-like 
drugs have been shown to bind with s100A11 proteins, which also bind to the 
annexin family, suggesting a potential interaction between these drugs and 
annexins. S100A11 is a homodimeric protein containing calcium-binding sites 
and it binds to the first 10-14 residues of Anx-A1 (Oyama et al., 1997).  
Work within our group has established that cromones inhibit PMN 
leukocyte activation in vivo (Yazid et al., 2010a) and eicosanoid release by 
U937 cells (Yazid et al., 2009). The cromone inhibitory effect depends on 
their ability to release Anx-A1 and is apparently caused by the inhibitory 
actions of the cromones on the phosphatase 2A (PP2A) enzyme, which 
normally terminates PKC activation. 
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However, these studies did not establish how endogenous Anx-A1 
actually mediated the effects of cromoglycate-like drugs on mast cell mediator 
release.  
1.5.3 Dual-action drugs 
Even though anti-histamines have been effective in treating allergic 
inflammation, they are not able to inhibit all the manifestations caused by the 
allergic disease, since histamine is not the only mediator that is being 
released by the mast cells. Therefore, simultaneous development of mast cell 
stabilisers paved the way for the highly effective dual-action anti 
histamine/mast cell stabiliser drugs that are currently popular choices for 
treating allergic inflammation. These compounds were preferred as they offer 
more sustained and prolonged efficacy, due no doubt, to their ability to inhibit 
cytokine mediated inflammation including up-regulation of adhesion molecule 
expression and chemokine release (Cook et al., 2002). 
 Dual-action drugs inhibit the degranulation of mast cells by preventing 
the cross-linking and activation of high affinity Ig-E receptor by allergen and 
thus interrupting the cascade of intracellular signalling. These drugs also 
have H1 antagonist actions, thus exerting effects further down the allergic 
cascade of events by preventing the activation of histamine receptors on the 
proximal cells.  These drugs have been demonstrated to have good efficacy 
and safety in the treatment of allergy and can therefore have an advantage as 
both prophylactic to prevent mast cell degranulation or as a therapeutic agent 
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to bring about symptomatic relieve (Chigbu, 2009) 
 Olopatidine, which is commonly used for the treatment of ocular 
allergy, has been shown to inhibit histamine, tryptase, PGD2 and TNFα in 
human conjunctival mast cells (Leonardi et al., 2010).  Another study has 
shown that ketotifen is more potent than olopatidine in inhibiting histamine 
release from mast cells, however ketotifen prevents mediator release at a 
concentration greater than the maximal effective dose, thus affording a 
smaller safety margin than olopatidine (Yanni et al., 1996). Ketotifen also 
inhibited chemotaxis and activation of eosinophils in vitro (Podleski et al., 
1984). Epinastine, which is another ‘dual-action’ drug used in this study, also 
inhibits the release of inflammatory mediators from mast cells, eosinophils, 
neutrophils (Amon et al., 2000) as well as oxygen radical generation by 
inflammatory cells (Fukuishi et al., 1995). Allergic rhinitis has been treated 
clinically with orally administered epinastine with minimal adverse effects 
(Abelson et al., 2004).  
It is noteworthy that mast cell heterogeneity exists between different 
tissues within the same species or other species, which causes the cells to 
respond differently to various secretagogues and drugs. Therefore drugs, 
which are effective on mast cells from one species, might not exert the same 
effect on mast cells retrieved from other source.  
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1.6 SCOPE OF THESIS 
1.6.1 Hypothesis 
Based on previous research highlighting the role of Anx-A1 in several 
models of allergic inflammation, the following hypothesis was formulated: 
anti-allergic drugs exert their effects on mast cells by stimulating the release 
of the anti-inflammatory endogenous protein Anx-A1 which acts through the 
FPR to prevent mediator release.  
1.6.2 Aims 
Although the anti-allergic drugs have been used for the treatment of 
allergy and asthma for many years, their mechanisms of pharmacological 
action have not been convincingly explained. Thus, this hypothesis will be 
challenged by addressing the following aims. 
Therefore, the first aim of this thesis was to investigate the ability of 
various anti-allergic drugs to induce Anx-A1 phosphorylation in U937 cells. As 
this rapid phosphorylation event is crucial for the translocation and export of 
Anx-A1 into the extracellular milieu, it is important to categorise the drugs on 
this ability. U937 cells were chosen because these cells are easy to culture, 
contain abundant levels of Anx-A1 and they respond well to anti-allergic 
drugs treatment. 
Since the main target for anti-allergic drugs are the mast cells, cord-
blood derived mast cells (CDMCs) and bone marrow derived murine mast 
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cells (BMDMCs), stimulated by compound 48/80 were utilised to investigate 
the next aims. It has been established that GCs activate PKC in U937 cells 
(Yazid et al., 2009), thus using biochemical and immuno-fluorescent 
techniques, the possible interaction between cromoglycate-like drug, 
nedocromil and the dexamethasone to activate PKC, thereby potentiating 
Anx-A1 phosphorylation and release was investigated. To further confirm if 
the other anti-allergic drugs, such as ketotifen and promethazine has similar 
mechanism of action as nedocromil, their ability to promote Anx-A1 
phosphorylation was demonstrated. 
To address the notion that the ability of the anti-allergic drugs to 
release Anx-A1 is critical for their acute mediator inhibitory effects in mast 
cells, the neutralising anti-Anx-A1 monoclonal antibody and the BMDMCs 
isolated from Anx-A1 null mice was utilised. The inhibitory effects of anti-
allergic drugs on the release of mast cell mediators such as β-
hexosaminidase, tryptase, histamine and PGD2 in activated CDMCs were 
analysed.  
The next aim was to explore the possibility that FPR2, which is one of 
the receptor for Anx-A1, might be involved in the mechanisms of action of 
cromones. To address this aim, the FPR2 antagonist, WRW4 peptide in 
CDMCs and the BMDMCs isolated from fpr2/3 null mice were utilised to 
ascertain the role of FPR2 in the acute effects of nedocromil. 
Since mast cell degranulation is governed by the signaling pathway, 
the MAPK downstream signaling that contributes to the ‘mast cell stabilising’ 
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effects of nedocromil was determined and also the role of Anx-A1 to elicit this 
pathway was investigated. Western blots were performed to analyse the 
phospho-p38 and phospho-JNK in stimulated CDMCs pre-treated with 
nedocromil. 
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2. MATERIALS AND 
METHODOLOGY 
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2.1 MATERIALS 
Nedocromil sodium was generously supplied by Sanofi-Aventis (Paris, 
France). Isotype matched irrelevant (IgG1) was obtained from ABD Serotec, 
Oxford, UK. Human recombinant protein Anx-A1 was a gift from Dr F. 
D’Acquisto. An in-house specific neutralising anti-Anx-A1 (clone 1B; 20 
µg/mL) was used. Unless otherwise stated, all materials were purchased from 
Sigma-Aldrich (Poole, UK).  
 
2.2 METHODOLOGY 
2.2.1 Cell culture 
2.2.1.1 U937 human pro-monocytic cell line 
U937 cells were obtained from the American Type Culture Collection 
and cultured in RPMI 1640 (Invitrogen, Paisley, UK), which were 
supplemented with 10% Fetal Bovine Serum (FBS; Gibco®, UK), 1% L-
glutamine, 1% non essential amino acids and 0.1% gentamycin, at 37°C with 
5% CO2 atmosphere. The culture flasks (Nunc, Thermo Scientific, 
Hempstead, UK) containing proliferating pro-monocytic cells were sub-
cultured when the cells were grown to 70-80% confluency. Analysis of 
proteins by Western blot, proliferating cells were transferred from flask into a 
12-well plate at a density of 1 million cells per well.  Upon plating, these cells 
were incubated in the presence of 10ng/ml phorbol 12-myristate 13-acetate 
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(PMA) for 24 h to acquire monocytic-like properties after which they become 
responsive to glucocorticoids (Solito et al., 1991a). U937 cells were chosen 
instead of other cells because U937 cells have been demonstrated to be 
responsive to both steroids and cromoglycate-like drugs (Yazid et al., 2009). 
The addition of PMA to U937 cells for 24 h resulted in a 2.4 fold increase in 
the cell surface level of Anx-A1 and inhibition of the ATP-induced Ca2+ 
response, thus making these cells responsive to steroids (Willmott et al., 
1997). Although PMA stimulates the activation of PKC, the incubation of 
U937 cells with PMA for 24 h has been shown not to influence the PKC 
dependency effects in these cells (Solito et al., 1991b).  
2.2.1.1.1 Passaging U937 cells 
10ml of the cell suspension in medium was centrifuged at 1100 g for 5 
min. Cell pellet was resuspended with 20ml of new medium and transferred 
into a T75 flask.  
2.2.1.1.2 Preparation of drugs 
Dexamethasone, promethazine, pheniramine, antazoline, nedocromil, 
cromoglycate, pemirolast, ketotifen, olopatidine and epinastine were prepared 
at 10µM (stock solution; dissolved in medium) and serial dilutions were 
prepared so that the final concentrations of the drugs were in the range of 2-
500nM. Water-soluble salts of the drugs were chosen for convenience. In 
some cases, the drug-treated cell aliquots were incubated for 20 min with a 
well-characterised (D'Acquisto et al., 2008) specific neutralising anti-Anx-A1 
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monoclonal antibody (clone 1B; 20 µg/mL), or isotype matched irrelevant 
(IgG1, ABD Serotec, Oxford, UK), monoclonal antibodies. Specific 
neutralising anti-Anx-A1 monoclonal antibody (was previously manufactured 
by Biogen Corp, Cambridge, MS, USA, but upon acquiring the clone (1B), this 
antibody has been produced in-house. This antibody is targeted to detect the 
N-terminus of Anx-A1 and no cross-reactivity has been reported with this 
antibody. Untreated mentioned in all the experiments means that the cells 
were incubated with media alone.  
 
2.2.1.2 Cord blood-derived human mast cells (CDMCs) 
CD34+ stem cells (Lonza, UK) were cultured in Stemspan serum free 
media containing 100ng/ml SCF and 50ng/ml IL-6, with 1 ng/ml IL-3 
(Peprotech, London, UK) added during the first 2 weeks. Medium 
supplemented with IL-6 and SCF was added weekly to the cells, with 10% 
FBS added from week 9. Cells were used for experiments between 11-18 
weeks of culture (Dahl et al., 2002). At week 8, un-stimulated CDMCs were 
immunophenotyped as >90% c-kit positive by FACS analysis. To further 
confirm the morphology, these cells were stained with toluidine blue which 
stains the metachromatic granules of the mast cells. The cells were 
maintained at a density of 1.0x106 cells/ml for no longer than 15 weeks. 
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2.2.1.3 Bone marrow-derived murine mast cells (BMDMCs) 
To generate primary bone marrow-derived murine mast cells 
(BMDMCs), femur bones from Anx-A1-/- BALB/C, FPR-/- C57/B6 and their 
respective WT mice (4-6 weeks old, Charles River, Kent, UK) were used. 
Animal work was performed according to UK Home Office regulations 
(Guidance on the Operation of Animals, Scientific Procedures Act, 1986) and 
was approved by the Queen Mary University of London Ethics Committee 
(London, UK).  
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2.2.1.3.1 Preparation of BMDMCs 
The donor mice were sacrificed by cervical dislocation. The mice and 
the surgical instruments were rinsed with 70% ethanol as needed prior to 
bone marrow extraction. The skin from the legs was removed using sterile 
forceps and scissors. The femur and tibia were removed and the tissue was 
scrapped away from bones using sterile scissors and scalpel blades.  
The bones were kept in PBS on ice until all the bones were collected.  
By using sterile instruments, the bone is picked up with forceps and the 
epiphysis of the bone was cut with scissors to expose medullary cavity. The 
marrow was flushed out of each bone with flushing medium (DMEM, 10% 
FBS, 2mM L-glutamine, 100 units/ml of penicillin, 100 µg/ml of streptomycin, 
0.1 mM non-essential amino acids and 50µM β-mercaptoethanol) using a 5ml 
syringe with a 25-gauge needle into a labeled 50ml Falcon collection tubes. 
The femoral and tibia bone marrow cells from each mouse were pooled into 
one collection tube.  
The bone marrow cells were gently aspirated and dispersed to 
generate a single cell suspension and were passed through a cell strainer 
(70µM).  The cells were then centrifuged (1000g for 5 min, 20°C) and the 
supernatant were removed and the pellet was resuspended in 10ml of culture 
medium which consist of DMEM (Invitrogen, Paisley, UK), 10% FBS, 2mM L-
glutamine, 100 units/ml of penicillin, 100 µg/ml of streptomycin, 0.1 mM non-
essential amino acids and 50µM β-mercaptoethanol, 5 ng/ml of r-murine IL-3 
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and 10ng/ml SCF (PeproTech, London, UK). The cells were placed in tissue 
culture flask of appropriate size (e.g., T25 for 1 mouse or T75 for 2 mice).  
 
2.2.1.3.2 Cell culture of BMDMCs 
The medium and suspended cells were transferred into a new flask 
after 1-2 days to remove debris and adherent cells. Fresh culture medium 
was added into the flask. In subsequent weeks, the culture medium was 
added every 3-4 days to maintain a cell density of 2.5x105 – 1x106 cells/ml. 
The suspended cells were transferred into a new flask once a week until no 
further adherent cells was observed in the culture flask. The differentiation of 
BMDMCs takes 4-6 weeks and phenotypic maturity of these cells was tested 
before using the cells for in-vitro experiments. 
2.2.1.4 Assessing phenotypic maturity of CDMCs and BMDMCs 
2.2.1.4.1 FACS Staining for c-kit (CD117) 
CDMCs or BMDMCs were diluted in PBC (PBS + 0.15% BSA and 
1.0mM CaCl2) buffer and plated in duplicate in a density of 1x105 cells per 
well in a 96-round bottom plate.  Cells were then washed three times by 
centrifugation with PBC at 1000g for 30 sec. Negative control wells contained 
20µl of IgG and 20µl of PBC whereas the isotype control wells had 20µl of 
isotype human IgG and 20µl of PBC. 20µl of IgG and 20µl of c-kit (CD117) 
antibody (Chemicon International, USA) were added to the sample wells. The 
plate was incubated on ice for 45 min. The washing procedure was repeated 
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twice with PBC and once with PBS. 200µl of PBC solution was added to the 
wells to resuspend the cells, which were then analysed using the FACS 
Caliber (Becton Dickinson).  
2.2.1.4.2 Assessing the degranulation of CDMCs and BMDMCs 
upon compound 48/80 stimulation using toluidine blue staining 
Toluidine blue staining was used to distinguish the metachromatic 
granules of the mast cells. Toluidine blue is a small weakly hydrophilic 
cationic dye, which turns blue when attached to DNA or RNA in chromatin, or 
purple when it is in contact with glycosaminoglycans in mast cell granules 
(Sridharan et al., 2012). CDMCs or BMDMCs were plated in duplicate at 
1x105 cells per well in a 96-well plate.  Cells were washed twice in cold 2% 
FBS-PBS and resuspended in 100µl of cold 1% BSA in PBS.  All the samples 
were kept on ice. Since the CDMCs and BMDMCs were in suspension the 
cells were deposited onto a slide using the cytospin at 2500g for 3 min. Slides 
were the left to air-dry prior to the removal of filters from the slides. Slides 
were then examined under microscope for proper adherence of cells. The 
slides were flooded with 0.5% of toluidine blue solution for 5 min and rinsed 
three times with ddH2O. Cover slips with mounting medium were placed over 
the specimen and viewed under the light microscope at 60x magnification 
(Figure 2.1).  
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Figure 2.1: Unchallenged cord-blood derived mast cell (CDMC) stained 
with toluidine blue.  
The metachromatic granules in the cell are stained red-purple confirming the mast 
cell phenoype. 
 
2.2.1.5 Treatment with drugs 
CDMCs/BMDMCs were stimulated with Compound 48/80 (10µg/ml) for 
10 min at 37°C with 5% CO2 atmosphere. Drugs or antibodies, to be tested in 
this system, were added 5 min prior to the addition of Compound 48/80.  
Samples were centrifuged at 1000g for 5 min before the cell-free 
supernatants were collected to measure histamine and PGD2 release. Cell 
lysates and supernatant were prepared for Western blots. Sample aliquots 
were stored at -80°C for further analysis.  
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2.2.1.6 Cryopreservation of cells  
Confluent cells were counted, sedimented by centrifugation, aliquoted 
at 106/vial, and cryopreserved in 1ml of solution containing 90% FBS and 
10% dimethyl sulphoxide (DMSO). The cells were frozen slowly at -80°C 
overnight before being transferred into a liquid nitrogen container. 
 
2.2.1.7 Thawing of cryopreserved cells 
Vials of frozen cells were removed from the liquid nitrogen tank and 
thawed immediately with 10ml of complete medium. The cells were washed 
by centrifugation at 1000g for 5 min to ensure complete removal of DMSO. 
Cell pellets were then resuspended with 10ml of complete medium and 
seeded into T25 flasks.  
 
2.2.1.8 Counting of cells 
Cells were counted using a Nueberg haemocytometer (Figure 2.2). 
The haemocytometer was cleaned with 70% ethanol prior to fixing the cover 
slip. 10µl of cells were diluted with 990µl of Trypan Blue (1 in 100 dilution). 
10µl of sample were transferred into the haemocytometer by pipette, and the 
cells were counted from the 4 quadrants of haemocytometer using a counter.  
90% of the cells were viable upon determination by trypan blue. Total number 
of cells was determined using the formula below: 
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Average of cells in 4 quadrants x dilution factor (100) x 104 = Number of 
cells/ml 
 
 
Figure 2.2: Illustrations of the counting grid on a Neubauer 
haemocytometer.  
Cells were counted in the four quadrants and an average was obtained. 
  
Q1 Q2 
Q3 Q4 
0.1mm 
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2.3 CHALLENGE OF CDMCS AND BMDMCS 
2.3.1 DNP-Ig-E activation 
BMDMCs were incubated overnight with anti-mouse monoclonal 
dinitrophenyl (DNP) - IgE (100 ng/mL; Sigma) to sensitise the cells and the 
following day they were activated by adding DNP-BSA (1 µg/mL; Sigma-
Aldrich, Dorset, UK). Cell-free supernatants were collected at 1h to measure 
histamine and/or PGD2 release. Aliquots were stored at -80°C for subsequent 
analysis. When drugs or antibodies were tested, these were added to cells 5 
min prior to DNP/IgE cross-linking. 
2.3.2 Compound 48/80 stimulation 
Aliquots of CDMCs and BMDMCs were stimulated with compound 
48/80 (10 µg/ml; Sigma-Aldrich, Dorset, UK) for 10 min at 37°C. Drugs or 
antibodies were added to the cells 5 min prior to challenge. Cell-free 
supernatants were taken to measure histamine and/or PGD2 release. Aliquots 
were stored at -80°C for subsequent analysis. 
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2.4 ANALYTICAL METHODOLOGY 
 
2.4.1 Chromatographic purification of antibody.  
Phosphorylated forms of Anx-A1 were detected using a purified 
specific antibody raised in rabbit against Anx-A1 phosphorylated at Ser27 
(Solito et al., 2003c).  MAbTrap kit Protein G affinity column (GE Healthcare, 
Buckinghamshire, UK) was used for the purification of monoclonal and 
polyclonal IgG from the rabbit serum. The rabbit serum was a kind gift from Dr 
Egle Solito.   
The column and buffers were warmed to room temperature prior to the 
purification process. Binding (2.5ml binding buffer concentrate + 22.5ml of 
dH2O to a total volume of 25ml) and elution buffer (0.5ml binding buffer 
concentrate + 4.5ml high quality water to a total volume of 5ml) were diluted.  
Collection tubes were prepared by adding 60-200µl of neutralising buffer per 
ml fraction to be collected. This allow for immediate renaturing of the purified 
IgG to preserve the activity of labile IgGs.  
The samples were centrifuged (1000g for 5 min) and filtered (0.45µm 
filter) to increase clarification and prevent back- pressure problems. The 
filtered serum then was diluted 1:1 with prepared binding buffer. The syringe 
or pump tubing were filled with distilled water and the top-cap was removed 
and the column and the syringe were connected through the luer connector. 
The connection is made to ‘drop by drop’ to avoid introducing air into the 
column. The snap-off end at the column outlet was removed. Ethanol 
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preservative were washed out with 5ml of distilled water at ~ 1 drop/sec.  The 
column was equilibrated with at least 3ml of binding buffer. The sample was 
applied using the syringe or by pumping onto the column. Thereafter, the 
column was washed with 5-10ml binding buffer or until no material appears in 
the effluent.  
Finally the elution buffer (3-5ml) was used to elute the sample. The 
protein concentration of the purified antibody was determined by using the 
nano drop (ND-100, LabTech) and resulted in a corresponding yield of 
0.88mg of pure rabbit polyclonal IgG1. The working dilution (1:1000) of this 
antibody (Anx-A1-P-Ser27) was optimised using the Western blots. The 
specificity of the antisera raised against phosphorylated Anx-A1 proteins was 
confirmed by the findings in Western blot and this antibody did not cross-react 
with the unphosphorylated protein human recombinant Anx-A11–188 (5 
µg/lane). 
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2.4.2 WESTERN BLOTTING PROTOCOLS 
2.4.2.1 Protein extraction 
Upon treatment with stipulated drugs, cells were centrifuged at 1000g 
for 5 min. Cell-free supernatant were removed, labelled and stored at -80°C 
for further analysis. Lysis buffer (100µl) was added to each sample for 10 
min. Lysis buffer was prepared in Tris-HCl (20mM) and is composed of NaCl 
(200mM), Tris X-100 (1%), 1mM EDTA to remove Anx-A1 attached to the cell 
surface, and a protease inhibitor cocktail comprising of aprotinin (0.03%), 
Na3VO4 (1mM), leupeptin (10uM), sodium fluoride (1mM) and PMSF 
(200µM).  
Protein extraction was performed on ice to retard any enzymatic 
digestion of extracted protein. Following the 10 min incubation with the lysis 
buffer, cells were scraped with cell-scraper and passed vigorously through a 
25G needle attached to a 1ml syringe and collected into an eppendorf tube.  
The samples were centrifuged at 11000xg for 10 min and the supernatant 
was collected into new tubes. Prior to performing Western blots, protein assay 
was carried out to determine the amount of protein in the samples.  
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2.4.2.2 Protein assay 
Total protein concentration of samples was determined by a 
colorimetric protein assay (BioRad, USA). This assay was based on the dye-
binding assay in which a differential colour change of a dye occurs in 
response to various concentrations of protein. The reduced species has a 
characteristic blue colour with maximal absorbance at 595nm and minimum 
absorbance at 465nm. Samples were prepared in x10 dilution for this assay.  
A linear range of 0.05 - 0.5 mg/ml of BSA standard was prepared. In 
accordance to the manufacturer’s protocol, 10µl of standards and samples 
were added in triplicates in 96-well plate. The dye reagent was prepared by 
adding 1 part of reagent concentrate with 4 parts of ddH2O. 200µl of the 
diluted dye was added to the standards and samples and read at 595 nm 
using a microplate reader (TitertekTM, Vienna, Austria).  Protein 
concentrations in each sample were extrapolated from the standard curve 
using the GraphPad Prism Software version 4 for Mac (GraphPad Software, 
San Diego, California, USA, www.graphpad.com).  
 
2.4.2.3 SDS-polyacrylamide gel electrophoresis 
Total proteins were separated by discontinuous SDS-PAGE according 
to the method of Laemmli (1970), under reducing conditions. As SDS is an 
anionic detergent, it imparts a negative charge to all proteins. Therefore, 
protein separation is based on molecular weight. The discontinuous stacking 
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gel is composed of a 4% acrylamide gel, where proteins are concentrated, 
and a 10% or 12% acrylamide resolving gel where proteins are separated. 
Thus, the resolving gel acrylamide is selected based on the range of sizes of 
protein that needs to be analysed.  The composition of the resolving and 
stacking gels are detailed in Table 2.1.  
The gels were poured into a gel sandwich made of 1 white gel holder 
and 1 glass holder separated by 1.5mm spacers. Resolving gel were made 
first and left to polymerize for 20 min before adding the stacking gel. A thin 
layer of water was added onto the resolving gel to release any air bubbles 
that might have been trapped during the polymerization process. Before the 
addition of stacking gel, the layer of water is gently tapped off the gel 
sandwich. The stacking gel was then poured into the casting frame and left to 
polymerise for 30 min. Thereafter, a 10-well comb was carefully inserted to 
avoid forming bubles.  Once the gel has hardened, either it could be used 
immediately or it is transferred into a wet tissue and kept in the fridge at 4°C 
until required.  
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Composition Resolving Gel Stacking 
gel 
(4%) 
10% 12% 
30% (w/v) Acrylamide: 0.8% 
Bis acrylamide solution 
(Protogel) 
 
 
13.3 ml 
 
16 ml 
 
3.9 ml 
Resolving gel buffer (1.5M 
Tris-HCl, pH 8.8 0.4%SDS 
 
 
10.4 ml 
 
10.4 ml 
 
- 
Stacking gel buffer (0.5M 
Tris-HCl, pH 6.8 0.4%SDS 
 
 
- 
 
- 
 
7.5 ml 
10% (w/v) Ammonium 
Persulphate (APS) 
 
 
400 µl 
 
400 µl 
 
150 µl 
 
dH2O 
 
 
15.8 ml 
 
13.2 ml 
 
18.3 ml 
Tetramethylethylenediamine 
(TEMED) 
 
 
40 µl 
 
40 µl 
 
30 µl 
Table 2.1: Composition of resolving and stacking SDS-PAGE gels.  
The volume stated is sufficient to make 4 gels. 
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2.4.2.4 Western blotting 
30µg of proteins and 6x Laemmli sample buffer (36% (w/v) glycerol; 
60% (w/v) 4x Tris-HCl/SDS, pH 6.8; 4% (w/v) distilled H2O; 0.1 g/ml SDS; 
0.093 g/ml dithiothreitol; 0.12 mg/ml bromophenol blue) were mixed and 
denatured by warming at 80°C for 5 min. The prepared gels were assembled 
into a chamber and submerged in electrophoresis running buffer (25mM Tris 
Base, 200mM glycin, 0.1% SDS, Sigma). Kaleidoscope pre-stained standards 
(GE Healthcare, Buckinghamshire, UK) were used to determine the molecular 
weight.  
Electrophoresis was carried out at 80 Volts for the first 20 min and then 
increased to 120 Volts once the sample had passed the stacking gel. 
Electrophoresis was stopped once the samples had reached the bottom of 
the gel. A PVDF Immobilon membrane was activated in methanol prior to the 
transfer. The proteins were then electrophoretically transferred onto the 
membrane. The gel sandwich was prepared in a cassette by layering sponge 
pad, filter paper, gel, PVDF membrane, filter paper and sponge pad 
respectively in this manner (Figure 2.3).  
The sandwich cassette was then placed in a tank set in a cold room 
submerged in chilled transfer buffer (25mM Tris base. 192mM glycine, 20% 
methanol).  The transfer was achieved by application of 100 Volts for 90 min. 
After the transfer, gels were stained with Coomasie blue to ensure that no 
protein is left on the gel and therefore equal amount of protein had been 
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transferred onto the membrane.  
 
 
Figure 2.3: Arrangement of the transfer stack. 
The protein from the polyacrylamide gel is transferred onto the PVDF membrane 
using a semi-dry transfer system, which consists of ‘sandwich’ stack soaked in 
transfer buffer. 
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2.4.2.5 Immunodetection of proteins 
Non-specific binding sites were blocked by incubation of the blots in 
5% non-fat dry milk or BSA in Tween 20-Tris Buffered Saline (TTBS; 150mM 
sodium chloride, 2mM Tris base, pH 7.4 containing 0.1% Tween 20, Sigma) 
according to the antibody manufacturer’s protocol on a rocking platform for 1 
h at room temperature or overnight at 4°C. Membranes were then incubated 
with specific primary antibody (Table 2.2) for 1 - 2 h at room temperature or 
overnight at 4°C. The membranes were washed three times for 10 min each 
with TTBS to ensure removal of unbound antibody. After washing, the blots 
were incubated with horseradish peroxidase (HRP)-conjugated secondary 
species-specific antibody (Table 2.3) for 1 h at room temperature. 
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Antigen 
 
Host Dilution Type Source Cat 
No 
Concen-
tration 
 
Anx-A1 
(1B) 
 
mouse 
 
1:2000 
 
Monoclonal 
 
In-house 
 
Clone 
1B 
 
10µg/ml 
 
Anx-A1 
 
rabbit 
 
1:2000 
 
 
Polyclonal 
 
Invitrogen 
 
71-
3400 
 
5µg/ml 
 
Ser27-Anx-
A1-P 
 
 
rabbit 
 
1:1000 
 
Polyclonal 
 
Neosystems, 
Strasbourg, 
France 
 
nil 
 
10µg/ml 
 
 
Pan P- 
PKC,  
P-PKCαβ,  
P-PKCδ, 
 P-PKCσ, 
total PKC 
 
 
 
rabbit 
 
 
 
1:1000 
 
 
 
Polyclonal 
 
 
Cell 
Signalling 
Technology 
 
9371 
9375 
9374 
9376 
2056 
 
 
 
10µg/ml 
 
 
Tryptase 
 
 
mouse 
 
1:1000 
 
Monoclonal 
 
Abcam 
 
Ab- 
2378 
 
10µg/ml 
 
 
α-tubulin 
 
mouse 
 
1:5000 
 
Monoclonal 
 
Sigma 
Aldrich 
Technology 
 
T5168 
 
2µg/ml 
 
 
Table 2.2: Primary antibodies used for Western blot. 
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Target 
IgG 
 
Host Dilution Type Source Cat No Concent-
ration 
 
Mouse 
 
 
goat 
 
1:5000 
 
Polyclonal 
 
Dako 
Cytomation 
 
 
P04470
1-2 
 
2µg/ml 
 
 
Rabbit 
 
 
goat 
 
1:2000 
 
Polyclonal 
 
Dako 
Cytomation 
 
 
P04480
1-2 
 
5µg/ml 
 
Table 2.3: Secondary antibodies used for Western blots. 
  
2.4.2.6 Enhanced chemiluminescence detection 
  Immunoreactive bands were visualised using an enhanced 
chemiluminescence (ECL) kit. ECL solution 1, which contains 1ml Luminol 
stock (250mM in DMSO, Sigma), 0.44ml p-coumaric acid stock (0.29/20ml 
dH2O, Sigma), 10ml 1M Tris base (pH 8.5) and 88.56 ml dH2O was prepared. 
ECL solution 2 contained 64µl of 30% H2O2, 10ml 1M Tris Base (pH 8.5) and 
90ml dH2O. Equal volume from ECL solution 1 and 2 were mixed and the 
immunoblots were submerged in this solution for 1 min to activate a 
chemiluminescence reaction. The excess fluid was drained and immunoblots 
were wrapped in plastic film prior to exposure to X-ray Hyperfilm ECL 
(Amersham, Pharmacia Biotech). The films were developed using the Jet X-
Ray SRX 101A Developer (Jet X-ray, UK). Immunoblots were kept wet and 
placed at 4°C until being stripped or reprobed. The illustrations of ECL 
reaction is depicted in Figure 2.4 
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. 
Figure 2.4: Schematic illustrations of ECL reaction.  
Chemiluminescence occurs when a chemical reagent containing stored energy 
releases light. The reagent is normally stable and does not emit light, but can be 
converted into a light-emitting product, for example after interaction with a specific 
enzyme. In most contemporary ECL systems, the enzyme horseradish peroxidase 
(HRP) conjugated to a secondary antibody is utilised to convert the substrate, 
producing light, which is then captured onto an autoradiographic film. The intensity of 
the light is proportional to the quantity of HRP enzyme and hence the protein of 
interest. 
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2.4.2.7 Stripping the membrane 
To recycle and probe the membrane with different antibodies, the 
membrane was stripped using a mild stripping solution (1.5g glycine, 0.1g 
lauryl sulphate and 1ml Tween 20 made up in 100ml dH20). Briefly, the 
membrane was washed once with TTBS and submerged in stripping buffer 
for 30 min at room temperature with gentle rocking. The membrane was then 
washed three times for 5 min in TTBS before being exposed to ECL detection 
in order to ensure complete removal of previous primary and secondary 
antibodies. Membranes were then washed with TTBS, blocked and re-blotted 
with primary antibody. Membranes were not stripped more than three times.  
2.4.2.8 Band quantification 
Western blotting films were scanned at high resolution and the images 
were downloaded using Image J software and the density of each band 
assessed and the protein band was normalised against the α-tubulin band of 
the same sample. Each Western blot was repeated three times and the 
densitometry results averaged.  
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2.5 Immunoassays 
2.5.1 Principal of the ELISA 
Enzyme linked immunosorbent assay (ELISA) is an immunoassay used to 
detect specific proteins. In a sandwich ELISA, the antigen of interest is 
bounded by two antibodies: the primary capture antibody, which is bound to 
the plate and the secondary, detection antibody found in the solution (Figure 
2.5). The antigen of interest must therefore contain at least two distinct 
antigenic sites or epitopes. The sequence of ELISA is as follows:  
 
1. Binding of capture antibody to 96-well plate. 
2. Blocking of non-specific sites. 
3. Binding of antigen to capture antibody. 
4. Binding of secondary antibody to antigen. 
5. Horseradish peroxidase (HRP) conjugated secondary antibody 
catalyses an enzymatic colorimetric reaction. 
6. Reaction is stopped at an appropriate time. 
7. Colour intensity is directly proportional to antigen concentration and is 
read on a spectrophotometer (maximum absorbance at 450nm). Cell 
supernatants for assays were collected and stored at -80°C prior to 
analysis.  
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Figure 2.5: Illustration of a ‘sandwich’ ELISA.  
The assay involves the capture of a multivalent antigen or target protein in a 
sandwich complex by a capture antibody adsorbed onto a coated plate and a 
detection secondary antibody. The secondary antibody is further detected by an 
HRP-conjugated tertiary antibody. HRP will convert a transparent TMB substrate into 
a coloured product which absorbance will be directly proportional to the amount of 
antigen present in the sample. 
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2.5.2 Measurement of Thromboxane B2 (TxB2) 
Commercially available enzyme immunoassay was used to detect and 
quantify TxB2 released in the supernatant (BioTrak Assay, Amersham, UK). 
The method was performed following the manufacturer’s instructions. A 
standard curve ranging from 0.5 - 6.4 pg/well was prepared using the reagent 
provided, 50µl of standard was added to the plate in duplicate and 50µl of the 
unknown samples were added into the appropriate wells, for 1 h incubation.  
The microtiter plate was pre-coated with donkey anti-rabbit IgG so that 
the rabbit anti-TxB2 binds to the immobilized antibody. This incubation 
allowed the unlabelled antigen present in the cell-free supernatants to bind to 
the resultant complex and to compete for a limited number of binding sites 
with the labelled peroxidase-TxB2 added in each well. Any sample that was 
unbound was removed by washing.  
The amount of peroxidase-TxB2 labelled bound to the antibody was 
determined by the addition of 150µl of a tetramethylbenzidine 
(TMB)/hydrogen peroxide enzyme substrate. After 15 min shaking at room 
temperature, the reaction was halted by the addition of 100µl of 1M sulfuric 
acid, which turns the sample from blue to yellow colour. The optical density 
was then read at 450nm in a microplate reader within 30 min. 
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2.5.3 Histamine assay  
CDMCs and BMDMCs were pre-treated with anti-allergic drugs or 
antibodies for 5 min and stimulated with compound 48/80 (10µg/ml) for 10 
min before the cell-free supernatants, and in some cases, the total cell lysate 
were collected for histamine determination. Histamine release was measured 
by a commercially available ELISA kit (SPI Bio, Bertin Pharma). The assay 
was performed according to the manufacturer’s protocol.  
This assay is based on the competition between unlabelled derivatised 
histamine and acetylcholinesterase (AChE)-linked histamine (tracer) for 
limited specific mouse anti-histamine antibody sites. Histamine is derivatised 
to increase the affinity for the histamine to the antibody and consequently 
increase the sensitivity of the assay. Standard concentrations were prepared 
respectively (0.39 – 50 nM) using the same culture medium as the samples. 
Derivatization reagent was reconstituted with 1mL of N-N-dimethylformamide 
(DMF). 200µl of standards and samples were derivatised with 50µl of 
derivatisation buffer and 20µl of the derivatization reagent and vortexed 
immediately. Whereas, 200µl of assay medium was used for the estimates of 
maximum binding evaluation. 
After the derivatisation process, the microtiter plate was washed five 
times with wash buffer. 100µl of the prepared derivatised solution of 
standards, samples and maximum binding was dispensed into the wells 
according to the plate set-up.  The plate was covered and incubated for 24 h 
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at 4°C. Prior to the developing process, the plate was washed five times with 
300µl of wash buffer. 200µl of Ellmans reagent was added into the wells and 
incubated with an orbital shaker in the dark at room temperature. The plate 
was read between 405 and 414nm using the spectrophotometer. The net 
histamine release (%) was calculated following the equation: 
 
The spontaneous histamine release (%) was calculated following the 
equation below: 
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2.5.4 PGD2 assay 
Cell-free supernatants from CDMCs and BMDMCs were collected and 
processed for the PGD2 assay immediately. The PGD2 assay (Cayman 
Chemical, US) was performed according to the manufacturer’s protocol.  This 
assay is based on the competition between PGD2–acetylcholinesterase 
(AChE) conjugate (PGD2 tracer) for a limited number of PGD2 monoclonal 
antibody binding sites. As the concentration of PGD2 tracer is held constant 
while the concentration of PGD2 varies, the amount of PGD2 tracer that is 
able to bind to the monoclonal antibody will be inversely proportional to the 
concentration of PGD2 in the well. Buffers and reagents used in this assay 
were prepared according to the protocol.  
The standards were in the range of 117.2 - 15000 pg/ml and were 
diluted with culture medium. The plate was pre-coated with goat anti-mouse 
polyclonal antibody and blocked with proprietary formulations of proteins. This 
plate contains blanks, non specific binding (NSB) wells, maximum binding 
wells, standards and samples which were assayed in duplicates.  For NSB 
wells, 50µl of EIA buffer and 50µl of culture medium were added and the 
maximum binding (B0) wells contain 50µl of culture medium only. 50µl of 
standards and samples were added in duplicate into the appropriate wells. 
50µl of PGD2 Tracer were added into all wells except the blanks. 
Subsequently, 50µl of prostaglandin D2 monoclonal antibody was added into 
all wells except NSB and blank wells. The plate was then covered with plastic 
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film and left to incubate for 2 h at room temperature on an orbital shaker.  
After incubation, the plate was washed five times with wash buffer and 
200µl of Ellman’s reagent (reconstituted immediately before use) was added 
into each well. The plate was then covered again with plastic film and left for 
60-90 min. This assay is typically complete when B0 wells have acquired ≥ 
0.3 absorbance unit (A.U). The product of this enzymatic reaction has a 
distinct yellow colour and absorbs strongly at 412nm. The intensity of this 
colour, determined spectrophotometrically, is proportional to the amount of 
PGD2 tracer bound to the well, which is inversely proportional to the amount 
of free PGD2 present in the well during the incubation. 
 
2.5.5 β-hexosaminidase assay 
10 µl of supernatant was mixed with 10 µl of β-hexosaminidase 
substrate (4-nitrophenyl N-acetyl-β-d-glucosaminide) solution adjusted to 
pH = 4.5 with citrate buffer, and incubated for 1 h at 37 °C. 250 µl of 0.1 M of 
Na2CO3/NaHCO3 solution was added, and absorbance at 405 nm was 
measured. Total release of mast cell contents was achieved by adding the 
cell lysate of unstimulated cells. Degranulation percentage was calculated 
using the formula: (β-Hex (supernatant)-A)/(β-Hex (total)-A) × 100, where A is 
the β-hexosaminidase released from unstimulated cells. 
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2.6 INVERTED LIGHT MICROSCOPY 
CDMCs were plated at a density of 105 cells per well. The cells were 
stimulated with 5, 10 and 20 µg/ml of compound 48/80 for 10 min. In a 
separate group, the cells were pre-treated with 10 nM of nedocromil for 5 min 
prior to the stimulation of 20 µg/ml of compound 48/80. The morphology of 
these cells was compared to that of unstimulated cells. The cells were then 
analysed and micrographs were taken using the Inverted light microscope 
(Nikon) at 40x magnification. The total cells and degranulated cells were 
counted in a blinded manner for each treatment groups (n=3) and the 
percentage of CDMCs degranulation was calculated. 
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2.7 IMMUNOFLUORESCENT STAINING  
2.7.1 Confocal microscopy studies to visualise Anx-A1 distribution 
in U937 cells 
U937 cells were plated at density of 105 cells per chamber in 
microscope chamber slides. PMA (10ng/ml) was added to the cells for 24 h. 
Cells were treated with anti-allergic drugs (10nM) on their own or in 
combination with dexamethasone (2nM) respectively for 5 min. Upon 
treatment, cells were washed with PBC once and fixed with 2% 
paraformaldehyde (PFA) in 0.1M PBS for 10 min on ice. Cells were washed 
again in 0.1M PBS and Phalloidin Red (Alexa Fluor 546) was added into the 
cells at 1:1000 dilution for 10 min. Cells were then permeabilised with 0.1% 
Triton X-100 in PBS for 5 min. Non-specific secondary antibody binding site 
were blocked by incubation in 10% FBS in PBS for 30 min.  
Primary antibody (Anx-A1, Zymed, Invitrogen) was diluted (1:1000) 
with 1% FBS in PBS and added into the chamber slides and left on the orbital 
shaker for 1 h at room temperature. Cells were then washed twice with PBS 
containing 1% FBS and incubated in the dark with fluorescent-labelled 
secondary antibody (Alexa Fluor 488) at 1:500 dilution.  
Cells were washed twice in PBS and nuclei counterstained with 
100ng/ml DAPI in ddH2O for 5 min. Slides were washed with ddH2O and air-
dried. Cover slips were carefully mounted onto the slides using the Prolong 
Gold Mountant. Slides were then analysed and micrographs were taken using 
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the confocal microscope (Leica) at 63x magnification. 
 
2.7.2 Confocal microscopy to observe the distribution of PKC, 
tryptase, and Anx-A1 in cord blood derived mast cells (CDMCs). 
CDMCs were plated at a density of 2x105 cells in a 1.5ml Eppendorf 
tube. Cells were treated with the stipulated drugs for 5 min prior to stimulation 
with compound 48/80. 2% PFA in 0.1M PBS was added into the Eppendorf 
for 10 min on ice to fix the cells. Since the CDMCs are non-adherent cells, 
each immunostaining steps were performed in 1.5ml Eppendorf tube and 
centrifuged at 1000g for 5 min between each methodological step and the 
supernatant was aspirated carefully with a vacuum without disrupting the 
pellet. After fixation, the cells were washed with 0.1M PBS. Cells were then 
permeabilised with 0.1% Triton X-100 in PBS for 5 min. Non-specific 
secondary antibody binding site were blocked by incubation of 10% FBS in 
PBS for 30 min.  
Primary antibody (refer to Table 2.4) was diluted with 1% FBS in PBS 
and left to incubate at 4°C overnight. The cells were washed twice with 1% 
FBS in PBS and incubated with fluorescent-labelled secondary antibody 
(refer to Table 2.4) for 1 h at room temperature. 
The cells were then washed with PBS and stained with 100ng/ml 4',6-
diamidino-2-phenylindole (DAPI; Invitrogen)) in ddH2O for 5 min. The cells 
were washed with 30µl ddH2O and dropped onto the slide using a pipette. 
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Cover slips were carefully mounted onto the slides using the Prolong Gold 
Mountant (Invitrogen). Slides were then analysed and micrographs were 
taken using the confocal microscope (Leica) at 63x magnification. 
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Primary 
Ab 
Host Dilution Type Source Secondary 
Ab 
 
Anx-A1 
(1B) 
 
mouse 
 
1:1000 
(10µg/ml) 
 
Monoclonal 
 
In-house 
(Clone 1B) 
 
Alexa Fluor 
488 (green) 
 
Anx-A1 
 
rabbit 
 
1:1000 
(10µg/ml) 
 
 
Polyclonal 
 
Invitrogen 
(71-3400) 
 
Alexa Fluor 
546 (red) 
 
Tryptase 
 
mouse 
 
1:100 
(100µg/ml) 
 
Monoclonal 
 
Abcam 
(ab2378) 
 
Alexa Fluor 
488 (green) 
 
Total PKC 
 
rabbit 
 
1:50 
(200µg/ml) 
 
Polyclonal 
 
Cell 
Signalling 
Technology 
(2056) 
 
Alexa Fluor 
546 (red) 
 
Table 2.4: Primary and secondary antibodies used for confocal 
microscopy. 
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2.8 STATISTICAL ANALYSES 
 
Before performing any relevant tests, the samples were analysed for 
normality. All values are presented as mean ± SEM pooled data from 3 
independent experiments. Data were analysed using a one-way analysis of 
variance (ANOVA), followed by a Bonferonni post hoc test unless otherwise 
stated. All statistical tests were performed with GraphPad Prism version 4 for 
Mac (GraphPad Software, San Diego, California, USA, www.graphpad.com). 
P < 0.05 was considered to be statistically significant. 
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3. RESULTS 
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3.1 THE EFFECTS OF ANTI-ALLERGIC DRUGS ON ANX-A1 
PHOSPHORYLATION.  
3.1.1 The effect of dexamethasone on Anx-A1 phosphorylation in 
U937 cells. 
Anx-A1, which is mainly found in the cytoplasm, translocates rapidly to 
the cell surface upon treatment with glucocorticoid and cromones (Solito et 
al., 1994; Yazid et al., 2009) and is secreted into the extracellular milieu 
where it exert its anti-inflammatory activities.  This rapid GR-dependent non-
genomic event is preceded by the phosphorylation of Anx-A1 on a specific 
amino acid residue Ser27 (Solito et al., 2003c; Solito et al., 2006b). In 
preliminary experiments, no effect of dexamethasone on Anx-A1 
phosphorylation was observed in the pro-monocytic cell line U937 in the 
absence of the PMA pre-treatment (Figure 3.1), because the cells need to 
acquire monocytic properties to become sensitive to the action of GC. 
However, upon ‘priming’ for 24 h with phorbol-12-myristate-13-acetate (PMA), 
the U937 cells were responsive towards the GC treatment (Solito et al., 
1991a).  
Since 5 min pre-treatment with GC and cromones produced the 
maximal effects on Ser27-Anx-A1 phosphorylation in U937 cells differentiated 
with 10ng/ml of PMA for 24 h (Yazid et al., 2009), this time point was chosen 
for all the experiments performed on U937 cells, in which the effects of anti-
allergic drugs (0 - 500nM) were determined. Dexamethasone (0 - 200nM) 
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increases Ser27-Anx-A1 phosphorylation in a concentration dependent-
manner in U937 cells (Figure 3.2).  
 
 
 
 
 
 
 
Figure 3.1: Ser27-Anx-A1-P detection in U937 cells with dexamethasone 
(2 nM) in the presence or absence of PMA (10ng/ml). 
(A) Determination of Ser27-Anx-A1-P by Western blot. Cells were treated with 
dexamethasone (2nM), with or without PMA (10ng/ml) and lysed with 100µl of lysis 
buffer. 30µg of sample were loaded after protein concentrations and were assessed 
by Bradford Assay. Equal loading was confirmed by total Anx-A1. (B) Densitometry 
values of 3 independent experiments were expressed as percentage of arbitrary 
units of Ser27-Anx-A1-P expressed in whole cell lysate. Data are expressed as mean 
± SEM; (** p<0.01 and *** p<0.001). 
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Figure 3.2: Dexamethasone increases Ser27-Anx-A1 phosphorylation in 
U937 cells in a concentration-dependent manner. 
(A) Detection of Ser27-Anx-A1-P was determined by Western blot in U937 cells 
treated for 5 min with dexamethasone at various concentrations (0 - 200nM). (B) 
Densitometry values from 3 independent experiments were expressed as mean 
percentage of control of the Ser27-Anx-A1-P normalised to total Anx-A1 expressed in 
the whole cell lysate. Data are expressed as mean ± SEM; **p<0.01 and ***p<0.001. 
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3.1.2 The ability of anti-allergic drugs to promote Ser27-Anx-A1 
phosphorylation in a concentration-dependent manner. 
Three H1 antagonist drugs, promethazine, pheniramine and antazoline 
were tested in this system. These drugs, which are known as anti-histamines, 
are commonly used in the treatment of allergic conditions. Immunoblotting 
techniques was utilised to determine the concentration-response of these 
drugs to promote the phosphorylation of Anx-A1 in U937 cells. Figure 3.3 
show that antazoline produced a weak effect from 2 - 50nM (2 fold change 
from control) and subsequently decreased below the basal level with 
increasing concentrations. Whereas, promethazine and pheniramine shares 
the same trend, whereby, from 2 - 100nM, these drugs did not promote 
phosphorylation of Anx-A1 at Ser27 residue. However, from 100 - 500nM, 
these drugs produced a weak concentration-dependent increase of Ser27-
Anx-A1-P, with maximal phosphorylation observed at 500nM with < 2-fold 
change.  
 ‘Mast cell stabilising’ drugs (nedocromil, cromoglycate and pemirolast) 
were used in this system to study the ability of these drugs to enhance the 
phosphorylation of Anx-A1. Based on the blots (Figure 3.4), all these drugs 
promoted the phosphorylation of Anx-A1 across increasing concentrations (0 
- 500nM). Among the three drugs, nedocromil has the highest efficacy by 
producing the maximal effect at 500nM (> 3-fold change), whilst cromoglycate 
and pemirolast induces maximal effects of only 2.5-fold change. 
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 ‘Dual-action’ drugs have the capacity to antagonise the H1 
receptor and ‘stabilise’ the mast cells upon allergic challenge. Ketotifen, 
epinastine and olopatidine were tested on U937 cells and their ability to 
promote Ser27-Anx-A1-P was determined by Western blotting. Figure 3.5 
shows that epinastine and ketotifen alone greatly potentiated the Anx-A1 
phosphorylation in a concentration-dependent fashion. Epinastine and 
ketotifen induce > 5-fold change and 4 fold-change respectively at the highest 
concentration. Whereas, olopatidine is not as efficacious as the other two 
drugs as it only promoted Anx-A1 phosphorylation by 2-fold at 500nM.  
To conclude this part, these anti-allergic drugs could be categorised on 
their ability to promote the phosphorylation of Anx-A1 at Ser27 residue (Table 
3.1).  H1 antagonist drugs only weakly increase phosphorylation of Anx-A1 (< 
2-fold). Drugs that moderately (< 2.5-fold) induce Anx-A1 phosphorylation are 
pemirolast, cromoglycate and olopatidine. Whereas, Anx-A1 is greatly (> 3-
fold) phosphorylated in the presence of nedocromil, ketotifen and epinastine.  
 
   
  160 
 
Figure 3.3: H1 antagonist drugs exert weak Ser27-Anx-A1 
phosphorylation in U937 cells. 
U937 cells were treated with increasing concentrations (2 - 500nM) of H1 antagonist 
drugs for 5 min and processed for cell lysis protocol and protein assay. 30µg of 
sample was loaded into each well and Anx-A1 phosphorylation was detected by 
Western blots. Data are expressed as mean ± SEM and is a representative of 3 
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independent experiments. (Promethazine: * p<0.05 vs untreated and pheniramine: + 
p<0.05 vs untreated). 
 
Figure 3.4: Individual treatment of cromoglycate and pemirolast exert 
moderate Anx-A1 phosphorylation, however nedocromil induce strong 
signal of Anx-A1 phosphorylation in U937 cells. 
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Aliquots of 2x105 U937 cells were cultured as described and incubated for 5 min with 
escalating concentrations of nedocromil, cromoglycate and pemirolast (2 - 500nM). 
The cell lysate were prepared for Western blotting to assess the intracellular 
concentrations of Ser27-Anx-A1-P. Data are expressed as mean ± SEM and is a 
representative of 3 independent experiments. (Nedocromil: * p<0.05, ** p<0.01, *** 
p<0.001, cromoglycate: + p<0.05, pemirolast: § p<0.05 vs untreated). 
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 Figure 3.5: ‘Dual-action’ drugs increases Ser27-Anx-A1 phosphorylation 
in a concentration-dependent manner in U937 cells. 
The cell lysate were prepared for Western blotting to assess the intracellular 
concentrations of Ser27-Anx-A1-P upon treatement with olopatidine, ketotifen and 
epinastine (2 - 500nM). Based on the densitometry analysis, ketotifen and epinastine 
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are able to promote strong Anx-A1 phosphorylation; meanwhile olopatidine only 
moderately increases phosphorylation of Anx-A1. Data are expressed as mean ± 
SEM and is a representative of 3 independent experiments.  (Epinastine: *** 
p<0.001, ketotifen: §§§ p<0.001, olopatidine: + p<0.05, ++ p<0.01 vs untreated). 
 
 
 
Anx-A1 
phosphorylation 
Weak 
(< 2 fold 
increase) 
Moderate 
(< 2.5 fold 
increase) 
Very active 
(> 3 fold 
increase) 
 
H1 antagonists 
only 
 
 
Promethazine 
Pheniramine 
Antazoline 
  
 
‘Mast cell 
stabilisers’ only 
 
  
Pemirolast 
Cromoglycate 
 
Nedocromil 
 
‘Dual-action’ 
drugs 
 
  
Olopatidine 
 
Ketotifen 
Epinastine 
 
Table 3.1: Fold change is based on densitometry analysis of Ser27-Anx-
A1-P in U937 cells treated with anti-allergic drugs. 
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3.1.3  Effects of anti-allergic drugs alone or in combination with 
dexamethasone (2nM) on the distribution and release of Anx-A1 in 
U937 cells. 
Anx-A1, mainly localised in the cytosol, is exported to the cell 
membrane when cells are briefly exposed to dexamethasone (Solito et al., 
2003c). Once at the cell membrane, Anx-A1 is secreted either in an autocrine 
or paracrine manner to exert its anti-inflammatory properties. A previous 
study has shown that nedocromil in combination with dexamethasone caused 
an increased release of Anx-A1 in U937 cells (Yazid et al., 2009). Therefore, 
in this study, the distribution of total Anx-A1 protein upon treatment with anti-
allergic drugs alone or in combination with dexamethasone was investigated. 
Supernatants from U937 cells treated with the drugs were collected and 
assessed for total Anx-A1 protein by Western blotting. Since this technique is 
semi-quantitative and Anx-A1 expression measured outside of the cell cannot 
be normalised to a standard protein, it is difficult to characterise the shape of 
the concentration-response curve across increasing concentrations. From 
these blots (data not shown), only the consecutive release of total Anx-A1 
upon treatment was observed. Hence, the Western blot analysis was 
corroborated by assessing the distribution and release of Anx-A1 by confocal 
microscopy imaging technique, whereby cells were stained with DAPI to view 
the nucleus (blue), Phalloidin Red Alexa Fluor® 546 labelling specifically the 
membrane phospholipids (red) and an antibody against Anx-A1 (Zymed, 
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Invitrogen) which labels total Anx-A1 (green).  
The effect of the H1 antagonists on the intracellular movement of Anx-
A1 at microscopic level was investigated. Positive controls are shown in 
Figure 3.6 (A). Cells treated with H1 antagonist drugs alone exhibit a very 
weak Anx-A1 signal (green), but in the presence of dexamethasone, distinct 
co-localisation, which is evident from the yellow signal, was observed, 
followed by the release of Anx-A1 (Figure 3.6). 
Confocal images show that all the three ‘mast cell stabilising’ drugs 
were able to release Anx-A1, in that, cells treated with these drugs (10nM) 
alone exhibit distinct co-localisation with the membrane and release of Anx-
A1. However, these effects are greatly enhanced in the presence of 
dexamethasone at 2 nM (Figure 3.7).   
Figure 3.8 shows that epinastine, ketotifen and olopatidine provoke 
strong release of Anx-A1 on their own with the evidence of membrane 
blebbing; however, dexamethasone does not produce any further effect when 
combined with these drugs.  
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Figure 3.6: H1 antagonist drugs promote weak Anx-A1 signal. 
Panel A shows positive control cells. U937 cells were stained with DAPI (blue), an 
antibody against total Anx-A1 (green) and phalloidin (red). (B) Confocal micrographs 
of U937 cells treated for 5 min with H1 antagonist drugs alone or in combination with 
dexamethasone (2nM). These drugs provoke very weak Anx-A1 release on their own 
but in the presence of dexamethasone, there is a striking degree of co-localisation 
between Anx-A1 and phalloidin red and evidence of membrane ‘blebbing’ was 
observed. Pictures were taken at x63 magnification. Scale bars indicate 10µm. 
These images are representative of 3 independent experiments. 
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Figure 3.7: Moderate Anx-A1 secretion was seen after treatment with 
‘mast cell stabilising’ drugs but is potentiated by dexamethasone.  
Confocal microscopy shows that in nedocromil treated cells, Anx-A1 is distributed at 
the plasma membrane, but in the presence of dexamethasone, prominent Anx-A1 
secretion was observed. Anx-A1 was found to be distributed mainly in the cytoplasm 
of U937 cells treated with both cromoglycate and pemirolast. However, when 
dexamethasone was administered to the cells, distinct Anx-A1 secretion was 
observed. Pictures were taken at x63 magnification. Scale bars indicate 10µm. 
These images are representative of 3 independent experiments. 
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Figure 3.8: Anx-A1 secretion was strongly induced by ‘dual-action’ 
drugs. 
Confocal micrographs show that dual-action anti-histamine drugs displayed 
prominent membrane protrusions (white arrow) and released Anx-A1 in a 
concentration-dependent fashion. Similar morphological changes were observed 
when ‘dual-action’ drugs were combined with dexamethasone. Pictures were taken 
at x63 magnification. Scale bars indicate 10µm. These images are representative of 
3 independent experiments. 
Olopatidine Ketotifen Epinastine 
‘Dual-action’ 
drugs alone 
(10nM) 
‘Dual-action’ 
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3.1.4 Nedocromil potentiates the inhibition of thromboxane B2 
(TxB2) release in the presence of dexamethasone in U937 cells. 
The ability of GCs to inhibit eicosanoid synthesis in many systems has 
been shown to depend on the release of Anx-A1 (Errasfa et al., 1989; Croxtall 
et al., 2003). TxB2 was measured because this mediator could be used as an 
index of eicosanoid production. U937 cells were used because TxB2 is 
generated in abundance by these cells compared to other eicosanoid 
mediators (Solito et al., 1991a). Figure 3.9 shows that increasing 
concentration of nedocromil (2 - 100nM) produces a modest suppression of 
TxB2 release into the supernatant of U937 cells with maximal inhibition of 18.2 
± 2.8% (p<0.05). Pre-treatment of dexamethasone alone (2nM) for 5 min, 
only produced 3.9 ± 0.5% inhibition. However in the presence of 
dexamethasone at 2nM, the actions of nedocromil was greatly potentiated 
across increasing concentrations, such that TxB2 was significantly (p<0.001) 
suppressed even further by 63.9 ± 1.8% at 100nM of nedocromil.  
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Figure 3.9: Measurement by ELISA assay of TxB2 release shows that 
nedocromil inhibits TxB2 released by U937 cells in a concentration- 
dependent manner in the presence of dexamethasone. 
When dexamethasone (2nM) is combined to the increasing concentrations of 
nedocromil for 5 min, a concentration-dependent potentiation of the inhibitory effects 
of TxB2 release was observed. Data are expressed as mean ± SEM and is a 
representative of 3 independent experiments.  **p<0.01 and ***p<0.001 and § p<0.05 
relative to untreated. 
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3.2 ANTI-ALLERGIC DRUGS STIMULATE ANX-A1 THROUGH 
A PKC-DEPENDENT MECHANISM IN CDMCS. 
3.2.1 Anx-A1 phosphorylation is abolished by an inhibitor of PKC.  
 Even though much work has been done on the effect of the 
cromoglycate-like drugs such as nedocromil on Anx-A1 and PKC 
phosphorylation in U937 cells (Yazid et al., 2009; Yazid et al., 2011), the main 
clinical target of these drugs are the mast cells. Thus, this led to the 
investigation on the interaction between the anti-allergic drugs, Anx-A1 and 
PKC in the human mast cells.  
 In a human folliculostellate cell line, the phosphorylation of Anx-A1 
produced by dexamethasone is the result of the activation of protein kinase C 
(PKC), mitogen-activated protein kinase (MAPK) and phosphatydilinositol 3-
kinase (PI3K) (Solito et al., 2003c). Yazid et al has shown that PKC activation 
is responsible for the phosphorylation of Anx-A1 in the U937 cells (Yazid et 
al., 2009). Since kinase activation may be dependent on cell type, the 
importance of PKC in the cord-blood derived mast cells (CDMCs) was 
assessed by using a PKC inhibitor (Gö 6983). The CDMCs were treated with 
10nM of nedocromil for 5 min, with or without the presence of PKC inhibitor 
for 30 min (10µM).  
 Figure 3.10 shows that nedocromil-induced Anx-A1 phosphorylation 
(136.3 ± 1.1%) is blocked significantly by the addition of PKC inhibitor (43.5 ± 
11.9%; *p<0.05 vs nedocromil alone). Even though there is a slight increase 
  173 
of Anx-A1 phosphorylation in the presence of nedocromil and PKC inhibitor 
as compared to cells incubated with PKC inhibitor alone, the statistical 
analysis revealed that these differences were not significant. It might imply 
that possibly a small residual activity of PKC was not completely abolished by 
the inhibitor. However, previous study has shown that the increase in Anx-A1 
phosphorylation by nedocromil was a result of PKC activation in U937 cells 
(Yazid et al., 2009).  
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Figure 3.10: The increase in Ser27-Anx-A1-P by nedocromil is a result of 
PKC activation in CDMCs. 
CDMCs were incubated with PKC inhibitor (Gö 6983; 10µM) for 30 min prior to the 5 
min pre-treatment of nedocromil (10nM). Densitometry analysis shows that 
nedocromil was not able to induce Anx-A1 phosphorylation in the presence of PKC 
inhibitor in CDMCs.  Representative blots of 3 independent experiments. Data are 
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expressed as mean ± SEM; *p<0.05 and **p<0.01 relative to untreated or nedocromil 
alone. 
3.2.2 Western blotting detection of specific PKC isoforms. 
Figure 3.10 show that phosphorylation of Anx-A1 in CDMCs is 
dependent on PKC phosphorylation but not which isoform. Hence, a panel of 
anti-phospho PKC isoforms antibodies were analysed using Western blot. 
Given that the molecular weight of the PKC using pan-specific PKC antibody 
was 78 - 85kDa, it suggested that the relevant isoforms were PKCδ (78kDa), 
PKCθ (79kDa) or PKCαβ (80 - 82kDa). Figure 3.11 shows that that PKCδ and 
PKCθ were not detected in CDMCs treated with 0 and 5 nM of nedocromil. 
However, the specific PKCα/βThr 638-641 antibody showed good reactivity with a 
band that increased with 5nM of nedocromil over a period of 5 min. Therefore 
it could be concluded that the main kinase responsible in this system is 
probably PKCα/β (80-82kDa). 
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 A) 
 
 
 
 
 
 
 
 
 
B) 
Figure 3.11: PKCα/βThr 638-641 isoform is responsible for nedocromil-
induced Ser27-Anx-A1-P in CDMCs.   
A) Analysis of the potential PKC isoform activated by nedocromil at 0 and 5nM was 
performed by Western blot. Blots were probed with different anti-sera specific for 
each isoform. Activated PKC α/βThr 638-641 was the only isoform to show a strong signal 
in response to nedocromil treatment in human mast cells. Representative blots of 3 
0 5
0
50
100
150
200
250
300
350
400
450
Nedocromil (nM)
Ph
os
ph
o 
PK
C
 α
/β
 (A
D
 u
ni
ts
) 
no
rm
al
is
ed
 to
 α
-tu
bu
lin
  177 
independent experiments. B) Densitometry analysis was performed for PKC α/βThr 638-
641 normalised to α-tubulin.  
3.2.3 The effects of anti-allergic drugs on Anx-A1 phosphorylation 
in CDMCs. 
Working with collaborators, our group has reported the anti-allergic 
action of the Anx-A1 derived peptide ac2-26 in a rat pleurisy model 
(Bandeira-Melo et al., 2005). Thus, the effect of the anti-allergic drugs such 
as promethazine, nedocromil and ketotifen, on Anx-A1 and PKC 
phosphorylation in the cord-blood derived mast cells (CDMCs) was assessed.  
Firstly, the optimal time point for PKC-P and Ser27-Anx-A1-P in 
CDMCs treated with nedocromil was established. Figure 3.12 shows that 
phosphorylation of Anx-A1 in response to nedocromil treatment was already 
maximal at 5 min (~ 2 fold) and declined within 15 min (27.4 ± 2.8% vs 100% 
control).  The same trend was observed when the blots were probed for PKC 
phosphorylation; at 5 min the optimal effect was observed (~ 4 fold).  
Therefore 5 min was chosen as the optimal time point for the anti-allergic 
drug treatment in CDMCs to study PKC and Anx-A1 phosphorylation.  
The concentration-dependency of Anx-A1 and PKC phosphorylation in 
CDMC cell lysates induced by anti-allergic drugs following 5 min incubation 
was established by Western blot.  In the untreated lane, small amounts of 
phospho-PKC and phospho-Anx-A1 were detected in the lysate. This is a 
common finding as these cells are already partly ‘activated’ by the presence 
of the stem cell factor (SCF) in the medium.  
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A panel (promethazine, nedocromil and ketotifen) of anti-allergic drugs 
(0 - 100nM) was compared in this experiment. Figure 3.13 show that 
increasing concentrations of promethazine did not significantly promote Anx-
A1 phosphorylation across increasing concentrations. However, at 
concentrations from 5 - 10nM, promethazine significantly (p<0.05) increased 
PKC phosphorylation by 173.1 ± 15%. Based on Figure 3.14, nedocromil 
produces a maximal effect of Anx-A1 and PKC phosphorylation at 20nM 
(approximately 249.4 ± 19.7% and 331.0 ± 19.6% from control respectively). 
In contrast, beyond 20nM, no further effect is seen. Figure 3.15 show that 
increasing concentrations of ketotifen displays a ‘bell-shaped’ curve, with a 
maximal effect on Anx-A1 (p<0.01) and PKC (p<0.001) phosphorylation at 
10nM (261.8 ± 9.4% and 304.8 ± 16.5% vs control) and thereafter a 
concentration-dependent decrease in the level of both Anx-A1 and PKC 
phosphorylation was observed. These results show that both nedocromil and 
ketotifen share similar ability to induce Anx-A1 and PKC phosphorylation, 
however promethazine did not significantly promote the phosphorylation of 
Anx-A1 and only weakly induced PKC phosphorylation. Based on the blots, it 
could be observed that Ser27-Anx-A1 phosphorylation mirrors PKC 
phosphorylation in all the three drugs that were tested. 
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Figure 3.12: PKC-P and Ser27-Anx-A1-P detection at 5 min in CDMCs 
treated with nedocromil (10nM). 
(A) CDMCs were treated with nedocromil for periods of 0-15 min, processed for 
Western blotting and probed for PKC-P, total PKC, Ser27-Anx-A1-P and total Anx-A1 
antibodies. Equal loading was confirmed by α-tubulin. (B) Densitometry values of 3 
independent experiments were normalised to total protein and expressed as 
percentage of control. Data are expressed as mean ± SEM. *p<0.05, *** p<0.001 vs 
control (Yazid et al., 2013). 
A) 
B) 
Time (min) 
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Figure 3.13: Promethazine only weakly promotes PKC-P at 
concentrations less than 10nM. 
Whole CDMC lysate was prepared in the presence of 0 - 100nM of promethazine. 
Densitometry analysis shows that promethazine provokes similar trend of Anx-A1-P 
and PKC-P, whereby at concentrations from 20 - 100nM, the level of phosphorylation 
of both the proteins are almost abolished. Equal loading are confirmed by α-tubulin. 
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Densitometry values of 3 independent experiments were expressed as percentage of 
control. Data are expressed as mean ± SEM. Phospho PKC: * p<0.05 vs untreated. 
 
 
 
 
 
 
 
 
 
 
Figure 3.14: Nedocromil promotes PKC-P and Ser27-Anx-A1-P at lower 
concentrations, however the level of Anx-A1 and PKC phosphorylation 
diminishes >20nM of nedocromil. 
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Detection of Anx-A1 and PKC phosphorylation was determined by Western blot. The 
phospho proteins were normalised to their respective total proteins. Densitometry 
values of 3 independent experiments were expressed as percentage of control. Data 
are expressed as mean ± SEM. Phospho PKC: * p<0.05, ** p<0.01, *** p<0.001 vs 
untreated and phospho Anx-A1: § p<0.05, §§ p<0.01, §§§ p<0.001 vs untreated. 
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Figure 3.15: Ketotifen promotes Anx-A1 and PKC phosphorylation 
exhibiting a ‘bell-shaped’ concentration-response curve. 
Densitometry values of 3 independent experiments were expressed as percentage of 
control. Data are expressed as mean ± SEM. Phospho PKC: ** p<0.01, *** p<0.001 
vs untreated and phospho Anx-A1: §§ p<0.01 vs untreated. 
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3.2.3  PKC phosphorylation induced by dexamethasone (2nM) is 
prolonged by the combination with nedocromil (10nM) in U937 
cells over time. 
It has been hypothesised that the level of Anx-A1 phosphorylation and 
subsequently the amount that is exported out of the cell depends on the 
reciprocal interaction between PKC and PP2A enzyme. Therefore, drugs that 
prolong the expression of PKC would enhance the phosphorylation of Anx-
A1. In line with this thought, the ability of nedocromil, dexamethasone or both 
drugs in combination, to promote phosphorylation of the PKC enzyme from 0-
60 min time points in U937 cells was determined by Western blot.  In Figure 
3.16, nedocromil (10nM) promotes maximal PKC activity at 20 min (2.5 fold 
change from control) but the effect eventually wears off. Maximal 
phosphorylation of PKC upon treatment with dexamethasone (2nM) was 
observed at 10 min (2 fold-change) after which the effect fades with 
increasing time. Interestingly, when cells were treated with both nedocromil 
(10nM) and dexamethasone (2nM), there was a distinct increase of PKC 
phosphorylation, with maximal effect seen at 60 min (4 fold-change).  This 
suggests that these drugs exhibit a strong synergistic action on PKC 
phosphorylation over time.  
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Figure 3.16: Nedocromil (10nM) in combination with dexamethasone 
(2nM) prolongs PKC phosphorylation in U937 cells. 
Western blot analysis of PKC phosphorylation at different time points in U937 cells 
treated with nedocromil (10nM), dexamethasone (2nM) and both in combination. In 
the presence of dexamethasone and nedocromil, PKC phosphorylation was 
potentiated by 4 fold at 60 min. Representative blots of 3 independent experiments. 
(nedocromil: ** p<0.01 vs untreated, dexamethasone: + p<0.05 vs untreated and 
dexamethasone+nedocromil: § p<0.05, §§ p<0.01, §§§ p<0.001 vs untreated). 
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3.2.4 Phosphorylation of PKC is prolonged over time when CDMCs 
are treated with dexamethasone (2nM) in combination with 
nedocromil (10nM). 
Since the synergistic effects of dexamethasone and nedocromil to 
prolong the PKC phosphorylation in the U937 cells were determined (Figure 
3.16), the next question that arises was if similar effects could be reproduced 
in the CDMCs. The same protocol was repeated with CDMCs and Western 
blot was performed to analyse PKC phosphorylation across increasing time 
points. CDMCs were treated with either 10nM of nedocromil, 2nM of 
dexamethasone or both drugs in combination for various time points (0-60 
min). Based on Figure 3.18 (panel A), it is evident that nedocromil was able to 
provoke maximal PKC phosphorylation at 10 min whereas treatment with 
dexamethasone produced an increase in the amount of PKC phosphorylation 
in the cell with no further effect seen beyond 5 min. However, both the drugs 
in combination were able to prolong the PKC phosphorylation (4 fold) across 
1h time point. The results obtained from CDMCs were similar to that 
performed on U937 cells, suggesting that dexamethasone and nedocromil 
synergistically promote PKC phosphorylation across increasing time and this 
mechanism is independent of the cell type.  
The increments in the phosphorylated isoform of PKCα/β would be 
indicative of the protein mobilization and secretion at the plasma membrane 
when activated and Anx-A1 is likewise recruited to the membrane upon 
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phosphorylation at Ser27 residue. To investigate the effect of dexamethasone 
alone or in combination of nedocromil on the patterns of intracellular 
trafficking of PKC and Anx-A1 across increasing time points at a fine level of 
detail, CDMCs were utilised and the effects of the drug treatment were 
analysed by confocal microscopy. 
 Figure 3.18 (panel A, B and C) shows an experiment where CDMCs 
were stained for total PKC (red; Alexa Fluor 546; anti-rabbit) and total Anx-A1 
(green; Alexa Fluor 488; anti-mouse). CDMCs were treated with 
dexamethasone (2nM) alone or in combination with nedocromil (10nM) 
across various time points. The untreated cells (panel A), show similar 
cytoplasmic distribution of total PKC and Anx-A1 across 5, 10 and 20 min. 
PKC and Anx-A1 was observed mainly in the cytoplasmic or peri-nuclear 
region apparently associated with vesicles. Both these proteins were not 
observed at the plasma membrane since there were no co-localisation 
between PKC and Anx-A1.  
 Figure 3.18; B shows that when CDMCs were treated with 
dexamethasone for 5 min, there is a certain degree of co-localisation at 
membrane level between total PKC and Anx-A1. However, this effect was 
short-lived, fading after 10 min. Interestingly, exposure of cells to nedocromil 
in the presence of dexamethasone (Figure 3.18; C) for 5 min shows 
substantial amounts of PKC has translocated to the plasma membrane and is 
co-localised with Anx-A1 and this effect is prolonged across increasing time 
point, suggesting that nedocromil was able to prolong the distribution of total 
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PKC at membrane level. Since a combination of nedocromil and 
dexamethasone potentiates Anx-A1 phosphorylation and secretion, 
apparently through an increase of PKCα/β activation at the membrane, it 
could be conjectured that this drug might act as a phosphatase (PP2A) 
inhibitor that prevents PKCα/β dephosphorylation at the membrane in 
CDMCs. It has been shown in the U937 cells that the catalytic activity of 
PKCα/β is limited by membrane phosphatases, in particular PP2A (Yazid et 
al., 2009). The confocal images are in agreement with the Western blots 
whereby nedocromil in combination with dexamethasone was able to prolong 
the ‘dwell’ time of PKC phosphorylation in CDMCs.  
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Figure 3.17: Nedocromil (10nM) in combination with dexamethasone 
(2nM) prolongs PKC phosphorylation in CBMCs. 
CBMCs whole lysate were treated with nedocromil (10nM), dexamethasone (2nM) or 
both in combination and processed for Western blot analysis of PKC phosphorylation 
at different time points. In the presence of dexamethasone and nedocromil, PKC 
phosphorylation was potentiated by 4 fold at 40 min. Densitometry values of 3 
independent experiments were expressed as percentage of control 
(dexamethasone+nedocromil: ** p<0.01, *** p<0.001 vs untreated). 
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Figure 3.18: PKC ‘dwell’ time at the cell membrane increases when 
nedocromil is combined with dexamethasone.  
The CDMCs were plated at a density of 2x105 cells and prepared following the 
protocol described in the methodology sections. Cells were stained for total PKC 
(red; Alexa Fluor 546; anti-rabbit) and total Anx-A1 1B (green; Alexa Fluor 488; anti-
mouse). The three columns represent the information from the two colour channels 
and the merged channel. The CDMCs were either treated with dexamethasone 
(2nM) for 5, 10 and 20 min or treated with both nedocromil (10nM) and 
dexamethasone (2nM) for the same time points. The white arrows indicate co-
localisation between PKC and Anx-A1. The images were taken at 63x oil 
magnification. The scale bars indicate 10µm. This figure is representative of three 
independent experiments. 
 
C) 
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3.3 COMPOUND 48/80 AS A MAST CELL SECRETAGOGUE.  
3.3.1 Compound 48/80-induced degranulation was prevented when 
CDMCs were pre-treated with nedocromil (10nM). 
Compound 48/80 is a N-methyl-p-methoxyphenethylamine 
condensation producer that is commonly used to degranulate mast cells. 
Prior to using this compound for our in-vitro assays, the optimal concentration 
of compound 48/80 that induces CDMCs degranulation was first established. 
In order to do this, the cells were treated with a range of compound 48/80 
concentrations (5 - 20 µg/ml) and the morphology of the cells was observed 
under phase contrast microscope. The CDMCs degranulation was observed 
and counted in a blinded manner. Figure 3.19 shows distinct characteristics 
of mast cell degranulation upon stimulation with varying concentrations of 
compound 48/80 (upper panel). Inverted light microscope images of 
untreated CDMC, were observed to be oval in shape with distinct cell 
membrane and cytoplasm containing fine granules (A). Upon stimulation with 
compound 48/80 at 5µg/ml, cells exhibit marked membrane protrusion (black 
arrow), which indicates the beginning of degranulation (B). CDMCs were 
observed to have extruded granules (black arrow) near the cell surface when 
stimulated with 10µg/ml of compound 48/80 (C). CDMCs were seen to 
markedly degranulate (black arrow) when treated with 20µg/ml of Compound 
48/80 (D). Interestingly, CDMCs pre-treated with mast cell stabiliser, 
nedocromil (10nM) for 5 min prior to compound 48/80 (20µg/ml) stimulation 
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did not degranulate (E). Figure 3.19 (lower panel) shows that 10µg/ml of 
compound 48/80 induces approximately 45% of CDMCs degranulation. Since 
10µg/ml of Compound 48/80 produces half maximal effect of mast cell 
degranulation, this concentration was used for the subsequent experiments.  
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Figure 3.19: Pre-treatment of nedocromil (10nM) for 5 min prevented 
compound 48/80-induced CDMC degranulation. 
Upper panel: Inverted light microscope image of CDMCs stimulated with compound 
48/80. A) Unstimulated CDMCs, B) CDMCs treated with 5µg/ml of compound 48/80, 
C) CDMCs stimulated with 10µg/ml compound 48/80, D) CDMCs stimulated with 
20µg/ml of compound 48/80, E) CDMCs pre-treated with 10nM of nedocromil for 5 
min and stimulated with 20µg/ml of compound 48/80 for 10 min. Lower panel: The 
bar graph depicts the percentage of human mast cell degranulation upon stimulation 
with compound 48/80. Nedocromil significantly (p<0.001) inhibits compound 48/80-
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induced degranulation in CDMCs. (**p<0.01 and ***p<0.001). Data are expressed as 
mean ± SEM of n=3 independent experiments. Bars indicate 10µm. 
3.3.2 Compound 48/80 promotes histamine and phospho-Anx-A1 
release in a concentration-dependent manner in CDMCs. 
 Since PKC itself is activated during mast cell degranulation, the next 
question that arises was whether the stimulation of mast cells by 48/80 would 
be a sufficient stimulus to promote phosphorylation and release of Anx-A1. 
The previous experiment showed that compound 48/80 elicits mast cell 
degranulation. Thus, the ability of compound 48/80 to release histamine in 
CDMCs at varying concentrations was assessed. Since, compound 48/80 is 
able to promote approximately 80% of mast cell degranulation at 20µg/ml 
(Figure 3.19), the stimulation of histamine release at lower concentrations of 
compound 48/80 ranging from 0.01 - 10 µg/ml was investigated.  
Figure 3.20 (panel A) indicates that compound 48/80 produces a linear 
increase in histamine release in concentrations ranging from 0.01 to 0.1 
µg/ml, but thereafter, from concentrations 1 - 10 µg/ml, the secretagogue 
reaches a plateau at about 50% of net histamine release  
As lower concentrations of compound 48/80 (0.01 to 0.1 µg/ml) 
promotes only about 10 - 30% of net histamine release, these were deemed 
ideal to investigate the ability of compound 48/80 to induce Anx-A1 
phosphorylation as it was essential to have a working concentration of 
compound 48/80 that did not induce maximal degranulation. The Western blot 
in Figure 3.20 (panel B) shows that compound 48/80 induces a concentration-
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dependent decrease in Anx-A1 phosphorylation at Ser27 residue, and this is 
reflected in the amount of phosphorylated Anx-A1 that is then released out 
into the medium.  
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Figure 3.20: Compound 48/80 promotes the release of histamine and 
exerts the phosphorylation and release of Anx-A1 in a concentration-
dependent manner in CDMCs. 
A) Lower concentrations of compound 48/80 (0.01-0.1µg/ml) induces 10 - 20% of 
histamine release, whilst approximately 30% of histamine release was induced by 
1µg/ml of compound 48/80 and it reaches a plateau thereafter at ~50% of net 
histamine release. Data are expressed as mean ± SEM of n=3 independent 
experiments,  (***p<0.001). B) Phosphorylation and release of Anx-A1 is stimulated 
in a concentration-dependent manner by compound 48/80. Exposure to compound 
48/80 (0.01 - 0.1µg/ml) caused a rapid concentration-dependent degranulation and a 
concomitant increase in phosphorylation of Anx-A1 at Ser27 and a release of the 
protein into the surrounding medium. Densitometry values of 3 independent 
experiments are expressed as mean ± SEM. 
 
3.3.3 Characterisation of compound 48/80 on Anx-A1 
phosphorylation across time.  
 To further provide additional support for the notion that nedocromil 
‘stabilises’ mast cells by inducing Anx-A1 phosphorylation in stimulated cells, 
Western blots were performed on CDMCs lysates that were either stimulated 
with compound 48/80 (0.05µg/ml) alone, treated with nedocromil (10nM) 
alone or pre-treated with nedocromil (10nM) prior to compound 48/80 
stimulation across increasing time points.  
 Figure 3.21 shows that compound 48/80 induces a maximal Anx-A1 
phosphorylation (1.4 fold change from control) at 5 min which thereafter 
decays with time indicating that the cells would have degranulated. CDMCs 
treated with nedocromil (10nM) alone shows maximal Anx-A1 
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phosphorylation (2.7 fold change from control) at 5 min and this subsequently 
decays around the next 40 min. However, pre-treatment of nedocromil prior to 
compound 48/80 stimulation was able to augment Anx-A1 phosphorylation at 
all time points measured with the maximal effect (4.5 fold change from 
control) observed at 40 min. This result indicates that nedocromil is able to 
prolong Anx-A1 phosphorylation in CDMCs stimulated by compound 48/80. 
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Figure 3.21: Nedocromil potentiates Ser27-Anx-A1 phosphorylation with 
time in stimulated CDMCs. 
Compound 48/80 (0.05µg/ml) increases Anx-A1 phosphorylation with a maximal 
effect seen at 5 min and pre-treatment with nedocromil alone potentiates Anx-A1 
phosphorylation at 5 min. However nedocromil (10nM) prolonged the effect of 
compound 48/80 by increasing Anx-A1 phosphorylation in a time-dependent manner. 
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Data are expressed as mean ± SEM. (n=3 independent experiments, * p<0.05, ** 
p<0.01; ++ p<0.01, +++ p<0.001; §§§ p<0.001 vs control). 
 
3.4 MECHANISM OF ACTION OF NEDOCROMIL IN CDMCS. 
3.4.1 Nedocromil (10nM) inhibits β-hexosaminidase, histamine and 
PGD2 release by CDMCs but the effect is reversed by neutralising 
anti-Anx-A1 monoclonal antibody. 
 To investigate further the mechanism by which nedocromil suppress 
mediator release from CDMCs, biochemical and immuno-neutralising 
techniques was used.  
 FirstIy, it was determined whether the cultured CDMCs responded with 
the release of β-hexosaminidase, which is commonly used as an indicator of 
degranulation in mast cells. To determine the role of Anx-A1 in maintaining 
the stability of mast cells, the effect of a specific neutralising monoclonal anti-
Anx-A1 antibody was tested. CDMCs were pre-incubated for 20 min with 
20µg/ml neutralising anti-Anx-A1, or an irrelevant isotype-matched, 
monoclonal antibody. Figure 3.22 (panel A) shows that unstimulated CDMCs 
spontaneously released 8.9 ± 0.3% of β-hexosaminidase. However, in the 
presence of neutralising anti-Anx-A1 monoclonal antibody, the CDMCs 
released 43.6 ± 3.6% of β-hexosaminidase, suggesting that without 
extracellular Anx-A1, CDMCs undergoes spontaneous degranulation. The 
irrelevant isotype control was inactive in this system.   
  203 
Next, the effect of the co-incubation of stimulated CDMCs with 
neutralising anti-Anx-A1 (or irrelevant) monoclonal antibody on the effect of 
the inhibitory action of 10nM nedocromil on β-hexosaminidase release was 
investigated. Figure 3.22;B shows that nedocromil significantly (p<0.01) 
inhibits the β-hexosaminidase release by 32.3% relative to stimulated cells. 
However this inhibitory effect of nedocromil was completely abolished in the 
presence of Anx-A1 neutralising Ab, suggesting that the acute inhibition of β-
hexosaminidase release from CDMCs by nedocromil is Anx-A1 dependent. 
The irrelevant isotype control was inactive in this system. 
The above experiment demonstrated that the acute effects of 
nedocromil as an inhibitor of mast cell degranulation in human CDMCs 
appeared to be mediated by Anx-A1. Histamine and PGD2 assays were 
carried out to determine the mechanism by which nedocromil suppressed 
these mediators. The results on histamine release are presented as the 
percent inhibition in order to normalise the baseline differences between 
cultures that might have occurred due to variation among the individual 
batches of CDMCs obtained from different donors (Yamaguchi et al., 1999; 
Tachimoto et al., 2000). 
Based on the assay, the spontaneous release of histamine from 
unstimulated CDMCs was approximately 3.5 ± 6.1% and this readout was 
taken into consideration when the net histamine level was calculated (see 
materials and methodology section). It is noteworthy to mention that, PGD2 
was not released in unstimulated CDMCs as this mediator release is only 
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triggered in the presence of stimulus.  Figure 3.23 shows that 10 min 
stimulation by 10µg/ml compound 48/80 in CDMCs provoked a release of 
approximately 40% of net histamine release and 1331 ± 237.8 pg ml-1 of 
PGD2. Pre-treatment of cells with nedocromil prior to compound 48/80 
stimulation, was able to significantly inhibit the release of histamine (p<0.001; 
10.7 ± .08 %) and PGD2 (p<0.01; 657.7 ± 38.2 pg ml-1) in CDMCs. However, 
in the presence of neutralising anti-Anx-A1 monoclonal antibody, the 
inhibitory action of nedocromil was reversed. Neither the neutralising anti-
Anx-A1 monoclonal antibody nor the irrelevant isotype control alone had any 
significant effect on the release of mediators. Since the neutralising anti-Anx-
A1 monoclonal antibody has effects on its own on the mast cell 
degranulation, one may argue that the effects of nedocromil is due to the 
presence of neutralising anti-Anx-A1 monoclonal antibody. It could be 
possible that the neutralising anti-Anx-A1 monoclonal antibody is masking the 
effects of nedocromil in these cells. However, previous study had 
demonstrated that nedocromil was not effective in the Anx-A1 KO mast cells 
(Yazid et al., 2013), thus further reiterating that the inhibitory effects of 
nedocromil is dependent on the presence of Anx-A1. 
  
  205 
 
Figure 3.22: CDMC degranulation was assessed by measuring β-
hexosaminidase release. 
A) The supernatants from CDMCs were assessed for β-hexosaminidase assay and 
based on the assay, these unstimulated cells release about 43.6% of β-
hexosaminidase in the presence of neutralising anti-Anx-A1 mAb. B) Nedocromil 
significantly (p<0.01) inhibits the β-hexosaminidase release by 32.3% relative to 
stimulated cells. However this effect was completely abolished in the presence of 
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neutralising anti-Anx-A1 mAb. Data were analysed using one-way analysis of 
variance (ANOVA), followed by a Bonferonni post-hoc test, ** p<0.01, *** p<0.001 vs 
unstimulated. Data are expressed as mean ± SEM of n=3 independent experiments. 
 
 
Figure 3.23: Nedocromil inhibits histamine and PGD2 release but is not 
effective in the presence of neutralising anti-Anx-A1 mAb. 
CDMCs were plated at a density of 2x105 cells per well and the stipulated groups 
were administered with neutralising anti-Anx-A1 mAb or an irrelevant isotype control. 
Subsequently, the cells were pre-treated with nedocromil (10nM) for 5 min prior to 
compound 48/80 (10µg/ml) stimulation for 10 min. Supernatants were collected from 
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the samples and assessed for histamine and PGD2 assay by ELISA. (* signifies 
p<0.05, ** signifies p<0.01, *** signifies p<0.001 relative to control). Data are 
expressed as mean ± SEM of n=3 independent experiments. 	  
3.4.2 Inhibition of histamine and PGD2 in murine BMDMCs by 
nedocromil is blocked by neutralising anti-Anx-A1 monoclonal 
antibody. 
It has been shown in the previous experiments in CDMCs that the 
acute effects of nedocromil were Anx-A1 mediated. To eliminate the 
possibility that the role of Anx-A1 in the inhibitory actions of nedocromil was a 
feature unique to CDMCs, BMDMCs isolated from transgenic mice in which 
the Anx-A1 gene was globally deleted were used.  
Murine mast cells from wild type and Anx-A1 null mice were cultured 
and matured from bone marrow precursors as described. Figure 3.24 shows 
the electron micrographs of the WT and Anx-A1-/- BMDMCs that were used in 
this study (courtesy of Dr Yazid, UCL). The BMDMCs from WT mice was first 
utilised to establish whether these cells behaved in the same manner to the 
human CDMCs. The spontaneous release of histamine in the unstimulated 
WT BMDMCs was approximately 5.9 ± 2.3 % of the total histamine content, 
whilst 8.1 ± 3.4% was released in the KO BMDMCs. Figure 3.25 A and B 
shows that nedocromil (10nM) significantly (p<0.001) inhibits histamine and 
PGD2, (approximately 40% and 30% from control respectively) to a similar 
extent to that observed in the CDMCs. Once again, in the presence of 
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neutralising anti-Anx-A1 monoclonal antibody, nedocromil was inactive in this 
model, suggesting that nedocromil is dependent on Anx-A1 to exert its anti-
inflammatory pathway  
  209 
 
  
Figure 3.24: Electron micrograph of BMDMCs isolated from the wild type 
and Anx-A1 null mice. 
The electron micrographs show that the BMDMCs have typical mast cell 
morphology. The cytoplasm is dense with secretory granules and the nucleus is 
centrally located whilst the cell surface is covered with fine microvilli. There was no 
obvious difference between the phenotype but planimetric analysis revealed some 
differences in granule morphology. 
 
 
  
Wild-type BMDMCs Anx-A1 KO BMDMCs 
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Figure 3.25: The inhibitory effect of nedocromil of compound 48/80 
stimulated histamine and PGD2 release from BMDMCs is Anx-A1 
dependent 
BMDMCs from the WT strain of BALB/C mice were prepared and stimulated with 
compound 48/80 (10µg/ml). Nedocromil (10nM) was administered alone or in the 
presence of either Anx-A1 neutralising antibody or an irrelevant isotype control 
(20µg/ml). Histamine (A) and PGD2 (B) were assessed by ELISA assay. Nedocromil 
significantly inhibits the release of histamine and PGD2 but in the presence of Anx-
A1 neutralising antibody, this effect was reversed. (* p<0.05, ** p<0.01, *** p<0.001 
vs control). Data are expressed as mean ± SEM of n=3 independent experiments. 
(Yazid et al., 2013). 
A) B) 
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3.4.3 Hr-Anx-A1 inhibits histamine and PGD2 release in Anx-/- 
BMDMCs.  
The inhibitory effects of a range of 5 concentrations of nedocromil (0.5 
- 10nM) using two different protocols in which mediator release was 
stimulated with either DNP-IgE/anti DNP induced IgE cross-linking or by 
compound 48/80 were tested. Figure 3.26; panel A and B shows that 
nedocromil produced a concentration-dependent inhibition of histamine and 
PGD2 release, respectively, from WT BMDMCs when this was elicited by 
either anti DNP-IgE/DNP-BSA cross-linking in the case of pre-sensitised cells, 
or compound 48/80 in un-sensitised cells. However, nedocromil was inactive 
in the KO BMDMCs, which further points to a crucial role of Anx-A1 in the 
acute inhibitory actions of nedocromil. 
To confirm that this was not due to the fact that the cells cultured from 
the Anx-A1 null mice were not responsive to Anx-A1, the cells were treated 
with a range of hr-Anx-A1 concentrations (0.1 - 20nM). Figure 3.26; panel C 
shows that the exogenous Anx-A1 produces a concentration-dependent 
inhibition of both histamine and PGD2 in the KO BMDMCs. This data shows 
that whilst the BMDMCs from the Anx-A1 null mice was not able to release 
Anx-A1, these cells retain their sensitivity to the exogenous hr-Anx-A1 
protein, which inhibits histamine and PGD2 release with an IC50 value of 
approximately 5nM.  
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Figure 3.26: Nedocromil is inactive but hr-Anx-A1 inhibits PGD2 and 
histamine in Anx-/- BMDMCs.  
Panel A and B: BMDMCs were prepared from Anx-A1-/- and wild type mice as 
described. Samples were stimulated with either DNP/anti DNP cross-linking or 
compound 48/80. Nedocromil was added in increasing concentrations of 0.05 – 
10nM and the supernatant was assessed by ELISA for histamine (A) and PGD2 (B) 
release. Panel C: BMDMCs from Anx-A1-/- were pre-treated with hr-Anx-A1 (0.1 – 
20nM) prior to stimulating the cells with compound 48/80 (10µg/ml). Histamine and 
PGD2 release were assessed by ELISA. Results were expressed as % of inhibition; 
mean ± SEM of n=3 independent experiments. (Yazid et al., 2013) 
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3.4.4 Release of tryptase by compound 48/80 was reversed by 
nedocromil in an Anx-A1 dependent manner.  
 Another important mediator that is released during mast cell 
degranulation is tryptase enzyme. Since nedocromil inhibited the release of 
histamine and PGD2 in an Anx-A1 dependent manner, CDMCs were utilised 
to investigate if the release of tryptase was similarly inhibited and whether 
Anx-A1 was in fact in tryptase granules. Thus, the confocal microscopy was 
performed to investigate whether there is any co-localisation between Anx-A1 
and tryptase granules in the CDMCs with or without the stimulation with 
compound 48/80. The cells were stained with an antibody against tryptase 
(green) and Anx-A1 (red). The confocal micrograph of unstimulated CDMCs 
(Figure 3.27; panel A) clearly illustrates that tryptase and Anx-A1 in CDMCs 
are not co-localised and are seemingly present in different subcellular 
locations. However, upon stimulation with compound 48/80 (panel B), the cell 
undergoes degranulation and some degree of co-localisation between 
tryptase and Anx-A1 was observed, suggesting that Anx-A1 may be recruited 
to tryptase granules in the cytoplasm or at the site of release at the 
membrane. 
Next, the inhibitory action on the release of tryptase in CDMCs upon 
stimulation was investigated. Western blot was performed on the lysates of 
CDMCs pre-treated for 5 min with nedocromil (10nM) prior to the compound 
48/80 (20µg/ml). Based on the blots (Figure 3.28; A), upon stimulation, 
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CDMCs significantly (p<0.01) released approximately 40% of intracellular 
tryptase (relative to the unstimulated cells). However, in the presence of 
nedocromil prior to stimulation with compound 48/80, about 90.8 ± 0.9 % of 
intracellular tryptase was retained in the cells. Interestingly, incubation of 
CDMCs the with neutralising anti-Anx-A1 monoclonal antibody for 20 min, 
reversed the inhibitory effects of nedocromil, as evidenced by a decrease in 
intracellular tryptase to 49.7 ± 4.5%. The presence of neutralising anti-Anx-A1 
monoclonal antibody in CDMCs also increases the release of tryptase as it 
has been previously demonstrated that the Anx-A1 KO mice undergoes 
spontaneous mast cell degranulation (Yazid et al., 2013), suggesting the 
important role of Anx-A1 in regulating the activation of mast cells.  
To accompany this data, the morphology of CDMCs treated under 
similar conditions using confocal microscopy was observed. Figure 3.28 
(panel B) shows that in the unstimulated cells, intracellular tryptase was 
observed in the cytoplasm. However, upon activation, the mast cell features 
an obvious disruption to the cell structure, whereby the tryptase was released 
out of the cell. Pre-treatment of nedocromil (10nM) before mast cell 
stimulation resulted in tryptase being retained intracellularly. In the presence 
of neutralising anti-Anx-A1 monoclonal antibody, nedocromil was not able to 
inhibit the release of tryptase as it is evident from the micrograph that the cell 
undergoes degranulation.  
To further investigation, the cells were stained with toluidine blue, 
which detects the metachromatic granules of the mast cells. Unstimulated 
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cells exhibit intracellular metachromatic granules (purple) with intact nucleus 
(blue). Upon stimulation with compound 48/80, fewer intact intracellular 
metachromatic granules and granule-plasma membrane fusions can be 
observed during exocytosis.  
Nedocromil inhibited mast cell degranulation but in the presence of 
neutralising anti-Anx-A1 monoclonal antibody, this effect was abrogated. 
CDMCs incubated with neutralising anti-Anx-A1 antibody alone have fewer 
metachromatic granules when compared to the control group. This suggests 
that without Anx-A1, the CDMCs spontaneously degranulate, and does not 
respond to nedocromil. 
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Figure 3.27: Localisation of tryptase and Anx-A1 in CDMCs.  
Mast cells isolated from human cord-blood were stained with tryptase (1:1000 
dilution) and Anx-A1 (1:2000) and were analysed by confocal immunofluorescence 
microscopy. Confocal images of unstimulated CDMCs (A) and stimulated with 
compound 48/80 (B) shows distinct degranulation of the mast cells in the presence 
of compound 48/80. These images clearly illustrate that tryptase (green) and Anx-A1 
(red) in CDMCs are not co-localised as the tryptase and Anx-A1 do not overlap in 
resting cells. However, some degree of co-localisation was observed when the cells 
undergo degranulation. Pictures were taken at x63 oil magnification. These images 
are representative of 3 independent experiments. Scale bars indicate 10µm. 
 
 
A) B) 
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Figure 3.28: Western blot analysis of intracellular tryptase level in 
CDMCs.  
The densitometry analysis on the Western blot shows that in the presence of 
degranulating stimuli, the tryptase level in the cell lysate is significantly reduced 
(p<0.05). Interestingly when the CDMCs were pre-treated with nedocromil (10nM), 
the tryptase remains in the cell. In the presence of the neutralising anti-Anx-A1 
monoclonal antibody alone or combined with nedocromil, the tryptase level is 
significantly (p<0.05) reduced in the cell lysate. Data are expressed as mean ± SEM. 
(n=3 independent experiments, ** p<0.01, *** p<0.001 vs unstimulated). 
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B) 
 
Figure 3.29: The inhibitory effect of nedocromil on tryptase release is 
Anx-A1 dependent in CDMCs. 
A) Using CDMCs, confocal microscopy was utilised to visualise tryptase (green), 
total Anx-A1 (red) and DAPI was used to stain the nucleus (blue). CDMCs were 
stimulated with compound 48/80 (10µg/ml). Tryptase was confined in the cytoplasm 
when CDMCs were pre-treated with nedocromil prior to stimulation but in the 
presence of neutralising anti-Anx-A1 monoclonal antibody (20µg/ml), more tryptase 
granules were released from the cell. The morphology of the unstimulated mast cells 
shows that the plasma membrane is intact and the granules containing tryptase are 
contained inside the cell. However, upon activation, the mast cell exhibits obvious 
disruptions of the cell structure. This data was corroborated with toluidine blue 
staining of the cells treated under similar conditions observed under light 
microscopy. These images are representative of 3 independent experiments. 
Confocal images were taken at x63 oil magnification and the light microscopy 
images were obtained at x60 oil magnification. Scale bars indicate 10µm. B) The 
percentage of the intensity of fluorescence was calculated for each combination of 
treatment by voxel analysis of each confocal plane of >10 cells using Fiji image 
processing software (** p<0.01, *** p<0.001 vs unstimulated).  
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3.5 THE EFFECTS OF ANTI-ALLERGIC DRUGS ON THE 
INHIBITION OF HISTAMINE AND PGD2. 	  
 
3.5.1 Inhibition of histamine and PGD2 release from CDMCs by 
nedocromil and ketotifen is mediated by Anx-A1, but promethazine 
exerts its anti-histamine effects independent of Anx-A1. 
 In previous experiments with CDMCs, nedocromil (Figure 3.14) and 
ketotifen (Figure 3.15) promoted Anx-A1 phosphorylation across various 
concentrations; however, promethazine (Figure 3.13) was not able to induce 
significant Anx-A1 phosphorylation in CDMCs. These drugs possess different 
pharmacological characteristics, in that promethazine is a H1 antagonist, 
nedocromil is a mast cell stabilizer only and ketotifen is a ‘dual-action’ drug, 
having both properties. For this reason, the ability of these drugs to inhibit the 
release of mediators such as histamine and PGD2 during mast cell 
degranulation and the role of Anx-A1 in their inhibitory effects was 
determined.  
  The drugs were prepared at a concentration of 10nM and incubated 
with the cells for 5 min prior to the compound 48/80 (10µg/ml) stimulation for 
10 min. To ascertain the role of Anx-A1 in the mechanisms of action of these 
drugs, CDMCs were pre-incubated for 20 min with neutralising anti-Anx-A1 
monoclonal antibody (20µg/ml), or irrelevant isotype matched antibody 
(20µg/ml) before proceeding with the drugs treatment. The supernatant was 
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collected and assayed for histamine or PGD2. Figure 3.30 shows the effects 
of the co-incubation of CDMCs with neutralising anti-Anx-A1 (or irrelevant) 
monoclonal antibody on the effect of the inhibitory action of nedocromil, 
ketotifen and promethazine on histamine and PGD2 release. Compound 
48/80 stimulation provoked 45.9 ± 1.1 % of net histamine release and 1802 ± 
199.2 pg/ml PGD2 release. In the presence of neutralising anti-Anx-A1 
monoclonal antibody, the release of histamine (58.3 ± 2.9%) and PGD2 (2216 
± 164.3 pg/ml) was increased. Nedocromil significantly inhibited the release of 
histamine (20.8 ± 0.5%) and PGD2 (743.9 ± 22.3pg/ml). However, in the 
presence of neutralising anti-Anx-A1 ab, nedocromil was not able to inhibit 
either the histamine or PGD2 release. Similar effects were exerted by 
ketotifen, whereby, histamine release was significantly (p<0.001) inhibited by 
19.1 ± 0.7% and PGD2 release was significantly (p < 0.001) decreased by 
508.5 ± 41.3 pg/ml. The ability of ketotifen to inhibit both histamine and PGD2 
release was abrogated in the presence of neutralising anti-Anx-A1 antibody, 
implying functional link between the action of this drug and the release of 
Anx-A1.  
Promethazine did not inhibit the release of PGD2 in stimulated CDMCs 
but was able to significantly (p<0.05) inhibit the release of histamine (27.5  ± 
1.6%). However, in the presence of neutralising anti-Anx-A1 antibody, 
promethazine was still able to significantly (p<0.05) inhibit the release of 
histamine, suggesting that the mechanism of inhibitory action of 
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promethazine is not dependent on Anx-A1. Irrelevant isotype control was not 
active in this system.  
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Figure 3.30: The inhibition of histamine and PGD2 release by nedocromil 
and ketotifen is regulated by Anx-A1 but promethazine exerts its anti-
histamine effects independent of Anx-A1. 
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CDMCs were cultured, pre-treated with the stipulated drugs and stimulated with 
compound 48/80 (10µg/ml) for 10 min as described. The cell culture supernatant 
was sampled and the PGD2 (pg/ml) release and % net histamine release was 
assessed by ELISA. Data are expressed as mean ± SEM. (n=3 independent 
experiments, * p<0.05, ** p<0.01, *** p<0.001 vs stimulated).  
 
3.5.2 The effects of anti-allergic drugs on BMDMCs.  
Nedocromil and ketotifen enhance the Anx-A1 phosphorylation in a 
concentration-dependent manner and these drugs inhibit the release of 
histamine and PGD2 in an Anx-A1 dependent manner in CDMCs. However 
the H1 antagonist, promethazine did not induce the phosphorylation of Anx-A1 
and was only able to inhibit histamine in an Anx-A1 independent fashion. The 
reproducibility of this data was determined by performing similar experiment 
on the BMDMCs from both the WT and Anx-A1 KO strain.  
Figure 3.31 (panel A) shows that compound 48/80-stimulated 
BMDMCs from WT mice released approximately 59.2 ± 0.7% of histamine 
and 628.4 ± 66.6 pg/ml of PGD2. Similar to the previous experiment in 
CDMCs, nedocromil (10nM) significantly inhibited the release of histamine 
(25.3 ± 2.0%) and PGD2 (244.8 ± 53.2pg/ml).  Ketotifen (10nM) also 
significantly (p<0.05) inhibited both the release of histamine (48.3 ± 1.1%) 
and PGD2 (263.3 ± 15.0pg/ml) in the WT BMDMCs. Promethazine (10nM) 
was not able to inhibit the release of either mediator from the WT BMDMCs.  
Figure 3.31 (panel B) shows that compound 48/80-stimulated cells 
from the Anx-A1 KO mice released about 51.3 ± 0.5% of histamine and 652.1 
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± 19.9 pg/ml of PGD2. Both nedocromil and ketotifen were inactive in the 
BMDMCs from the Anx-A1 null mice. The inhibitory action of the anti-
inflammatory glucocorticoid dexamethasone (10nM), which is known to exert 
many effects through the release of Anx-A1 in these cells was tested. 
However, dexamethasone was without effect in the cells cultured from Anx-
A1 null mice. Interestingly, promethazine was able significantly to inhibit both 
histamine (31.6 ± 1.9%) and PGD2 (310.6 ± 35.1) in the KO BMDMCs, 
suggesting that promethazine is efficacious without Anx-A1. As observed 
previously, the human recombinant Anx-A1 was able to significantly 
(p<0.001) inhibit the release of both histamine (16.3 ± 0.2%) and PGD2 
(190.6 ± 39.1pg/ml) in these cells. 
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Figure 3.31: Nedocromil and ketotifen inhibit histamine and PGD2 in WT 
BMDMCs but were not active in the Anx-A1 null cells. Promethazine was 
not active in the WT cells but was able to inhibit both mediators in the 
Anx-A1 null BMDMCs.  
BMDMCs from the WT and Anx-A1 KO mice were cultured and pre-treated with the 
drugs prior to the stimulation with compound 48/80 (10µg/ml) before being assessed 
for histamine and PGD2 release. Nedocromil and ketotifen inhibit the release of both 
the mediators in the WT BMDMCs but these drugs were inactive in the BMDMCs 
from KO mice. However promethazine inhibited both histamine and PGD2 release in 
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the KO BMDMCs but not in the WT BMDMCs. Data are expressed as mean ± SEM. 
(n=3; * p<0.05, ** p<0.01, *** p<0.001 vs stimulated). 
 
3.6 THE ROLE OF FPR2 IN THE MECHANISMS OF MAST 
CELL DEGRANULATION BY NEDOCROMIL. 
Formyl-peptide receptor 2 (FPR2) has been shown to transduce many 
biological activities of Anx-A1. Since it has been demonstrated in the previous 
experiments that Anx-A1 mediates the anti-allergic activity of nedocromil in 
mast cells, the possibility that FPR2 plays any significant role in the inhibition 
of histamine and PGD2 release by nedocromil in CDMCs was determined.  
To address this question, FPR2 antagonist, WRW4 peptide (10µm) 
was utilised. Figure 3.32 (panel A) indicates that the inhibition of PGD2 
release by nedocromil (520.9 ± 29.4 pg/ml) was reversed in the presence of 
WRW4 peptide, suggesting that nedocromil depends on the presence of 
FPR2 to exert its inhibitory effects. In contrast (panel B), the FPR2 antagonist 
did not prevent nedocromil (10nM) from inhibiting the release of histamine 
(20.8 ± 1.3%) in CDMCs, indicating that the acute inhibition of histamine by 
nedocromil is not dependent on FPR2. An interesting observation was that 
CDMCs incubated with WRW4 peptide alone, seems to have some inhibitory 
effects (p<0.05) on histamine release. 
To provide additional data on the role of FPR2 in the mechanism of 
action of nedocromil, the BMDMCs from WT and fpr2/3 null mice were 
utilised. The cells were pre-treated for 5 min with a range of concentrations of 
nedocromil (0 - 50nM) prior to the stimulation of compound 48/80 (10µg/ml) 
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for 10 min. The supernatant from these cells were collected and assayed for 
either histamine or PGD2 readouts. To measure the net level of histamine 
release, the spontaneous release of histamine from unstimulated cells were 
subtracted from the stimulated cells. The basal level of histamine is 57.1 ± 
2.7% in the stimulated BMDMCs from the WT and 75.4 ± 12.3% in the 
BMDMCs retrieved from the fpr2/3 null mice. The levels of PGD2 in stimulated 
WT BMDMCs were 1301 ± 601.4 pg/ml and 1806 ± 56.7 pg/ml in the fpr2/3 
KO BMDMCs.  Figure 3.33 (panel A) shows that nedocromil inhibited the 
release of PGD2 in a concentration-dependent manner in the WT BMDMCs 
with an approximate IC50 value of 10nM, but nedocromil did not inhibit PGD2 
in the fpr2/3 KO BMDMCs. However, nedocromil exert a concomitant 
reduction in histamine levels across increasing concentrations in the 
BMDMCs from both the WT and the fpr2/3 null mice (panel B).  
Collectively data from these two different cell types, CDMCs and 
BMDMCs, suggest that the inhibition of PGD2 release by nedocromil is 
mediated by the release of Anx-A1 acting on FPR2, however, even though 
nedocromil inhibits the release of histamine by releasing Anx-A1, this 
mechanism does not seem to act through FPR2 but could be interacting with 
another member of the FPR family. 
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Figure 3.32: Inhibition by nedocromil (10nM) of PGD2 but not histamine 
is FPR2 dependent in CDMCs. 
The FPR2 antagonist (WRW4 peptide) at 10µM reversed the PGD2 inhibitory effects 
of nedocromil, but was without effect in the inhibition of histamine suggesting that the 
inhibition of PGD2 by nedocromil depends on the FPR2 pathway. Data are 
expressed as mean ± SEM. (n=3 independent experiments, ** p<0.01, *** p<0.001 
vs stimulated). 
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Figure 3.33: Nedocromil inhibits both histamine and PGD2 in a 
concentration-dependent manner in the WT BMDMCs whilst in the fpr2/3 
KO BMDMCs, nedocromil inhibits histamine but not PGD2 release.  
Nedocromil significantly inhibits the release of PGD2 in the WT BMDMCs but not in 
the BMDMCs from fpr2/3 KO mice. However, nedocromil was able to significantly 
inhibit the release of histamine in a concentration dependent manner in BMDMCs 
from both the WT and fpr2/3 KO mice. Data are expressed as mean ± SEM. (n=3 
independent experiments, ** p<0.01, *** p<0.001 vs stimulated). 
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3.7 NEDOCROMIL DOWN-REGULATES THE ACTIVATION OF 
p38 AND JNK IN CDMCS STIMULATED WITH COMPOUND 
48/80. 
GCs down-regulate mast cell activation by inducing dephosphorylation 
of protein kinases involved in the inflammatory signal transduction pathway 
(Oppong et al., 2013). In line with this thought, a question that arised was if 
nedocromil promotes mast cell stabilization by altering the down-stream 
signaling of MAPK pathway, particularly p38 and pJNK in stimulated CDMCs.  
 To proceed with this experiment, compound 48/80-stimulated 
(10µg/ml) CDMCs pre-treated with nedocromil (10nM) was utilised. To 
determine the mechanism of nedocromil inhibition, neutralising anti-Anx-A1 
monoclonal antibody (20µg/ml) was used. The lysates were analysed by 
Western blot using phospho-specific antibodies to p38 and pJNK. As a 
control, the levels of total kinases were also determined. 
 The densitometry analysis of the blot in Figure 3.34 indicates that 
compound 48/80 significantly (p<0.001) increased p38 phosphorylation 
(265.5 ± 8.3%) in CDMCs in comparison with the unstimulated cells. 
However, nedocromil inhibited p38 phosphorylation in stimulated CDMCs. In 
the presence of neutralising anti-Anx-A1 antibody, nedocromil did not down-
regulate the activation of p38, suggesting that Anx-A1 indeed plays a role in 
the abrogation of p38 phosphorylation by nedocromil. 
 Figure 3.35 shows that compound 48/80-stimulated CDMCs 
significantly (p<0.001) induced JNK phosphorylation by 245.5 ± 3.5% in 
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comparison with the unstimulated cells. Nedocromil inhibited the 
phosphorylation of JNK, however immuno-neutralisation of Anx-A1 in CDMCs 
was without effect. Even though only a small component of down-stream 
signaling pathway was tested in this study, the mechanistic signaling 
signature of nedocromil could be identified, where by Anx-A1 plays a 
differential role in the nedocromil-induced down-regulation of p38 and JNK 
activation in mast cells.  
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Figure 3.34: Compound 48/80-induced p-38 phosphorylation was 
reduced in CDMCs pre-treated with nedocromil, but not when Anx-A1 is 
immuno-neutralised. 
Compound 48/80 stimulation of CDMCs increased p38 phosphorylation, however 
this effect was inhibited by nedocromil (10nM). Neutralising anti-Anx-A1 monoconal 
antibody (20µg/ml) reversed the phospho-p38 inhibitory actions of nedocromil. Data 
are expressed as mean ± SEM. (n=3 independent experiments; *** p<0.001 vs 
unstimulated). 
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Figure 3.35: Nedocromil inhibits JNK phosphorylation in stimulated 
CDMCs in an Anx-A1 independent manner.  
Densitometry analysis shows that compound 48/80-induced JNK phosphorylation 
was reduced in the presence of nedocromil (10nM). The presence of neutralising 
anti-Anx-A1 monoclonal antibody did not alter the inhibitory actions of nedocromil on 
JNK phosphorylation. Data are expressed as mean ± SEM. (n=3 independent 
experiments; *** p<0.001 vs unstimulated). 
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4. DISCUSSION 
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The anti-allergic cromones were discovered over five decades ago, but 
their mechanism of action until recently, was very vague. This thesis seeks to 
understand the mechanisms of pharmacological action of these drugs on 
mast cells. Given that Anx-A1 is an important endogenous anti-inflammatory 
mediator, the fundamental mechanistic relationship between Anx-A1 and anti-
allergic drugs in the mast cell model was addressed.  
Anx-A1 is both induced and secreted by many differentiated cell types 
but is particularly abundant in neutrophils, eosinophils, macrophages and 
mast cells (Kamal et al., 2005). Surprisingly though, the actual molecular 
mechanism of Anx-A1 secretion is not well understood. Since the protein 
does not contain a canonical signal sequence, a generally accepted notion is 
that secretion occurs through a non-classical pathway, and some evidence 
suggests that the ABC transporters may be involved (Wein et al., 2004) or 
that the ceramide platform in cells could preferentially bind Anx-A1 and 
promote externalisation (Babiychuk et al., 2008). GCs induce Anx-A1 release 
via a cascade of signalling events (Solito et al., 2003c; John et al., 2004), in 
which activation of PKC triggers Anx-A1 phosphorylation at Ser27 residue and 
possibly other sites prior to externalisation (Solito et al., 2006b). 
 In this thesis, a possible mechanistic explanation for the acute 
pharmacological actions of cromoglycate-like drugs and other anti-allergic 
drugs is proposed which may shed some light on a new pathway whereby the 
release of mediators from mast cells could be modulated. 
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4.1 Mechanism of action of anti-allergic drugs in U937 cells. 
Because Anx-A1 export is a prerequisite for its extracellular anti-
inflammatory activities, it was deemed important to characterise the ability of 
these drugs to promote the phosphorylation of Anx-A1. Incidentally, GCs 
promote tyrosine phosphorylation of Anx-A1 in the human lung carcinoma 
cells (A549 cell line) (Croxtall et al., 2002), a finding that contrasts with 
another study performed on human folliculostellate cells (Solito et al., 2003c), 
raising the possibility that GCs promote phosphorylation of Anx-A1 in a cell-
and tissue-specific manner. 
GCs have a dual effect on Anx-A1 disposition, in that they not only 
potentiate rapid non-genomic action (Croxtall et al., 2000) but also increase 
Anx-A1 mRNA, or at least in U937 cells (Solito et al., 1992). In this thesis, the 
non-genomic effects of these drugs were focused upon.  
To assess the ability of anti-allergic drugs to stimulate phosphorylation 
of Anx-A1, the human pro-monocytic cell line, U937 was chosen as the first 
model because these cells respond well to GC stimulation and express 
significant amount of intracellular Anx-A1 protein. In line with the data 
obtained by other investigators, no effect of GCs was observed in the 
absence of PMA ‘priming’ for 24 h before treatment, as studies have revealed 
that dexamethasone-induced mRNA expression of Anx-A1 only occurs in 
differentiated U937 cells (Solito et al., 1991a). The 5 min time point was 
chosen for the treatment of anti-allergic drugs on U937 cells based on 
previous reports which have identified that this time point to be optimal for 
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Anx-A1 phosphorylation in folliculostellate cells stimulated with LPS (Solito et 
al., 2006b) and GCs treatment on U937 cells (Yazid et al., 2009).  
Evidence from the biochemical and imaging studies performed here 
has shown that ‘pure’ H1 antagonist drugs have only weak effects on Anx-A1 
phosphorylation and release. The ‘mast cell stabilising’ drugs used in this 
study have differing abilities to promote Anx-A1 phosphorylation. 
Cromoglycate and pemirolast have a moderate ability to promote Anx-A1 
phosphorylation. However, nedocromil greatly enhanced Anx-A1 
phosphorylation. Congruent with its clinical efficacy, it is noteworthy that 
nedocromil is 10 times more potent than cromoglycate in this respect (Yazid 
et al., 2009). Although cromoglycate is less effective as a mast cell stabiliser 
than nedocromil in our system, it has more clinical efficacy in asthma and 
allergic conjunctivitis. Whilst there are apparent differences between these 
drugs in clinical efficacy or potency in-vitro, it could be interpreted that this 
could be due to the differences in pharmacokinetics and biodistribution of 
these drugs. It is argueable that the low concentrations used in the in-vitro 
assays may suggest that the therapeutic benefit is not related to the 
mechanisms described here, however, it is important to note that these drugs 
are clinically used as inhalers or eye drops, and thus the dosing reflects on 
the fraction of drug that is absorbed into the body. 
The cromones have distinct pharmacological actions (Cox, 1967; Cox, 
1970; Cox et al., 1970) in that other ‘mast cell stabilising’ drugs such as β 
agonists do not share the same characteristic gamut of activity of the 
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cromones (Shichijo et al., 1998). Of the ‘dual-action drugs, olopatidine only 
moderately enhances Anx-A1 phosphorylation, whereas ketotifen and 
epinastine greatly enhanced this effect.  
Since these drugs seem to act by promoting the release of Anx-A1, 
their eicosanoid inhibitory activities were investigated. Congruent with past 
studies (Yazid et al., 2009), thromboxane (Tx) B2 inhibition by nedocromil was 
greatly potentiated by low concentrations of dexamethasone. A speculation 
would be that nedocromil accomplishes this mechanism by prolonging PKC 
activation at the plasma membrane, thereby potentiating Anx-A1 
phosphorylation and release, but only when the cells were primed by 
dexamethasone or other PKC activating stimulus. Indeed, the use of a 
specific neutralising anti-Anx-A1 monoclonal antibody has supported this 
hypothesis and confirmed earlier reports that TxB2 inhibitory effect is 
mediated by Anx-A1 (Solito et al., 1991a; Solito et al., 1993). 
 
4.2 The role of PKC in Anx-A1 export in mast cells. 
 PKC is a family of isoenzymes that undergoes translocation from one 
subcellular compartment to another in response to extracellular stimulation 
(Yamaguchi et al., 1995). When activated by diacylglycerol (DAG), 
phospholipids or calcium, PKC is phosphorylated first at Ser657 residue, which 
controls the accumulation of phosphate at other sites and contributes to its 
phosphatase resistance conformation (Bornancin et al., 1997). These post-
translational modifications convert the soluble inactive form to an active 
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enzyme that translocates from the cytoplasm to the plasma membrane, 
possibly mediated by the receptors for activated-C kinases (RACKs). It is at 
the membrane that the enzyme principally phosphorylates its target 
substrates (Mochly-Rosen et al., 1991). The classical or conventional PKC 
isozymes (cPKCs; α, βI, βII, γ) are Ca2+-dependent, activated by DAG and 
bind to negatively charged membrane phospholipids, in particular 
phosphatidylserine (PS). Novel PKCs (nPKCs; ε, δ, θ, η) are Ca2+-
independent and only need DAG and PS for activation, whereas the atypical 
PKCs (aPKCs; ζ, λ/ι) require neither Ca2+ nor DAG, but can be activated by 
PS (Hoque et al., 2014).  
 Investigation of the mechanism by which PKC activity is terminated by 
dephosphorylation at the membrane was beyond the scope of this thesis, 
however previous work from several authors suggest that this was caused by 
the Ser/Thr phosphatase PP2A followed by ubiquitination (Hansra et al., 
1996; Boudreau et al., 2002; Lee et al., 2008). PP2A is a heterotrimeric 
enzyme, which comprises one each of two catalytic and structural subunits 
together with one modulatory or targeting subunit. PP2A undergoes post-
translational modifications, such as phosphorylation and methylation, which in 
turn, regulate its enzymatic activity. It plays a critical role in cellular 
processes, such as cell proliferation, signal transduction and apoptosis 
(Lambrecht et al., 2013). In many cell types, including macrophages, PKCα is 
controlled by the activity of the phosphatase, which limits the catalytic action 
of the kinase by dephosphorylation (Ricciarelli et al., 1998; Boudreau et al., 
  241 
2002). Moreover, an elegant study has demonstrated the physical association 
of PKC and PP2A in resting mast cells, which confirms a functional interaction 
between these two enzymes (Boudreau et al., 2002). It has been reported 
previously in U937 cells that the degree of Anx-A1 phosphorylation, hence 
the amount exported, will depend on the net catalytic activity of the PKC-
PP2A complex, which in turn results from the reciprocal interactions between 
the two enzymes (Yazid et al., 2009). 
 Even though much work has been done on the effect of cromoglycate-
like drugs on the GC-Anx-A1 system in the U937 cells (Yazid et al., 2009), the 
main target for the cromones and the anti-allergic drugs are the mast cells. 
Thus, the majority part of this thesis was focused on work performed on cord-
blood derived mast cells (CDMCs) and bone marrow derived murine mast 
cells (BMDMCs).  
 The results described here confirmed previous reports (Solito et al., 
2003b; Solito et al., 2006b) that in these cells, Anx-A1 translocation from the 
cytoplasm on to the cell surface is preceded by the phosphorylation of Anx-
A1 and established that the kinase described is PKC, more specifically the 
α/β isoenzymes (Yazid et al., 2013). 
 The time course of nedocromil action was monitored and revealed that 
5 min was the most optimal time point to record maximal PKC and Ser27-Anx-
A1-P in CDMCs. This time point is identical to the time course of LPS action 
on Anx-A1 phosphorylation in the folliculostellate cells (Solito et al., 2006a) 
and GC-induced Anx-A1 phosphorylation in the U937 cells (Yazid et al., 
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2009). Therefore, 5 min time point was chosen to treat the CDMCs with anti-
allergic drugs to monitor their ability to exert acute effects. 
This data here clearly indicates that nedocromil, prolongs PKC 
activation and subsequently phosphorylation, externalization and release of 
Anx-A1 from CDMCs. Other anti-allergic drugs such as ketotifen and 
promethazine were also tested in this model and the results show that whilst 
ketotifen promotes Anx-A1 and PKC phosphorylation in a concentration-
dependent manner, promethazine was not active in inducing Anx-A1 
phosphorylation in CDMCs. It is noteworthy to mention that the anti-allergic 
drug ketotifen, a non-cromone member appears to have similar actions on the 
Anx-A1 system. Ketotifen is a H1 antagonist that has long been observed to 
have additional ‘mast cell stabilising’ properties (Cook et al., 2002).  
Though the inhibition of PP2A by anti-allergic drugs is not directly 
investigated in this study, an indirect way was used to show that the 
cromoglycate-like drugs prolong the duration of PKC activation by GCs. The 
Western blot analysis demonstrated that the treatment of CDMCs with a 
combination of both dexamethasone and nedocromil synergistically 
potentiated the PKC phosphorylation with time when compared with 
dexamethasone alone, suggesting that indeed nedocromil is able to prolong 
the ‘dwell’ time of PKC activation, perhaps by limiting the catalytic action of 
the PP2A enzyme. To further study the ability of dexamethasone and 
nedocromil to mobilise PKC in CDMCs, confocal microscopy was performed 
using fluorescent-labelled antibody against PKC. The micrographs show that 
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PKC has translocated to the plasma membrane upon treatment with 
dexamethasone for 5 min, however this effect was not maintained across 
time. This observation indicates that the phosphatase enzyme at the plasma 
membrane has terminated the PKC activation. Interestingly, when CDMCs 
were treated with dexamethasone and nedocromil simultaneously, the PKC 
‘dwelling’ time at the plasma membrane is prolonged and is still detectable at 
60 min, supporting the notion that this effect is brought about following 
inhibition of cromoglycate-like drugs of a phosphatase, probably PP2A, which 
secondarily prolongs the activation of PKC thereby further stimulating Anx-A1 
phosphorylation and release. 
There have been scattered reports of an interaction between 
cromoglycate and PKC stretching back over some years. Indeed, there has 
been a study that investigated the possibility that these drugs inhibited PP2A, 
but were unable to detect an effect in their system (Wang et al., 1999). Other 
reports have a correlation between the action of cromoglycate-like drugs in 
vivo in a rat passive cutaneous anaphylaxis model and inhibition of another, 
alkaline phosphatase (Schwender, 1981; Schwender et al., 1982; Ye et al., 
2009). 
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4.3 The possibility that the mechanisms of action of some 
anti-allergic drugs are mediated by Anx-A1 in mast cells. 
 
Evidence from biochemical and imaging studies described here have 
further confirmed that the ability of these anti-allergic drugs to release Anx-A1 
is critical for their acute mediator inhibitory actions in CDMCs and BMDMCs. 
This mechanism is common to several types of cells as was demonstrated in 
previous observations using U937 cells (Yazid et al., 2009) and PMN (Yazid 
et al., 2010b), where a similar autocrine Anx-A1 dependent inhibition of cell 
function was observed following cromone treatment. It has been reported that 
dexamethasone, a GC known to release Anx-A1 using this pathway 
(D'Acquisto et al., 2008), also inhibits histamine and PGD2 release in these 
cells (Yazid et al., 2013). 
For this study, compound 48/80 was utilised as a stimulant to activate 
the mast cells. Extensive literature is available on the IgE mediated 
mechanism of mast cell activation, but the mechanisms by which 
cromoglycate-like drugs inhibit compound 48/80-induced mast cell 
degranulation is rather scarce. Thus, this led to the investigation of the effects 
of cromoglycate-like drugs and other anti-allergic drugs on CDMCs and 
BMDMCs stimulated by compound 48/80.  This mast cell secretagogue 
activates mast cell secretory processes by increasing the rate of GTPγS 
binding to G-proteins. This eventually triggers intracellular signaling events 
such as activation of phospholipase D (PLD), protein kinase C (PKC) and 
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Ca2+ signaling which ultimately results in mast cell degranulation (Palomäki et 
al., 2006). This data indicates that compound 48/80 induces the release of 
histamine across increasing concentrations in CDMCs, and similar trend was 
reported in mast cells purified from the peritoneal cavity of male Wistar rats 
(Aridor et al., 1990).  
Since compound 48/80 activates intracellular signaling, which 
culminates in PKC signaling, the ability of the secretagogue to promote 
phosphorylation of Anx-A1 itself was analysed. Another important observation 
noted was that Anx-A1 phosphorylation induced by compound 48/80 was 
short-lived, decaying after 5 min, however nedocromil was able to prolong 
Anx-A1 phosphorylation to 40 min in CDMCs stimulated by compound 48/80. 
This suggest that nedocromil exerts its ‘mast cell stabilising’ effects in 
stimulated cells by enhancing the phosphorylation of Anx-A1 and therefore 
the export of the protein out of the cell. Even though both the compound 
48/80 and cromoglycate-like drugs triggers PKC activation, the downstream 
activation undergoes a divergent pathway, which results in different 
outcomes. This is probably because compound 48/80 triggers a different PKC 
isoform as opposed to the cromones.  
Based on the Western blots data, it is important to note that there is a 
distinct difference between the ability of the anti-allergic drugs to enhance 
Anx-A1 phosphorylation in the U937 cells or CDMCs. Ketotifen and 
nedocromil potentiated Anx-A1 phosphorylation in a concentration-dependent 
manner in the U937 cells, however in the CDMCs, there was bell shaped 
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curve across increasing concentrations. A possible explanation for this 
phenomenon could be that U937 cells were pre-treated with PMA, which is an 
activator of PKC, thus the cells are already ‘primed’ and there is already a 
small pool of phosphorylated intracellular Anx-A1 present in these cells even 
before drug treatment leading to a potentiation at higher concentration of 
drugs. Interestingly, promethazine, which is a H1 antagonist drug, does not 
potentiate Anx-A1 phosphorylation in either U937 cells or CDMCs, although it 
has been shown elsewhere that promethazine, a phenothiazine-derived drug 
is able to interact with Anx-A1 in neutrophils (Blackwood et al., 1995).  
The data further suggest that Anx-A1 plays an important role in 
‘stabilising’ mast cells as unstimulated CDMCs undergo spontaneous 
degranulation indicated by β-hexosaminidase release when Anx-A1 is 
depleted by immune-neutralisation. Although the release of β-
hexosaminidase is a widely used indicator of secretory lysosome exocytosis 
from mast cells, it is unclear whether the release of this single granule marker 
accurately reflects the behavior of all secretory granules in mast cells. Thus, 
in addition to β-hexosaminidase, the inhibition of tryptase, histamine and 
PGD2 release by the anti-allergic drugs were measured. An interesting 
observation was noted in the model of ‘seasonal allergic conjunctivitis’ (SAC), 
whereby the Anx-A1 KO mice display a more pronounced allergic 
conjunctivitis after sensitisation with ragweed pollen when compared to wild 
type counterparts, further reinforcing the role of Anx-A1 in regulating mast cell 
stability (Yazid et al., 2014 unpublished). 
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To determine whether tryptase and Anx-A1 are present in the same 
granules or whether there is heterogeneity within the secretory granule 
population of mast cells, immunofluorescence techniques were used. 
Observation from the confocal images shows that the distribution of tryptase 
and Anx-A1 are present in different granules, as they don’t co-localise in 
resting cells. The Western blot and immunofluorescence data clearly 
indicates that compound 48/80-stimulated CDMCs release tryptase into the 
extracellular milieu, but nedocromil inhibits the release of tryptase in an Anx-
A1 dependent manner. This data is in agreement with previous reports, which 
suggest that nedocromil inhibits the release of tryptase as part of its ‘mast cell 
stabilising’ effects (Calhoun et al., 1996; Kempuraj et al., 2005), though the 
results presented here shows a novel finding that Anx-A1 is indeed 
responsible for the acute inhibitory effects of nedocromil on tryptase release. 
The data has therefore clearly shown that not only is Anx-A1 exported out of 
the mast cells upon treatment of cromones but is also thought to be critical for 
the inhibition of mediator release from the mast cells. 
The amounts of Anx-A1 released from CDMCs treated with nedocromil 
and ketotifen, yields concentrations in the nM range, that are substantial 
enough to reduce histamine and PGD2, as indicated by the experiments with 
recombinant human Anx-A1. This effect is brought about by Anx-A1, since 
both the drugs were unable to inhibit the mediator release as in the BMDMCs 
isolated from Anx-A1 null mice. (Yazid, Sinniah et al., 2013). This effect of 
eicosanoid release and inflammation was also observed in the Anx-A1-/- null 
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mice in which dexamethasone was shown to be inactive (Croxtall et al., 
2003). These experiments have clearly demonstrated that nedocromil and 
ketotifen are dependent on Anx-A1 release to exert its anti-inflammatory 
effects. Since ketotifen exerts similar mechanism of action to nedocromil, it is 
interesting to speculate that all the H1 antagonists, which are also mast cell 
stabilisers, that have this additional action, may have a secondary 
pharmacology as PP2A inhibitors and that this could be a useful screen to 
evaluate this drug’s property. 
The action of promethazine differs from nedocromil and ketotifen. At 
10nM, the drug was not able to inhibit the release of PGD2 from activated 
mast cells, but significantly inhibited the release of histamine from CDMCs. 
But immuno-neutralisation techniques in these cells have shown that the 
inhibitory action of promethazine is not mediated by Anx-A1. When similar 
experiments were repeated on the WT BMDMCs, promethazine did not inhibit 
the release of both histamine and PGD2, which would imply a considerable 
species-variation in the response to this drug. However, promethazine 
significantly inhibited the mediator release in BMDMCs from Anx-A1 null 
mice, suggesting that promethazine only exerts its inhibitory effect in the 
absence of Anx-A1. A possible speculation for this anomalous observation 
could be that in the Anx-A1 null mice, the H1 receptors are overexpressed, 
hence promethazine is able to function better in these mice.  
It is important to note that the cromones can only exert appreciable 
effect on mediator release if Anx-A1 phosphorylation is already triggered by 
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another stimulus, such differences could reflect the relative degree of 
activation of cells from different sources or subjected to different experimental 
protocols. Perhaps this explains why the cromoglycate drugs have only a 
variable effect when given in the absence of an appropriate ‘priming’ stimulus 
that triggers this effect. This observation might also explain some of the 
anomalous dose-response relationships that have been reported (Church et 
al., 1987; Okayama et al., 1992b). In this context it is interesting to note that 
the CDMCs cultured as described here are partly activated by the presence 
of SCF and that there is already a small pool of intracellular Ser27 phospho 
Anx-A1 present in these cells even before challenge with antigen or drug 
treatment.  
However there are some anomalous observations, which indicate that, 
cromones have failed to inhibit histamine release from anti-IgE stimulated 
human conjunctival mast cells (Canonica et al., 1997) and human connective 
tissue type mast cells (Okayama et al., 1992a; Okayama et al., 1992b). A 
recent study has suggested that cromoglycate is not active at all in the mouse 
model (Oka et al., 2012) although the results presented here show that 
nedocromil responds well in the BMDMCs model. This heterogeneity between 
species and different mast cell subtypes in response to the drugs is a 
conundrum. Contributing to this could be the timing and concentrations of 
cromones pre-treatment prior to mast cell degranulation, which were thought 
to relate to the differing sensitivity (Shichijo et al., 1998). Another speculation 
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is that the existence of different Anx-A1 pools within mast cells from different 
sites (Oliani et al., 2000) could explain the variation of the cromones effects.  
The dependency of nedocromil on Anx-A1 for its anti inflammatory 
effect presented here is novel but there have been previous observations in 
the past suggesting that cromones trigger the phosphorylation of intracellular 
protein substrates including the erythrocyte band 4.1 group protein moesin, 
which leads to the modification of downstream mediators of molecular targets 
in mast cells (Theoharides et al., 2000). Interestingly, cromones were also 
shown to have an interaction with PKC (Lucas et al., 1987; Bansal et al., 
1997), which fits well in the hypothesis. Moreover, cromoglycate sodium, 
which inhibits IgE mediated mast cell degranulation has been shown to 
interact with S100-Ca2+ binding proteins which bind to Anx-A1 to Anx-A5 
(Oyama et al., 1997), suggesting a potential interaction between cromones 
and annexins. 
There has been recent revival in cromone literature and it has also 
been suggested that cromones produce their therapeutic effects by 
interacting with GPR35 through the Gi pathway (Jenkins et al., 2010; Yang et 
al., 2010). Apparently GPR35 is present in human mast cells stimulated with 
IgE cross-linking, although it’s significance to mast cell mediator release is not 
fully understood. How this notion could be integrated into Anx-A1 dependent 
mechanism is unclear, but it is worth noting that the effects of cromones that 
was detailed here occurred within 5 min and possibly at longer duration of 
cromone treatment the GPR35 mechanisms may be important.  
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4.4 The role of FPR2 in the inhibitory effects of mediator 
release by nedocromil. 
 Because there is compelling evidence to support the notion that 
nedocromil exerts its effect through the Anx-A1 pathway, the possibility that 
one of the principal receptor for this protein, FPR2 might also be involved in 
the mechanism of action of nedocromil was explored. This was a point of 
interest, since both Anx-A1 protein and the FPR2 are expressed in mast cells 
(Lee et al., 1997; Oliani et al., 2000). To address this aim, not only FPR2 
antagonist, WRW4 peptide was utilised but also BMDMCs isolated from the 
fpr2/3 null mice colony was used to further ascertain the role of FPR2 in the 
acute effects of nedocromil.  
The release of two mediators of mast cells, histamine and PGD2 were 
tested. Based on the results obtained from CDMCs, nedocromil inhibits PGD2 
through the activation of FPR2, as in the presence of FPR2 antagonist the 
acute inhibitory effect of nedocromil was reversed. In contrast, inhibition of 
histamine release by nedocromil was not mediated by FPR2 activation since 
nedocromil was still able to significantly inhibit histamine release in the 
presence of WRW4 peptide. This observation reflects that even though the 
inhibition of histamine release by nedocromil is mediated by Anx-A1, it does 
not require the activation of its receptor FPR2.  
 To further rule out species-specific variation, similar experiments were 
repeated in BMDMCs isolated from WT and fpr2/3 null mice. As previously 
observed, both histamine and PGD2 release was inhibited by nedocromil in a 
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concentration-dependent manner in the WT BMDMCs. Whereas, in the fpr2/3 
null BMDMCs, nedocromil was unable to inhibit PGD2 release but was able to 
decrease the release of histamine across increasing concentrations. These 
data from both CDMCs and BMDMCs suggest that the inhibition of histamine 
by nedocromil is dependent on Anx-A1 but is not mediated through FPR2.  
A possible speculation for this latter phenomenon could be that Anx-A1 
might be interacting with FPR1, which is also another receptor for Anx-A1 
(Dufton et al., 2010b). Moreover, nedocromil rapidly causes internalisation of 
both FPR1 and FPR2 in neutrophils (Yazid et al., 2010b). Another study has 
shown that the Ac2-26-induced effect on wound closure was blocked by the 
FPR1 receptor antagonist cyclosporin H (CsH), which also blocked the pro-
migratory effects of Ac2-26. However, the peptide WRW4, which is known to 
antagonize FPR2, did not influence Ac2-26–mediated wound closure. These 
findings suggest that the pro-migratory effects of Ac2-26 are mediated by 
FPR1 and not likely mediated by FPR2 (Leoni et al., 2013). 
Differential release of pre-formed and de-novo synthesised mediators 
by IgE-dependent and non-immunological stimuli has previously been 
demonstrated in human mast cells (Benyon et al., 1989; Levi-Schaffer et al., 
1989). Another study has shown that inhibition of histamine release is caused 
by an inactivation of an immediate downstream event following receptor 
engagement, whereas, key events involved in the inhibitory pathways for 
PGD2 release may have higher sensitivity to β-adrenoceptor-derived signals 
and their inhibitory functions may be longer lasting than those for histamine 
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release in cultured human mast cells (Tsuji et al., 2004). Such differential 
signaling events leads to a discrepancy in the mediator release, which could 
also be explained in this system whereby, FPR2 mediates the release of 
PGD2 but not histamine. 
Other authors (Church et al., 1987) have noted that some drugs blocks 
specific release of mast cell mediators and eventually their contribution to the 
resolution of inflammation. They have shown that sodium cromoglycate 
inhibits the release of PGD2 more effectively than that of histamine, therefore 
reflects a differential inhibition of mediator release.  
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4.5 Could the MAPK downstream signalling pathway 
contribute to the ‘mast cell stabilising’ effects of nedocromil? 
 The liberation of all mast cell inflammatory mediators is regulated by 
signaling either after the aggregation of FcεRI by multivalent antigens 
(Metcalfe et al., 1997; Galli et al., 2005b) or by mast cell secretagogue (Aridor 
et al., 1990). Although only a small subset of the downstream intracellular 
signaling pathway of MAPK was tested, the results indicate that Anx-A1 
differentially regulates the activation of MAPK in CDMCs pre-treated with 
nedocromil.   
The mammalian MAPKs comprise three major groups, which are the 
ERKs, the JNKs and p38 that are classified on the basis of their differential 
activation of agonists, sequence similarity, and substrate specificity (Chang et 
al., 2001). The activation of ERK1/2 has been linked to cell survival, whereas 
JNK and p38 are linked to the induction of apoptosis (Xia et al., 1995)  
Based on the results, Anx-A1 release induced by nedocromil yielded 
specific signaling profiles in CDMCs. Compound 48/80 stimulated the 
expression of both phospho-p38 and phospho-JNK in CDMCs and 
nedocromil was able to stimulate dephosphorylation of both the MAP kinases. 
However, in the presence of neutralising anti-Anx-A1 monoclonal antibody, 
nedocromil was only able to activate p38 but not p-JNK. This suggests that 
nedocromil suppresses the activation of p38 in an Anx-A1 dependent manner 
but then this endogenous protein does not play a role in the 
dephosphorylation of JNK by nedocromil. 
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Indeed, there is evidence which suggest a differential role for MAPKs 
in IgE-dependent signaling in human peripheral blood basophils, whereby in 
contrast to p38 MAPK, JNK is poorly expressed and does not appear to 
control mediator release (Gibbs et al., 2005). TNF-alpha expression and 
histamine exocytosis stimulated by exposure of rat peritoneal mast cells to 
substance P requires the activation of both p38 and JNK MAPKs pathways 
(Azzolina et al., 2002). Another study has indicated that the release of PGD2 
is mediated through the activation of p38 MAPK pathway in mast cells and 
macrophages in the skin (Kaur et al., 2013).  
Thus far, there has not been any investigation into the ability of 
nedocromil to influence the MAPKs to exert its inhibitory effects on mast cells. 
Even though the results presented here are really preliminary, it has certainly 
opened up possible avenues to study the mechanism of action of nedocromil 
in regards to the signaling of MAPKs. This could lead to the delineation of a 
novel-signaling pathway by which Anx-A1 mediates nedocromil to exert its 
anti-allergic effects on mast cells. 
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5. CONCLUSIONS  
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Collectively, the data presented here indicates a novel paradigm for 
the actions of the anti-allergic drugs involving the anti-inflammatory Anx-A1 
protein in mast cells. Initial speculation was that a possible mechanistic 
relationship existed between anti-allergic drugs and Anx-A1.  The anti-allergic 
drugs that were tested here are from different categories, being either H1 
antagonists, mast cell stabilisers or ‘dual-action’ drugs. These drugs elicit 
different pharmacological profiles in respect to the Anx-A1 system, which 
bears on the question of how they exert their anti-allergic effects.  
Indeed, cromones like nedocromil prolongs the ability of GCs to induce 
Anx-A1 release and thus produce its anti-inflammatory effects. This could be 
due to the ability of nedocromil to inhibit the phosphatase enzymes, in 
particular PP2A. It could be speculated that a formulation comprising small 
doses of GC sufficient to express the Anx-A1 pool within the cell on to the 
plasma membrane, when combined with a critical dose of nedocromil could 
lead to superior therapeutic effect with less adverse reactions. Indeed, a new 
formulation consisting of a combination of azelastine, a ‘dual-action’ drug and 
fluticasone propionate, a corticosteroid, has been recently marketed as a 
nasal spray to treat seasonal allergic rhinitis patients (Kelso, 2008).  
The acute mechanism of action of the nedocromil is mediated by Anx-
A1. Nedocromil inhibits the release of several mediators from mast cells 
stimulated with compound 48/80 and does so in an Anx-A1 dependent 
manner (Figure 5.1). These new findings could potentially greatly enhance 
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the therapeutic use of cromones, or other compounds with similar mechanism 
of action, to treat allergic conditions. 
The timing of cromone administration relative to the degranulating 
stimulus is also thought to be crucial (Shichijo et al., 1998) to their effects as 
these drugs exhibit strong tachyphylaxis (Sung et al., 1977a; Sung et al., 
1977b; Church et al., 1987). Indeed, the refractory period that 
characteristically follows an application of these drugs, led to early 
speculation that the release of a labile rapidly-depleted anti-inflammatory 
substance (Thomson et al., 1973) or other transient intracellular phenomenon 
(Theoharides et al., 1980; Wells et al., 1983) may be involved in their action. 
The results presented here are consistent with such an interpretation and 
thus reinforces the concept that the hypothesised ‘anti-inflammatory’ 
substance is actually Anx-A1.   
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Figure 5.1: Diagrammatic representation of the mechanism of action of 
drugs treatment in mast cells. 
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These illustration depicts the pathway by which nedocromil exerts its ‘mast cell 
stabilising’ properties in mast cells. A model system in which nedocromil acts 
through the Anx-A1 protein is proposed. A) In resting mast cells, PKC and Anx-A1 is 
distributed in the cytoplasm and the granules are intact. B) Upon depletion of Anx-
A1, the mast cell undergoes spontaneous degranulation. C) Compound 48/80 
stimulation induces the activation of PKC, hence the phosphorylation of Anx-A1, but 
this action is short-lived and the provoked Anx-A1 exportation is not sufficient 
enough to inhibit mast cell degranulation. D) Occupancy of GR with GC activates 
PKC, which in turn enhances the phosphorylation of Anx-A1 and this complex would 
then be exported out of the cells to act via FPR to inhibit mast cell degranulation. E) 
Nedocromil potentiates the PKCα/β phosphorylation, probably by inhibiting the PP2A 
enzyme and increases the PKC activation and Anx-A1 phosphorylation and release 
to exert its ‘mast cell stabilising’ properties. F) Nedocromil increases the ‘dwell’ time 
of PKC activation by dexamethasone, thus increases the PKCα/β phosphorylation, 
which in turn, enhances the Anx-A1 phosphorylation at the Ser27 residue. This 
complex would then be exported out of the cell to act either in an autocrine or 
paracrine manner via the FPR to exert its anti-inflammatory effects.  G) The inhibition 
of the release of PGD2 by nedocromil occurs in a FPR2 dependent manner, but the 
inhibition of histamine release, might be mediated by other FPR members. H) 
Nedocromil decreases the phosphorylation of p-38 through the Anx-A1 pathway 
whilst, the dephosphorylation of p-JNK by nedocromil occurs in an Anx-A1 
independent manner.  
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FUTURE PERSPECTIVES 
Further extension into this project would provide additional insights into 
the mechanisms of anti-allergic drugs in regards to the Anx-A1 pathway in 
mast cells.  
Our group has previously collaborated with Dr Andy Vinter of RePharm 
to determine the molecular docking of nedocromil into the PP2A structure. 
We hope to pursue further our collaboration to determine the molecular 
docking of other anti-allergic drugs into the PP2A molecule. This might 
indicate which anti-allergic drugs interact and thereby prolong PKC activation. 
The use of PP2A inhibitors would also provide additional data on the 
mechanistic relationship between these drugs and the phosphatase enzymes.   
Since promethazine was observed to have a rather puzzling action 
apparently being more efficacious without Anx-A1, we would like to explore its 
potentiating mechanism. One possibility is that in the Anx-A1 null cells the 
possibility that this drug and Anx-A1 are competing for the same receptor, 
probably H4 receptor. This key observation, if confirmed, will further support 
the possibility that Anx-A1 binds with other GPCRs to exert its anti-
inflammatory effects. 
Another interesting avenue that could be pursued is the question of co-
localisation of S-100 A11 proteins and Anx-A1 in mast cells. It appears that 
Anx-A1 may reside in mast cells in a complex with S-100 A11 and that the 
phosphorylation is induced by PKC may cause the dissociation of this 
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complex, allowing Anx-A1 to localize to the plasma membrane prior to 
secretion.  
In this thesis, some interesting evidence of MAPK signaling pathway 
elicited by nedocromil in stimulated CDMCs is gathered. We will attempt to 
further dissect out the signaling profile of other cromones or anti-allergic 
drugs to understand if indeed Anx-A1 does play a role in this pathway.  
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